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Physical and mental suffering caused by disease are known to 
anyone, even when experiencing a mild cold. But disease also 
has economic consequences to individuals, households and 
societies that not everybody might be aware of. Depending 
on the disease and on the context of the affected individuals, 
these consequences might lead to economic hardship and 
even to impoverishment. Neglected tropical diseases (NTDs) 
are a group of communicable diseases associated with 
chronic, disabling and disfiguring morbidity, but also death, 
most of them affecting extremely poor populations. This 
thesis aimed at providing an improved understanding on the 
socioeconomic eﬀect of NTDs on individuals and society, 
on the costs of a new diagnostic strategy to combat one of 
the NTDs, and on the impact of disease-related direct costs 
and productivity loss on the likelihood of impoverishment. 
This evidence can increase health policy dialogue and further 
encourage NTD prevention and control actions, assuring 
funders and policymakers that resources committed to these 
efforts will not only address poverty and the fundamental 
right to health, but are also a good investment.
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Health is with no doubt one of the most important - if not the most important- good in 
a person’s life. Not only is health a direct constituent of a person’s well-being, it also 
enables one to follow goals and carry out projects, functioning as an agent. It 
encompasses and goes beyond the utility theory concept of health as the means to 
increasing one’s human capital or income. Health allows a person to choose the life she 
wants to live. [1] 
 
1.1 Health and welfare 
Economic welfare theory considers that what individuals and populations value the most 
is to maximize utility. This is done through the best possible combination of the 
consumption of goods and services: some that can be bought and sold and some that 
cannot, but that nevertheless have discernable value. Besides consuming goods and 
services, utility might also be generated via leisure, including spending time with family 
and friends or taking care of others.[2] There are three ways through which health 
contributes to individual utility or social welfare: people prefer to be more healthy than 
less; health influences the enjoyment of consumption of other goods and services; the 
absence of health compromises other economic objectives that allow people to consume 
market goods (e.g. generating income). One reservation that has to be made is that 
consumption of health goods and services does not yield welfare directly, as the 
consumption of most types of goods and services. Despite people’s preference for not 
incurring these kind of expenses, they pay them believing it will protect or promote their 
health. Therefore, it can be said that health status, leisure and the consumption of ‘non-





1.2 Economic consequences of disease 
There are several ways of defining categories of health-related costs. We used the same 
terminology as in the ‘WHO guide to identifying the economic consequences of disease 
and injury’, but instead of using direct/indirect costs (they can have other meanings, for 
instance indirect costs mean overhead costs in a company’s perspective), we used out-
of-pocket payments (OPPs) and productivity loss (for the sake of clarity). Economic 
impact of ill-health can be investigated from a macroeconomic perspective (societal or 
population-level) or a microeconomic one, concentrating in the economic effects that ill-
health can have on households (including impoverishment). The types of costs included 
in an economic impact study will depend on the question being asked, the chosen scope 
or perspective (for instance, if only market losses - quantifiable – or if non-market losses 
will also be included). [2] 
Out-of-pocket payments - OPPs   
Out-of-pocket payments can be described as the expenses attributable to a specific 
illness. They can be directly related to medical costs (e.g. consultation, diagnostic tests 
and other emergency, ambulatory or inpatient interventions, medication, nursing care, 
rehabilitation) or to non-medical costs (e.g. transportation costs, caregiver time and 
subsistence costs while attending a hospitalized household member, special food needs, 
changes to the household structure to accommodate disease consequences – such as 
wheel chair access). In developing countries, individuals or households often have to pay 
for the costs themselves when illness occurs, since they cannot rely much on 
universal/social insurance schemes. At the household level, costs incurred in the 
acquisition of health services to enhance and restore the health of individuals or 
population groups should represent the resources that could have been used for other 
types of consumption had the disease or illness not occurred, including the costs of health 
insurance borne by households. If not paid by the individuals/households, they can be 
sometimes paid by firms (depending on the working agreements). [2,3] 
Productivity loss 
Productivity loss here refers to the short-term or long-term productivity loss resulting 
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individual, household, firms or societal perspective. It usually considers absenteeism 
(work absence due to sickness), presenteeism (the person is present at work, but not fully 
functioning due to sickness) and/or mortality (present value of future earnings lost by 
individuals who die prematurely from the disease). It can be particularly important in 
developing countries, where employment opportunities tend to depend more on physical 
endurance and strength. Productivity loss can be calculated using the human capital 
approach (which involves multiplication of the total number of absent days by the wage 
rate of the absent worker) or the friction cost method (which restricts the estimation of 
the potential production losses to the 'friction period' needed to find a replacement 
worker, providing a level of correction in the short term). [2,4,5] 
Social consequences 
Besides economic losses, disease also imposes social consequences, affecting people’s 
feelings, thoughts, behavior and ultimately wellbeing. These consequences might come 
from the symptoms and suffering of the particular disease, but also from the economic 
hardship/impoverishment imposed by it. For instance, households might reduce 
expenditures on education in the short-term, a child might not go to school due to disease 
symptoms, or the child might show suboptimal school achievements due to inadequate 
nutrition from reduced available resources. This might lead to potentially long-term 
consequences to a child being out of school, impacting human/social capital formation. 
Also, time spent seeking health care and time spent by a household member taking care 
of a sick person could have been spent on leisure activities. In short, besides economic 
losses, disease also has a negative impact on households’ repository of knowledge, 
experiences, and social networks, plus its stock of health and wellbeing. [2] 
Economic hardship due to disease and poverty 
Illness-related economic losses can have an important impact on the amount of resources 
available for consumption, forcing the reduction of basic expenditures (such as food and 
shelter) or children’s education. Furthermore, they can cause or accentuate household 
poverty. When OPPs are especially large compared to a household’s total income (or 
consumption), they are considered to be catastrophic. Using a definition of large 
expenditures as 10% of total household expenditure, the global incidence of people 




the estimated worldwide incidence of impoverishment due to health related OPPs was 
97 million people. [7] 
Economic hardship due to disease and poverty (from disease and from other causes) are 
unfortunately still so relevant that two of the Sustainable Development Goals are devoted 
to these causes. The first SDG is ‘To end poverty in all its forms everywhere by 2030’ 
and SDG 3 ‘Good health and well-being - Ensure healthy lives and promote well-being 
for all’ has a specific goal to ‘Achieve universal health coverage, including financial risk 
protection, access to quality essential health-care services and access to safe, effective, 
quality and affordable essential medicines and vaccines for all’. [8,9] 
Socioeconomic 
The term ‘socioeconomic’ is widely used and has no consensual definition. Some of the 
various interpretations include ‘the use of economics in the study of society’, or ‘how 
economic activity interferes and is influenced by social processes’. [10] In this context, 
socioeconomic refers to the interaction of both economic and social consequences of 
NTDs on individuals, households and countries/societies, which can also include how 
social processes related to the disease might interfere with economic activity.  
1.3 Neglected Tropical Diseases (NTDs)  
NTDs are a group of communicable diseases diverse in biological and transmission 
characteristics. They are associated with chronic, disabling and disfiguring morbidity, but 
also death. Most of them affect forgotten people, the extreme poor with little political 
capital, living in slums or in rural areas, frequently also affected by conflict, predominantly 
in low–and middle-income countries (LMIC). Almost everyone in the poorest bottom 
billion in the world has at least one NTD, which also contributes to keep them trapped 
in poverty. The number of prioritized NTDs by the WHO is currently 20, although other 
organizations might define them differently. The public health importance of 13 parasitic 
and bacterial infections (that are the highest burden NTDs) together (in disability-
adjusted life years) was considered to rank closely with HIV/AIDS, malaria, ischemic 
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NTD control or elimination targets for the year 2020 were set out in the World Health 
Organization (WHO) Roadmap of 2012 and endorsed by partners of the London 
Declaration in the same year. This declaration included the ten following diseases: Guinea 
worm disease, lymphatic filariasis (LF), leprosy, sleeping sickness (human African 
trypanosomiasis - HAT), blinding trachoma, schistosomiasis, soil-transmitted 
helminthiases (STH), Chagas disease, visceral leishmaniasis (VL) and river blindness 
(onchocerciasis). [15-17] 
The WHO recommends five interventions to reach the NTDs targets: preventive 
chemotherapy (PCT) by mass drug administration (MDA); innovative and intensified 
disease management (IDM); vector ecology and management; veterinary public health 
services; and the provision of safe water, sanitation, and hygiene. [17,18] 
PCT is used for LF, onchocerciasis, schistosomiasis, STH and blinding trachoma. It 
involves largescale delivery of safe, single-dose medicines to eligible populations at 
regular intervals, donated to and distributed by the WHO. In the many areas where the 
diseases treated with PCT are coendemic, integrated delivery of treatment is 
recommended. Since the side effects of PCT medications are relatively mild, treatment is 
delivered without the need for specific diagnosis. [17] 
IDM is the strategy for Chagas, HAT, leprosy, and VL. It involves caring for infected 
individuals and those at risk of infection by diagnosing as early as possible, providing 
treatment to reduce infection and morbidity, and managing complications. This 
intervention is the main strategy for controlling and preventing NTDs for which there 
are no medicines available for preventive chemotherapy. Due to the relative toxicity of 
medicines, diagnostic confirmation is needed before treatment. [17,18] 
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London Declaration targets and Sustainable Development Goals 
NTD control or elimination targets for the year 2020 were set out in the WHO Roadmap 
of 2012 and endorsed by partners in the London Declaration of the same year. [15-17] 
According to the London Declaration, Guinea worm should be eradicated by 2020; LF, 
HAT, leprosy and trachoma should be eliminated; schistosomiasis, STH, Chagas disease, 
VL and onchocerciasis should be controlled, as shown in Table 1. The partners signing 
the declaration commit to provide drugs, technical support, funding to implement 
programs, collaboration for more efficiency, research of new treatments and 
interventions in order to achieve these targets. [16] 
To reach the London Declaration targets, each disease poses its particular challenges. For 
the diseases treated with ivermectin (LF and onchocerciasis), one of them is co-
endemicity with loiasis (another disease endemic in Central Africa caused by the filarial 
parasite Loa loa), which offers the possibility of severe adverse reaction (even death) 
following ivermectin treatment. Therefore, new strategies to diagnose loiasis before 
treatment are needed, so that treatment for LF and onchocerciasis can be offered in the 
regions also facing loiasis. [22-24] Diseases treated via MDA still need more research to 
ensure effective MDA coverage and evaluation of programs’ effectiveness and efficiency. 
Vector transmitted diseases need more monitoring of and research on insecticide 
resistance. In general, improved access to and affordable diagnostics and treatment is 
needed (especially drugs for IDM diseases), one of the reasons for many partners to 
defend universal health coverage (UHC) guaranteed at least for NTDs.[25,26] WHO’s 
new NTD roadmap for the years 2021-2030 sets a target of ‘100% of the population at 
risk protected against out-of-pocket health payments due to NTDs by 2030’.[20]  
Improvement of the delivery of existing products/strategies through responsive and 
resilient health systems is essential to reach the London Declaration targets. This is also 
needed to meet the aspiration of NTD ‘endgame’ as mentioned by SDG 3.3: “By 2030, 
end the epidemics of AIDS, tuberculosis, malaria, and neglected tropical diseases and 
combat hepatitis, water-borne diseases, and other communicable diseases.” and to meet 
the specific 3.3.5 goal for NTDs ‘a 90% reduction in the number of people requiring 
interventions against NTDs by 2030’.  [14,25-28]  
 
 
Not only increased investments directly aimed at NTDs, but improvements in education, 
water sanitation and hygiene are fundamental to reaching NTDs targets. Since 
populations endemic for NTDs are the less likely to access these services, many SDGs 
may be reached once they do: 1-No poverty, 2-Zero hunger, 3-Good Health and 
Wellbeing, 4-Quality education, 6-Clean Water and Sanitation, 8- Decent Work and 
Economic Growth, 10- Reduced Inequalities, 11-Sustainable Cities and Communities, 
improving the wellbeing of vulnerable groups and equity.[14,28,29] 
Economic aspects of NTDs 
The disease burden of NTDs has been estimated in DALYs (Disability-Adjusted Life 
Years, expressed as the number of years lost due to ill-health, disability or early death). 
Although DALYs tend to underestimate the burden of NTDs due to underreporting or 
missing data from LMICs, in 2012 NTDs accounted for approximately 22 million 
globally (about 1% of the global total). [18] 
In addition to the disease burden, the economic burden that NTDs inflict on patients 
and their families is also heavy. Compared to studies of the epidemiology and health 
consequences of NTDs, relatively few studies have investigated the impact of NTDs on 
OPPs and productivity loss for individuals, households, and societies. An improved 
understanding of the economic effect of NTDs on individuals, households and countries 
is important to forecast economic implications of any changes in effective and equitable 
implementation strategies and to better estimate the benefits of addressing NTDs. These 
advances in estimating economic costs could help in the advocacy for prevention and 
control actions, in increasing health policy dialogue, and in convincing funders and 
policymakers that investments in these actions are worth making. [30,31]  
 
1.4 Objectives and research questions 
The main objective of this thesis is to study the socioeconomic eﬀ ects of NTDs on 
individuals and society by answering the following four specific research questions:  
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b. How much economic benefit can be expected from reaching the targets for the 
10 London Declaration NTDs? 
c. What are the costs and cost drivers related to a new strategy aimed at reaching 
the targets? The example of Loa loa 
d. What are the effects of combining OPPs and productivity loss in the assessment 
of illness-related impoverishment?  
1.5 Structure of the thesis 
This thesis contains 6 more chapters. Chapter 2 describes a systematic literature review 
to identify and examine publications describing the impact of lymphatic filariasis, 
onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, trichuriasis, and 
hookworm infection) and trachoma on productivity loss in adults. Chapters 3 and 4 
report on the estimation of economic benefit (to individuals) of meeting the 2020 WHO 
targets for PCT and IDM NTDs respectively. This meant estimating how much of the 
economic loss faced by affected individuals due to productivity loss and out-of-pocket 
payments secondary to these diseases would be avoided by reaching these targets. 
Chapter 5 presents the costs of a pilot round in Cameroon for a new strategy to treat 
onchocerciasis in areas where Loa loa is coendemic. Chapter 6 examines the joint impact 
of OPPs and productivity loss on the likelihood of illness-related impoverishment, using 
Chagas disease as an example. Chapter 7 concludes this thesis with a discussion of the 
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Neglected Tropical Diseases (NTDs) not only cause health and life expectancy loss, but 
can also lead to economic consequences including reduced ability to work. This article 
describes a systematic literature review of the effect on the economic productivity of 
individuals affected by one of the five worldwide most prevalent NTDs: lymphatic 
filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, 
trichuriasis, and hookworm infection) and trachoma. These diseases are eligible to 
preventive chemotherapy (PCT). 
Methodology/Principal Findings 
Eleven bibliographic databases were searched using different names of all NTDs and 
various keywords relating to productivity. Additional references were identified through 
reference lists from relevant papers. Of the 5316 unique publications found in the 
database searches, thirteen papers were identified for lymphatic filariasis, ten for 
onchocerciasis, eleven for schistosomiasis, six for soil-transmitted helminths and three 
for trachoma. Besides the scarcity in publications reporting the degree of productivity 
loss, this review revealed large variation in the estimated productivity loss related to these 
NTDs. 
Conclusions 
It is clear that productivity is affected by NTDs, although the actual impact depends on 
the type and severity of the NTD as well as on the context where the disease occurs. The 
largest impact on productivity loss of individuals affected by one of these diseases seems 
to be due to blindness from onchocerciasis and severe schistosomiasis manifestations; 
productivity loss due to trachoma-related blindness has never been studied directly. 
However, productivity loss at an individual level might differ from productivity loss at a 
population level because of differences in the prevalence of NTDs. Variation in estimated 
productivity loss between and within diseases is caused by differences in research 
methods and setting. Publications should provide enough information to enable readers 
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Most of the people affected by Neglected Tropical Diseases (NTDs) are impoverished 
and marginalized populations, with low visibility and little political voice.  They are not 
considered a priority market for pharmaceutical manufacturers or a health risk for the 
wealthier parts of the world. [1-3]  Nevertheless, NTDs have an important impact on 
child development, school attendance, learning, nutritional status, pregnancy outcomes, 
and worker productivity, especially in poor rural settings, where physical labor is the 
major subsistence mode. As any other disease, they can lead to productivity loss in many 
ways, including reduced productivity at work (presenteeism), absence from work 
(absenteeism) or even job loss, depending on the type, severity and duration of the 
disease. [2-12] 
Many publications in the literature describe the epidemiological and physical aspects of 
NTDs. In contrast, the impact of NTDs on paid and unpaid work and the productivity 
of individual men and women has been less frequently studied. Most of the data about 
the economic burden of NTDs come from small studies in restricted geographical 
areas.[13]  
The costs of treatment, mainly long-term ones, can inflict further economic difficulties 
in populations already struggling to live with less than US$ 1 a day. Besides the obvious 
advantages of decreasing the healthcare costs due to lack of care or delayed care, 
investments in health improvement would also help to increase economic growth of the 
affected regions since healthier populations are more economically productive. [14-16] 
As part of the movement to increase the attention given to NTDs, a coalition of many 
stakeholders gathered in January 2012 to discuss the importance of reaching the 2020 
WHO goals for this group of diseases. As a result, the London Declaration was signed 
by many partners, committed to eradicate Guinea worm disease, eliminate three NTDs 
(lymphatic filariasis, leprosy, African sleeping sickness (human African trypanosomiasis) 
and blinding trachoma) and control the others (schistosomiasis, soil-transmitted 




A better understanding of the effect that NTD have on people’s economic livelihood 
would be an additional argument in favor of controlling or eliminating them. With this 
in mind, we performed a systematic literature review to identify and examine publications 
describing the impact of the London Declaration NTDs. Here we present the results for 
the five most prevalent ones, which are the ones eligible for preventive chemotherapy 
(PCT diseases): lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted 
helminths (ascariasis, trichuriasis, and hookworm infection) and trachoma on 
productivity loss in adults. [7,19,20]  
 
Methods 
We performed a comprehensive search of the literature relating to the economic impact 
of all of the NTDs included in the London Declaration. Databases searched included 
Embase, Medline (OvidSp), Web of Science, Scopus, CINAHL, PubMed publisher, 
Cochrane, Popline, Lilacs, Scielo and Google Scholar. The search terms aimed at 
identifying articles about direct costs of treatment (such as consultation fees, medication, 
transport, food, assistance, accommodation), as well as indirect labor costs arising from 
decreased working hours and reduced economic activity attributable to morbidity. The 
search strategy included the names of the ten London Declaration NTDs (since many 
articles mention more than one) and words such as: ‘economic', 'financ', 'cost', 
'productivity', 'absenteeism', 'employment', and 'cost'. A detailed list of the keywords used 
for each database is found in Supporting Information (S1 File). The search only 
considered title and abstracts, did not use any time restriction, and was restricted to the 
English language. The main database search was conducted in November 2013. There is 
no review protocol registered. This search included not only productivity loss, but also 
direct costs for all 10 London Declaration NTDs for a larger project. The results found 
in this article are limited to the results of the literature search regarding productivity loss 
from PCT NTDs. 
The databases were merged according to the order shown in Table 1. Duplicates were 
removed automatically using Endnote and the remaining articles were then compared 
manually using author, year, title, journal, volume and pages to identify any additional 
duplicates. [21] After duplicates were excluded, we selected the articles that were related 
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to each particular disease and screened the abstract and title of all papers to identify the 
ones that might provide information on productivity or indirect costs. The full-text 
versions of all remaining articles were then examined. Articles that did not contain any 
information on productivity, or only qualitative information on productivity loss (without 
any quantitative measures) were excluded, as well as articles that investigated productivity 
loss in children. Since the number of relevant publications was expected to be small, no 
restrictions were made regarding populations (participants), interventions, comparisons, 
outcomes, study design, or length of follow-up. Articles that could not be retrieved 
through their respective journals, contacting libraries, or after contacting the authors 
were classified as ‘not available’ and excluded from the selection. Any additional relevant 
articles identified when reading the full-text articles or checking their reference lists (i.e., 
the ‘snowball’ search strategy) were screened using abstract and title and then examined 
in more detail if they were considered potentially relevant.  
In addition to searches using databases relating to the ‘white’ literature, we also searched 
the grey literature by screening websites of relevant organizations (i.e. World Health 
Organization, the Centre for Neglected Tropical Diseases, the Carter Center) (see S2 
File). The list of selected articles for each disease was sent to disease experts identified in 
the literature and from institutions researching/combating NTDs, to check if the 
selection was comprehensive.  
Data were extracted from selected articles independently, using a standardized Excel 
sheet, for the variables: author, year, study design, population, sample size, follow-up 
period, country, region, disease sequela, definition of productivity loss and results. 
Disease sequelae are disease manifestations, which for this review were defined by the 
Global Burden of Disease 2010 study (see S1 Table). [22] No summary measure was 
chosen beforehand. Instead, the results were presented separately per disease and study 
and described as they were reported in the articles; results were not statistically combined. 
If the productivity loss was not already described in percentages of annual productivity 
in the articles, we calculated it whenever the unit of measurement made it possible, for 
the sake of comparability between studies and diseases. A working year was assumed to 
consist of 300 working days. [23] 
 
 
Since the outcome of interest was productivity loss, various study designs were expected. 
The studies were therefore critically appraised regarding general criteria of selection, 
performance, attrition, detection, and reporting biases, as specified in the Cochrane 
Handbook for Systematic Reviews of Interventions. [24,25] Therefore, each article was 
given a rating regarding the risk of bias (possible options: low, high or unclear) for each 
criterion as well as a summary rating. [24,25] We added an extra criterion about the degree 
of relevance that the study outcomes defined as productivity loss had in terms of 
quantifying productivity loss in adults due to an NTD. This ‘relevance’ criterion was also 
rated as low or high. This review was conducted according to the PRISMA checklist for 
systematic reviews. 
Results 
Results of the database searches  
Table 1 provides an overview of the databases searched and the number of articles 
identified through each of them. In total, 11,449 articles regarding all 10 NTDs were 
identified using the database searches. Of these, 5,316 articles remained after duplicates 
were removed. There was no duplication across the various NTDs. 
Table 1. Results of database searches 
Database Hits After exclusion of duplicates 
Embase.com  2913 2854 
Medline (OvidSP)  2887 682 
Web-of-science   1224 478 
Scopus 3339 660 
CINAHL 282 126 
PubMed publisher  175 150 
Cochrane   60 7 
Popline 176 147 
Lilacs 257 100 
Scielo 36 26 
Google Scholar 100 87 
Total  11449 5316 
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From the main database, 281 peer reviewed papers were related to lymphatic filariasis 
(LF). The grey literature search and snowballing method added 24 more articles, resulting 
in 305 articles being screened by title and abstract. Of the 72 full-text publications that 
were examined, 13 quantitatively described productivity loss related to LF (S1 Fig).  
Lymphedema and hydrocele due to lymphatic filariasis are the two sequelae considered 
by the GBD study for this disease. Acute dermatolymphangioadenitis (ADLA) is part of 
these sequelae as acute inflammatory attacks suffered by most of the chronic patients, 
sometimes many times a year.[23] 
An overview of the studies that used a quantitative method to describe productivity loss 
from lymphatic filariasis can be seen in Table 2, together with the calculated percentages 
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Productivity loss in LF patients can occur because of ADLA or the chronic sequelae of 
the disease (lymphedema and hydrocele). Our search identified six studies that examined 
only the acute attacks (ADLA), five articles that described the impact of chronic sequelae, 
and two that measured both. 
The range in estimated productivity loss during ADLA attacks was 77-100% during the 
days of the attacks. The ranges in annual productivity loss reported in the literature were 
10-26% for lymphedema and 15-19% for hydrocele (only the chronic sequelae). 
However, studies of productivity loss due to lymphedema and hydrocele rarely 
considered the different stages and varying severity of these symptoms. Most of the 
studies describing productivity loss due to LF measured it by comparing lost working 
hours or days amongst workers with LF with those seen amongst healthy workers. 
Onchocerciasis 
Of the 5316 articles in the source database, only 167 articles were related to 
onchocerciasis. In addition, 52 articles were found through the ‘snowball’ search and grey 
literature sources, which meant that a total of 219 articles were screened on abstract and 
title. Of these, 57 articles remained for full-text examination; from which only 10 
contained quantitative information on productivity losses related to onchocerciasis (S2 
Fig). 
The GBD sequelae (disease manifestations) considered for onchocerciasis were skin 
disease and vision loss. 
Table 3 provides an overview of studies that have quantitatively examined productivity 
loss resulting from onchocerciasis. Only one study - by Thomson - reported productivity 
loss due to onchocerciasis in general, of 20%.[26] The other papers focused on the effects 
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Four studies examined productivity loss related to onchocerciasis skin disease (OSD) [27-
30]. Two of these studies compared Ethiopian coffee plantation workers with OSD to 
uninfected workers at the same plantation: Workneh et al.[28] concluded that workers 
with OSD had a one-year income that was 25% lower than that of healthy workers while 
Kim et al. [28] found 10-15% lower daily wages of individuals with OSD compared to 
those without. The study by Oladepo et al. [27] focused on the utilization of land and 
found that men with OSD had a significantly smaller (34%) amount of land than men 
without OSD. The study by the World Bank [30] found that individuals with 
onchocerciasis spent less time per day performing productive activities (farming and non-
farming) and household activities than healthy individuals. However, these differences 
were not statistically significant.  
Evans (1995) discussed the economic impact of blinding onchocerciasis [30], and found 
that visual acuity was strongly associated with occupational status. Approximately 80% 
of people that were blind due to onchocerciasis did not work, compared to 60% of the 
visually impaired (due to onchocerciasis) and 2% of the sighted.  
Three studies (Thomson [26]; Wogu et al. [32] and Okeibunor et al. [33]) described in 
more general terms the socioeconomic consequences of onchocerciasis. For instance, 
Wogu et al. [32] reported that 13.5% of individuals with onchocerciasis-related itching 
experienced reduced concentration at work. In addition, 14% of the individuals with 
ocular lesion reported that they gave up their jobs because of visual impairment. Similarly, 
Okeibunor et al. [33] found that 76% of their subjects reporting increased productivity 
after (community based) treatment with ivermectin. 
In addition to the observational studies of onchocerciasis-related productivity loss, we 
also identified several economic evaluations that considered productivity loss in their 
analyses. Two cost-benefit analyses, one by Benton and another by Kim, included 
productivity gains due to prevention of onchocerciasis blindness as part of the benefits 
of prevention. [34,35]. However, these gains were not actually observed in a patient 
population but based on the assumption that blind individuals are not productive at all. 
Kim et al. [35] assumed that each prevented case of blindness would result in 20 years of 
extra productivity. 
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From the main search database, 670 articles referred to schistosomiasis, including 
publications identified through ‘snowball’ searching and grey literature sources. Of these, 
26 articles were retrieved for full-text examination and eleven of them contained 
quantitative information on productivity losses caused by schistosomiasis (S3 Fig).  
Three different worms of the genus Schistosoma can cause schistosomiasis: Schistosoma 
haematobium, Schistosoma mansoni, and Schistosoma japonicum. Ten sequelae were included for 
schistosomiasis in the GBD study: mild diarrhea, mild anemia, moderate anemia, severe 
anemia, hepatomegaly, hematemesis, ascites, dysuria, bladder pathology, and 
hydronephrosis due to schistosomiasis.  
Table 4 provides a list of the studies investigating productivity loss attributable to 
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The studies vary regarding schistosomiasis being caused by S. haematobium, S. mansoni or 
S. japonica and also regarding the sequela they focused on. Most of the studies we 
identified compared productivity loss between infected and uninfected workers in a 
company or municipality, whereas Blas et al. and Wright et al. calculated the costs of 
productivity loss based on assumptions and not on empirical data. [36,37]  Productivity 
loss was also measured using different units: lost man-days/work days [38-41], reduced 
earnings/bonus/incentives [42-44], cane cut [45], and lost working hours [43]. 
Soil-transmitted helminths 
In total, 538 articles in the source database were related to soil-transmitted helminths 
(STH) -ascariasis, trichuriasis and hookworm disease. The snowballing method and the 
gray literature search yielded an additional 48 articles, which meant that 586 articles were 
screened by title and abstract. Of the 72 publications that were fully read, only 6 had 
information related to productivity loss and STH (S4 Fig).  
The GBD study lists the following sequelae related to each of the STH diseases: 
infestation, severe wasting, and mild abdominopelvic problems, as well as anemia only 
for hookworm disease.  
Table 5 shows the list of studies, the summary of their findings regarding productivity 
loss as a consequence of STH, and the yearly percentages that were calculated wherever 
needed. 
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Productivity loss from STH infection was generally measured by comparing infected to 
uninfected controls. Wolgemuth et al. observed that road construction workers with 
infection showed 6% less productivity (measured using volume of earth moved) than 
other workers. [46] Tanner et al. compared the agricultural and hunting or fishing yields 
reported in a 24-hour period among an indigenous Amazonian group of hunter–
horticulturalists. There was a negative association of hookworm infection for both 
women and men, with hookworm-infected people reporting an average quantity of crops 
that was 35.29% less than uninfected people (no statistical significance). [47] 
Productivity loss associated with anemia was mostly measured in women with three 
studies, by Casey et al., Gilgen et al., and Selvaratnam et al. [48-50] One study by Basta 
et al. investigated men [51] and one by Wolgemuth et al. investigated both women and 
men.[46] Two studies compared anemic versus non-anemic workers - Basta, and Gilgen 
[51,52], while three studies examined the productivity of the same individual twice, once 
while anemic and infected by STH and once after an intervention to increase the 
hemoglobin level - Casey, Selvaratnam, Wolgemuth [46,48,50], with or without 
deworming. The only randomized controlled trial was performed by Gilgen et al., 
assessing iron supplementation with and without deworming, with a significant negative 
association between hookworm infection and ferritin levels. Furthermore, anemic 
workers had a poorer performance regarding kilograms of leaves plucked and wages 
earned by day, as well as more sick and absent days compared to non-anemic workers. 
[52] There were two studies describing a positive linear association between hemoglobin 
and productivity. Selvaratnam et al found that an increase in 1g/dL in hemoglobin 
corresponded with an increase in 26% in a worker’s productivity. [50] Wolgemuth et al. 
described a linear increase in productivity ranging from 3.5% to 5.6% (depending on the 
formula used in the study) for each 1g/L in hemoglobin gain.[46]  
Trachoma 
In total, 538 articles from the initial search were related to trachoma and 11 articles were 
found through the ‘snowball’ search and grey literature sources, which led to a sum of 
549 articles that were screened on title and abstract. Of these, 22 articles remained for 
full-text examination (S5 Fig).  
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The only sequela considered by the GBD study for trachoma was vision loss (from low 
vision to blindness). 
A summary of the main features of the studies that investigated productivity loss due to 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































The only sequela considered by the GBD study for trachoma was vision loss (from low 
vision to blindness). 
A summary of the main features of the studies that investigated productivity loss due to 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of the studies we identified, none of them directly observed the extent of productivity 
loss caused by trachoma in a population. The three studies that examined this topic made 
assumptions about productivity loss in order to calculate the costs. [53-55] These studies 
assumed a productivity loss of either 60% or 100% for blindness and 24.5% for visual 
impairment and these percentages were based on the disability weights that existed at the 
time of the studies.  
Risk of bias 
Sixty percent of the selected articles had a high overall risk of bias (26 articles of 42), 
mostly due to detection bias (24 of 42 articles), selection bias (21 articles of 42), and 
attrition bias (10 of 42 articles). Twenty-two articles were rated as relevant, and of these 
studies, two-thirds (14/21) had a high overall risk of bias, 2 had a low overall risk of bias 
and 6 had an unclear overall risk. Only 6 articles had a low overall risk of bias, of which 
only 2 were relevant, and 9 had an unclear summary rating, of which 6 were relevant (as 
described before). No particular trend was observed, regarding over- or underestimation 




Neglected tropical diseases can have a profound effect on the health and economic 
livelihood of the individuals suffering from them as well as that of their families. We 
examined what has been published in the literature regarding the loss in productivity seen 
amongst patients with the NTDs that are eligible for preventive chemotherapy: lymphatic 
filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, 
trichuriasis, and hookworm infection) and trachoma. In general, our systematic literature 
review revealed that few studies have actually examined the degree of productivity loss 
related to these NTDs, which to some extent might have been influenced by the focus 
on literature written in English. Table 7 shows a summary of the flowcharts for all PCT 
NTDs, which shows the relatively small numbers of articles containing quantitative 
information on productivity loss related to PCT NTDs compared to the number of the 
publications screened by title and abstract. 
 
 




Onchocerciasis Schistosomiasis STH Trachoma 
Papers screened on 
title and abstract 
305 219 670 586 549 
Assessed full text 72 57 26 72 22 
Studies with 
quantitative info on 
productivity losses 
13 10 10 6 3 
 
We also found large variation in the definition of productivity loss as well as the estimated 
productivity loss as reflected in percentage productivity loss over a one-year period. This 
is not surprising given the diversity in the methods chosen to quantify absolute and 
relative productivity loss, the many symptoms that these NTDs can cause, and the many 
different contexts of the different countries and regions where these diseases are 
endemic. 
Many of these studies were performed many years ago and involved very specific 
populations in specific countries. However, besides biological reasons, there are 
methodological reasons for this variation. One explanation is simply random variation, 
where the results of two studies with the very same study design simply differ due to 
chance. A more important issue relates to the fact that studies varied in their approach 
when examining productivity loss. First of all, studies varied in their selection of the study 
population. Many studies focused on workers on large plantations, while others observed 
road workers, and the different studies were performed in different settings and 
countries, which might differ in important ways from other professions and other 
populations suffering from the same NTD elsewhere. The generalizability of the results 
from one study to another population must therefore be carefully considered.  
The second type of variation in study design relates to the choice of comparison group. 
Most studies chose workers who did not have the NTD as the comparison group (only 
one, Gyapong 1996, compared patients with lymphatic filariasis with patients with other 
febrile diseases). The sometimes tacit assumption made with this comparison is that any 
difference in productivity can be attributed to the NTD and its symptoms. However, the 
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validity of this comparison can be questioned, certainly if no correction is made for 
background characteristics such as age, sex, job experience, diet, height, and BMI (body 
mass index), which can affect productivity. Fortunately, some but not all studies included 
these factors when analyzing and reporting their results. Other studies did not compare 
two different populations but used a before-after study design to see how much 
productivity improved after treatment. This approach focuses directly on the productivity 
gain that can be achieved using available treatments.  
The third type of variation relates to the actual measure of productivity. Many studies 
used the number of hours or days to quantify productivity. In contrast, some studies used 
other, arguably more accurate, methods which involved examining the volumes that were 
actually collected or processed per day (i.e. how many kilograms of tea were plucked per 
day). [47] Some studies even used multiple outcomes to study productivity loss. 
Ultimately, one could argue that the choice of outcome measure should be based on what 
a decision-maker considers important. For example, an employer might be particularly 
interested in volume outcomes since workers with an NTD who never miss a day at work 
may nevertheless be less productive than other workers. Another point worth 
considering when measuring productivity loss is that the adjustment of worker behavior 
and the associations between nutrition, body composition, and work productivity may 
be more complex. Workers might adapt work pace or intensity, allowing them to 
minimize the effects of poor health on work productivity. [47]  
The fourth type of variation relates to the length of time that productivity loss is 
measured. Most studies used a fixed length of time (e.g., year) when measuring 
productivity, also to account for seasonality, which could also influence productivity 
along the year. In some instances, however, the length of time was disease-based (e.g., 
length of an episode). This approach may reveal that productivity loss is very high 
(>50%) if the symptoms are extreme, but the impact of disease on productivity over a 
longer period (e.g., one year) may be small if these episodes last just a few days and only 
occur a couple of times per year.  
Other limitations of the studies are worth mentioning. Firstly, many studies did not check 
for other concomitant NTDs prevalent in the same region. One possible reason for this 
could be the assumption that the control group has the same risk to be affected by the 
 
 
non-investigated disease as the case group. Secondly, measurement of productivity loss 
in working populations may lead to an underestimation of impact due to the ‘healthy 
worker effect’, since people who had to stop working because of the disease are excluded 
from the study [38]. Thirdly, most of the studies that diagnosed NTDs using stool 
examination took only one sample, which resulted in a high probability of false negatives  
and a possible underestimation of productivity loss due to the NTD. [56-58] Lastly, 
correction of hemoglobin levels for altitude or for smoking status of the patients was not 
mentioned by any of the anemia studies, which could also lead to an underestimation of 
the productivity loss. [59] 
Based on the literature, the NTDs with the greatest impact on an individual’s productivity 
loss are onchocerciasis and trachoma, because both of them can lead to blindness. The 
studies of actual patients revealed an increased likelihood of stopping with work or a 
substantial decrease in productivity. However, other studies simply assumed that 
productivity loss would be high. 
It is important to distinguish between productivity loss at an individual level from 
productivity loss at a population level. For example, while the individual productivity loss 
from an NTD like STH may be much less than loss from another NTD like 
onchocerciasis, the overall impact of STH at a population level may be greater than that 
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quintile in India in 2005) and an average productivity loss due to hookworm anemia of 
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years or countries are considered. These estimates can help to estimate the impact on 
productivity of achieving the targets described in the 2012 London Declaration. [18] 
Some recommendations regarding future studies of productivity loss can also be made. 
The assessment of productivity loss secondary to NTDs should be further researched to 
enable a better understanding of the economic burden it generates. Additional research 
is needed to develop standard methods to describe absolute and relative productivity loss. 
However, this will not be an easy task, given the diverse symptoms caused by these 
diseases and the variety of countries and cultures where these diseases are endemic; with 
some NTDs such as lymphatic filariasis, a distinction between treated and untreated 
patients will have to be made as well. As described above, there are some factors that 
should be considered when designing future studies: the choice of the comparison group 
(preferably a comparable assuredly non-infected group), the outcome measure assessing 
productivity (preferably quantitative), the length of the assessment (not only during acute 
attacks, accounting for seasonal variation), and confounders of the disease effect on the 
productivity/work performance (for instance nutrition, BMI, type of work/profession). 
These elements should be transparently described and their (missing) values discussed, 
to determine how much they might have influenced the results. In particular, researchers 
should provide sufficiently detailed information to enable readers to assess the quality 
and relevance of the study. 
 
Conclusion 
Various studies have examined productivity loss in patient populations having one of the 
five most prevalent NTDs. While is clear that these diseases reduce productivity, the 
actual impact depends on the type, severity and duration of the NTD as well as on the 
setting. Variation in estimated productivity loss between and within diseases is caused by 
differences in the different definition of productivity loss, research methods and setting. 
It is therefore important to examine the literature carefully to understand what was 
actually observed in order to draw conclusions about the generalizability of the studies. 
Since productivity loss is an important aspect of the burden of diseases, further research 
on better estimates of the magnitude of the productivity loss caused by NTDs would 
 
 
enable a more complete picture of their economic burden to individuals, countries, and 
globally, adding an additional persuasive argument in favor of their control. 
This review already contributes to a better perception of the magnitude of the effect of 
an NTD on people’s working and economic situation, and can already offer additional 
arguments in favor of controlling and eliminating them. However, there is still much 
room for further research in this field to improve the understanding on NTDs’ effects 
on individuals’ productivity loss. 
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Supporting Information  
S1 File. Literature Search Syntax 
Embase.com  
('African trypanosomiasis'/de OR 'Chagas disease'/de OR 'trypanosomatid 
infection'/exp OR leprosy/exp OR 'Helminthiasis'/de OR 'Ascariasis'/de OR 
'Trichuriasis'/de  OR 'Hookworm infection'/exp OR 'Schistosomiasis'/exp OR 
'Trachoma'/de OR 'Chlamydiasis'/de OR 'Chlamydiaceae infection'/de OR 
'Dracunculiasis'/de OR 'Lymphatic filariasis'/exp OR 'Elephantiasis'/de OR 
'Filariasis'/de OR 'Onchocerciasis'/de OR (((sleeping OR Hansen* OR neglected OR 
Robles) NEAR/3 (disease* OR sickness)) OR ((NTD* OR GWD) AND disease*) OR 
Chagas* OR leishmaniasis OR trypanosomiasis OR ((leishmania OR trypanosom* OR 
schizotrypanum OR worm* OR hookworm* OR whipworm* OR ancylostoma* OR 
Euglenoz* OR kinetoplast*) AND (infect* OR infestat* OR disease* OR transmiss*)) 
OR 'black fever' OR 'kala azar' OR lepros* OR lepra* OR helminth* OR ascari* OR 
trichuria* OR trichocephal* OR bunostomias* OR schistosom* OR bilharzi* OR 
'Katayama fever' OR Trachoma* OR 'Egyptian ophthalmia' OR (chlamydia NEAR/3 
conjunctiv*) OR dracuncul* OR draconti* OR filari* OR philar* OR wucher* OR 
brugia* OR elephantias* OR onchocerc* OR (river NEXT/1 blindness)):ab,ti) AND  
(productivity/de OR absenteeism/de OR 'job performance'/de OR 'return to work'/de 
OR 'work capacity'/de OR 'working time'/de OR 'cost of illness'/de OR 'patient 
transport'/de OR income/de OR salary/de OR 'medical leave'/de OR workload/de OR 
retirement/de OR employment/exp OR unemployment/de OR (((economic* OR 
financ* OR cost* OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 
(patient* OR individual* OR personal* OR household)) OR fee OR fees OR productivit* 
OR unproductivit* OR absenteeis* OR presenteeis* OR ((job OR work* OR profession* 
OR occupation* OR labour) NEAR/3 (perform* OR efficien* OR return* OR back OR 
capacit* OR abilit* OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing 
OR restrict* OR reduct* OR input*)) OR (work* NEXT/1 (time OR week* OR day* 
OR load*)) OR workweek* OR workday* OR ((caregiver* OR illness* OR disease*) 
NEAR/3 burden) OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR 
physician* OR 'health care')) OR 'patient transport' OR 'health shock' OR income* OR 
 
 
salary OR salaries OR payment* OR ((medical OR sick) NEXT/1 leave) OR workload* 
OR 'time off work' OR retire* OR employment* OR employed* OR unemploy* OR 
'societal perspective' OR 'human capital' OR 'friction cost' OR 'lost time' ):ab,ti)  NOT 
([animals]/lim NOT [humans]/lim) 
Medline (OvidSP)  
("Trypanosomiasis, African"/ OR exp "Chagas disease"/ OR exp "Euglenozoa 
Infections"/ OR exp leprosy/ OR "Helminthiasis"/ OR "Ascariasis"/ OR 
"Trichuriasis"/ OR exp "Hookworm infection"/ OR exp "Schistosomiasis"/ OR 
"Trachoma"/ OR "Chlamydiaceae Infections"/ OR "Chlamydia Infections"/ OR 
"Dracunculiasis"/ OR "Elephantiasis, Filarial"/ OR "Elephantiasis"/ OR "Filariasis"/ 
OR exp "Onchocerciasis"/ OR (((sleeping OR Hansen* OR neglected OR Robles) ADJ3 
(disease* OR sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR 
leishmaniasis OR trypanosomiasis OR ((leishmania OR trypanosom* OR 
schizotrypanum OR worm* OR hookworm* OR whipworm* OR ancylostoma* OR 
Euglenoz* OR kinetoplast*) AND (infect* OR infestat* OR disease* OR transmiss*)) 
OR "black fever" OR "kala azar" OR lepros* OR lepra* OR helminth* OR ascari* OR 
trichuria* OR trichocephal* OR bunostomias* OR schistosom* OR bilharzi* OR 
"Katayama fever" OR Trachoma* OR "Egyptian ophthalmia" OR (chlamydia ADJ3 
conjunctiv*) OR dracuncul* OR draconti* OR filari* OR philar* OR wucher* OR 
brugia* OR elephantias* OR onchocerc* OR (river ADJ blindness)).ab,ti.) AND  
("Psychology, Industrial"/ OR absenteeism/ OR exp "Task Performance and Analysis"/ 
OR "underachievement"/ OR "return to work"/ OR "Work Capacity Evaluation"/ OR 
"cost of illness"/ OR exp "Transportation of Patients"/ OR exp income/ OR workload/ 
OR retirement/ OR employment/ OR unemployment/ OR "Health Services 
Accessibility"/ OR (((economic* OR financ* OR cost* OR pharmacoeconomic* OR 
expend* OR expens*) ADJ3 (patient* OR individual* OR personal* OR household)) 
OR fee OR fees OR productivit* OR unproductivit* OR absenteeis* OR presenteeis* 
OR ((job OR work* OR profession* OR occupation* OR labour) ADJ3 (perform* OR 
efficien* OR return* OR back OR capacit* OR abilit* OR disabilit* OR unab* OR limit* 
OR impair* OR loss OR losing OR restrict* OR reduct* OR input*)) OR (work* ADJ 
(time OR week* OR day* OR load*)) OR workweek* OR workday* OR ((caregiver* OR 
illness* OR disease*) ADJ3 burden) OR (distan* ADJ3 (hospital* OR facilit* OR doctor* 
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Embase.com  
('African trypanosomiasis'/de OR 'Chagas disease'/de OR 'trypanosomatid 
infection'/exp OR leprosy/exp OR 'Helminthiasis'/de OR 'Ascariasis'/de OR 
'Trichuriasis'/de  OR 'Hookworm infection'/exp OR 'Schistosomiasis'/exp OR 
'Trachoma'/de OR 'Chlamydiasis'/de OR 'Chlamydiaceae infection'/de OR 
'Dracunculiasis'/de OR 'Lymphatic filariasis'/exp OR 'Elephantiasis'/de OR 
'Filariasis'/de OR 'Onchocerciasis'/de OR (((sleeping OR Hansen* OR neglected OR 
Robles) NEAR/3 (disease* OR sickness)) OR ((NTD* OR GWD) AND disease*) OR 
Chagas* OR leishmaniasis OR trypanosomiasis OR ((leishmania OR trypanosom* OR 
schizotrypanum OR worm* OR hookworm* OR whipworm* OR ancylostoma* OR 
Euglenoz* OR kinetoplast*) AND (infect* OR infestat* OR disease* OR transmiss*)) 
OR 'black fever' OR 'kala azar' OR lepros* OR lepra* OR helminth* OR ascari* OR 
trichuria* OR trichocephal* OR bunostomias* OR schistosom* OR bilharzi* OR 
'Katayama fever' OR Trachoma* OR 'Egyptian ophthalmia' OR (chlamydia NEAR/3 
conjunctiv*) OR dracuncul* OR draconti* OR filari* OR philar* OR wucher* OR 
brugia* OR elephantias* OR onchocerc* OR (river NEXT/1 blindness)):ab,ti) AND  
(productivity/de OR absenteeism/de OR 'job performance'/de OR 'return to work'/de 
OR 'work capacity'/de OR 'working time'/de OR 'cost of illness'/de OR 'patient 
transport'/de OR income/de OR salary/de OR 'medical leave'/de OR workload/de OR 
retirement/de OR employment/exp OR unemployment/de OR (((economic* OR 
financ* OR cost* OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 
(patient* OR individual* OR personal* OR household)) OR fee OR fees OR productivit* 
OR unproductivit* OR absenteeis* OR presenteeis* OR ((job OR work* OR profession* 
OR occupation* OR labour) NEAR/3 (perform* OR efficien* OR return* OR back OR 
capacit* OR abilit* OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing 
OR restrict* OR reduct* OR input*)) OR (work* NEXT/1 (time OR week* OR day* 
OR load*)) OR workweek* OR workday* OR ((caregiver* OR illness* OR disease*) 
NEAR/3 burden) OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR 
physician* OR 'health care')) OR 'patient transport' OR 'health shock' OR income* OR 
 
 
salary OR salaries OR payment* OR ((medical OR sick) NEXT/1 leave) OR workload* 
OR 'time off work' OR retire* OR employment* OR employed* OR unemploy* OR 
'societal perspective' OR 'human capital' OR 'friction cost' OR 'lost time' ):ab,ti)  NOT 
([animals]/lim NOT [humans]/lim) 
Medline (OvidSP)  
("Trypanosomiasis, African"/ OR exp "Chagas disease"/ OR exp "Euglenozoa 
Infections"/ OR exp leprosy/ OR "Helminthiasis"/ OR "Ascariasis"/ OR 
"Trichuriasis"/ OR exp "Hookworm infection"/ OR exp "Schistosomiasis"/ OR 
"Trachoma"/ OR "Chlamydiaceae Infections"/ OR "Chlamydia Infections"/ OR 
"Dracunculiasis"/ OR "Elephantiasis, Filarial"/ OR "Elephantiasis"/ OR "Filariasis"/ 
OR exp "Onchocerciasis"/ OR (((sleeping OR Hansen* OR neglected OR Robles) ADJ3 
(disease* OR sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR 
leishmaniasis OR trypanosomiasis OR ((leishmania OR trypanosom* OR 
schizotrypanum OR worm* OR hookworm* OR whipworm* OR ancylostoma* OR 
Euglenoz* OR kinetoplast*) AND (infect* OR infestat* OR disease* OR transmiss*)) 
OR "black fever" OR "kala azar" OR lepros* OR lepra* OR helminth* OR ascari* OR 
trichuria* OR trichocephal* OR bunostomias* OR schistosom* OR bilharzi* OR 
"Katayama fever" OR Trachoma* OR "Egyptian ophthalmia" OR (chlamydia ADJ3 
conjunctiv*) OR dracuncul* OR draconti* OR filari* OR philar* OR wucher* OR 
brugia* OR elephantias* OR onchocerc* OR (river ADJ blindness)).ab,ti.) AND  
("Psychology, Industrial"/ OR absenteeism/ OR exp "Task Performance and Analysis"/ 
OR "underachievement"/ OR "return to work"/ OR "Work Capacity Evaluation"/ OR 
"cost of illness"/ OR exp "Transportation of Patients"/ OR exp income/ OR workload/ 
OR retirement/ OR employment/ OR unemployment/ OR "Health Services 
Accessibility"/ OR (((economic* OR financ* OR cost* OR pharmacoeconomic* OR 
expend* OR expens*) ADJ3 (patient* OR individual* OR personal* OR household)) 
OR fee OR fees OR productivit* OR unproductivit* OR absenteeis* OR presenteeis* 
OR ((job OR work* OR profession* OR occupation* OR labour) ADJ3 (perform* OR 
efficien* OR return* OR back OR capacit* OR abilit* OR disabilit* OR unab* OR limit* 
OR impair* OR loss OR losing OR restrict* OR reduct* OR input*)) OR (work* ADJ 
(time OR week* OR day* OR load*)) OR workweek* OR workday* OR ((caregiver* OR 
illness* OR disease*) ADJ3 burden) OR (distan* ADJ3 (hospital* OR facilit* OR doctor* 







OR physician* OR "health care")) OR "patient transport" OR "health shock" OR 
income* OR salary OR salaries OR payment* OR ((medical OR sick) ADJ leave) OR 
workload* OR "time off work" OR retire* OR employment* OR employed* OR 
unemploy* OR "societal perspective" OR "human capital" OR "friction cost" OR "lost 
time").ab,ti.)  NOT (exp animals/ NOT humans/) 
 
 
Cochrane   
((((sleeping OR Hansen* OR neglected OR Robles) NEAR/3 (disease* OR sickness)) 
OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis OR 
trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR 
hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND 
(infect* OR infestat* OR disease* OR transmiss*)) OR 'black fever' OR 'kala azar' OR 
lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR 
bunostomias* OR schistosom* OR bilharzi* OR 'Katayama fever' OR Trachoma* OR 
'Egyptian ophthalmia' OR (chlamydia NEAR/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river NEXT/1 blindness)):ab,ti) AND  ((((economic* OR financ* OR 
cost* OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 (patient* OR 
individual* OR personal* OR household)) OR fee OR fees OR productivit* OR 
unproductivit* OR absenteeis* OR presenteeis* OR ((job OR work* OR profession* 
OR occupation* OR labour) NEAR/3 (perform* OR efficien* OR return* OR back OR 
capacit* OR abilit* OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing 
OR restrict* OR reduct* OR input*)) OR (work* NEXT/1 (time OR week* OR day* 
OR load*)) OR workweek* OR workday* OR ((caregiver* OR illness* OR disease*) 
NEAR/3 burden) OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR 
physician* OR 'health care')) OR 'patient transport' OR 'health shock' OR income* OR 
salary OR salaries OR payment* OR ((medical OR sick) NEXT/1 leave) OR workload* 
OR 'time off work' OR retire* OR employment* OR employed* OR unemploy* OR 
'societal perspective' OR 'human capital' OR 'friction cost' OR 'lost time'):ab,ti)  
 
 
Web-of-science   
TS=(((((sleeping OR Hansen* OR neglected OR Robles) NEAR/3 (disease* OR 
sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis OR 
trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR 
hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND 
(infect* OR infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala azar" OR 
lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR 
bunostomias* OR schistosom* OR bilharzi* OR "Katayama fever" OR Trachoma* OR 
"Egyptian ophthalmia" OR (chlamydia NEAR/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river NEAR/1 blindness))) AND  ((((economic* OR financ* OR cost* 
OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 (patient* OR individual* 
OR personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) NEAR/3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* 
OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR 
reduct* OR input*)) OR (work* NEAR/1 (time OR week* OR day* OR load*)) OR 
workweek* OR workday* OR ((caregiver* OR illness* OR disease*) NEAR/3 burden) 
OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR physician* OR "health 
care")) OR "patient transport" OR "health shock" OR income* OR salary OR salaries 
OR payment* OR ((medical OR sick) NEAR/1 leave) OR workload* OR "time off 
work" OR retire* OR employment* OR employed* OR unemploy* OR "societal 
perspective" OR "human capital" OR "friction cost" OR "lost time")) AND (human* 
OR patient*))  
Scopus    
TITLE-ABS-KEY(((((sleeping OR Hansen* OR neglected OR Robles) W/3 (disease* 
OR sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis 
OR trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* 
OR hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) 
AND (infect* OR infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala 
azar" OR lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* 







OR physician* OR "health care")) OR "patient transport" OR "health shock" OR 
income* OR salary OR salaries OR payment* OR ((medical OR sick) ADJ leave) OR 
workload* OR "time off work" OR retire* OR employment* OR employed* OR 
unemploy* OR "societal perspective" OR "human capital" OR "friction cost" OR "lost 
time").ab,ti.)  NOT (exp animals/ NOT humans/) 
 
 
Cochrane   
((((sleeping OR Hansen* OR neglected OR Robles) NEAR/3 (disease* OR sickness)) 
OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis OR 
trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR 
hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND 
(infect* OR infestat* OR disease* OR transmiss*)) OR 'black fever' OR 'kala azar' OR 
lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR 
bunostomias* OR schistosom* OR bilharzi* OR 'Katayama fever' OR Trachoma* OR 
'Egyptian ophthalmia' OR (chlamydia NEAR/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river NEXT/1 blindness)):ab,ti) AND  ((((economic* OR financ* OR 
cost* OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 (patient* OR 
individual* OR personal* OR household)) OR fee OR fees OR productivit* OR 
unproductivit* OR absenteeis* OR presenteeis* OR ((job OR work* OR profession* 
OR occupation* OR labour) NEAR/3 (perform* OR efficien* OR return* OR back OR 
capacit* OR abilit* OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing 
OR restrict* OR reduct* OR input*)) OR (work* NEXT/1 (time OR week* OR day* 
OR load*)) OR workweek* OR workday* OR ((caregiver* OR illness* OR disease*) 
NEAR/3 burden) OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR 
physician* OR 'health care')) OR 'patient transport' OR 'health shock' OR income* OR 
salary OR salaries OR payment* OR ((medical OR sick) NEXT/1 leave) OR workload* 
OR 'time off work' OR retire* OR employment* OR employed* OR unemploy* OR 
'societal perspective' OR 'human capital' OR 'friction cost' OR 'lost time'):ab,ti)  
 
 
Web-of-science   
TS=(((((sleeping OR Hansen* OR neglected OR Robles) NEAR/3 (disease* OR 
sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis OR 
trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR 
hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND 
(infect* OR infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala azar" OR 
lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR 
bunostomias* OR schistosom* OR bilharzi* OR "Katayama fever" OR Trachoma* OR 
"Egyptian ophthalmia" OR (chlamydia NEAR/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river NEAR/1 blindness))) AND  ((((economic* OR financ* OR cost* 
OR pharmacoeconomic* OR expend* OR expens*) NEAR/3 (patient* OR individual* 
OR personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) NEAR/3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* 
OR disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR 
reduct* OR input*)) OR (work* NEAR/1 (time OR week* OR day* OR load*)) OR 
workweek* OR workday* OR ((caregiver* OR illness* OR disease*) NEAR/3 burden) 
OR (distan* NEAR/3 (hospital* OR facilit* OR doctor* OR physician* OR "health 
care")) OR "patient transport" OR "health shock" OR income* OR salary OR salaries 
OR payment* OR ((medical OR sick) NEAR/1 leave) OR workload* OR "time off 
work" OR retire* OR employment* OR employed* OR unemploy* OR "societal 
perspective" OR "human capital" OR "friction cost" OR "lost time")) AND (human* 
OR patient*))  
Scopus    
TITLE-ABS-KEY(((((sleeping OR Hansen* OR neglected OR Robles) W/3 (disease* 
OR sickness)) OR ((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis 
OR trypanosomiasis OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* 
OR hookworm* OR whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) 
AND (infect* OR infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala 
azar" OR lepros* OR lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* 







OR bunostomias* OR schistosom* OR bilharzi* OR "Katayama fever" OR Trachoma* 
OR "Egyptian ophthalmia" OR (chlamydia W/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river W/1 blindness))) AND  ((((economic* OR financ* OR cost* OR 
pharmacoeconomic* OR expend* OR expens*) W/3 (patient* OR individual* OR 
personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) W/3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* OR 
disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR reduct* 
OR input*)) OR (work* W/1 (time OR week* OR day* OR load*)) OR workweek* OR 
workday* OR ((caregiver* OR illness* OR disease*) W/3 burden) OR (distan* W/3 
(hospital* OR facilit* OR doctor* OR physician* OR "health care")) OR "patient 
transport" OR "health shock" OR income* OR salary OR salaries OR payment* OR 
((medical OR sick) W/1 leave) OR workload* OR "time off work" OR retire* OR 
employment* OR employed* OR unemploy* OR "societal perspective" OR "human 
capital" OR "friction cost" OR "lost time")) AND (human* OR patient*))  
CINAHL  
(MH "Trypanosomiasis" OR MH Leishmaniasis OR MH leprosy OR MH 
"Helminthiasis+" OR MH "Ascariasis" OR MH "Hookworm infections" OR MH 
"Schistosomiasis+" OR MH "Trachoma+" OR MH "Chlamydiaceae Infections+" OR 
MH "Chlamydia Infections+" OR MH "Dracunculiasis" OR MH "Elephantiasis, 
Filarial+" OR MH "Elephantiasis" OR MH "Filariasis" OR MH "Onchocerciasis+" OR 
(((sleeping OR Hansen* OR neglected OR Robles) N3 (disease* OR sickness)) OR 
((NTD* OR GWD) AND disease*) OR Chagas* OR leishmaniasis OR trypanosomiasis 
OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR hookworm* OR 
whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND (infect* OR 
infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala azar" OR lepros* OR 
lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR bunostomias* OR 
schistosom* OR bilharzi* OR "Katayama fever" OR Trachoma* OR "Egyptian 
ophthalmia" OR (chlamydia N3 conjunctiv*) OR dracuncul* OR draconti* OR filari* 
OR philar* OR wucher* OR brugia* OR elephantias* OR onchocerc* OR (river N1 
blindness))) AND  (MH "Psychology, Occupational+" OR MH absenteeism+ OR MH 
 
 
"Task Performance and Analysis+" OR MH "Job Re-Entry+" OR MH "Job 
Performance" OR MH "Work Capacity Evaluation+" OR MH "Economic Aspects of 
Illness+" OR MH "Transportation of Patients+" OR MH income+ OR MH workload+ 
OR MH retirement+ OR MH employment+ OR MH unemployment+ OR MH "Health 
Services Accessibility+" OR (((economic* OR financ* OR cost* OR 
pharmacoeconomic* OR expend* OR expens*) N3 (patient* OR individual* OR 
personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) N3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* OR 
disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR reduct* 
OR input*)) OR (work* N1 (time OR week* OR day* OR load*)) OR workweek* OR 
workday* OR ((caregiver* OR illness* OR disease*) N3 burden) OR (distan* N3 
(hospital* OR facilit* OR doctor* OR physician* OR "health care")) OR "patient 
transport" OR "health shock" OR income* OR salary OR salaries OR payment* OR 
((medical OR sick) N1 leave) OR workload* OR "time off work" OR retire* OR 
employment* OR employed* OR unemploy* OR "societal perspective" OR "human 
capital" OR "friction cost" OR "lost time"))  NOT (MH animals+ NOT humans+) 
PubMed publisher  
((((sleeping[tiab] OR Hansen*[tiab] OR neglected[tiab] OR Robles[tiab]) AND 
(disease*[tiab] OR sickness[tiab])) OR ((NTD*[tiab] OR GWD[tiab]) AND 
disease*[tiab]) OR Chagas*[tiab] OR leishmaniasis[tiab] OR trypanosomiasis[tiab] OR 
((leishmania[tiab] OR trypanosom*[tiab] OR schizotrypanum[tiab] OR worm*[tiab] OR 
hookworm*[tiab] OR whipworm*[tiab] OR ancylostoma*[tiab] OR Euglenoz*[tiab] OR 
kinetoplast*[tiab]) AND (infect*[tiab] OR infestat*[tiab] OR disease*[tiab] OR 
transmiss*[tiab])) OR black fever[tiab] OR kala azar[tiab] OR lepros*[tiab] OR 
lepra*[tiab] OR helminth*[tiab] OR ascari*[tiab] OR trichuria*[tiab] OR 
trichocephal*[tiab] OR bunostomias*[tiab] OR schistosom*[tiab] OR bilharzi*[tiab] OR 
Katayama fever[tiab] OR Trachoma*[tiab] OR Egyptian ophthalmia[tiab] OR 
(chlamydia[tiab] AND conjunctiv*[tiab]) OR dracuncul*[tiab] OR draconti*[tiab] OR 
filari*[tiab] OR philar*[tiab] OR wucher*[tiab] OR brugia*[tiab] OR elephantias*[tiab] 
OR onchocerc*[tiab] OR (river blindness[tiab]))) AND  ((((economic*[tiab] OR 
financ*[tiab] OR cost*[tiab] OR pharmacoeconomic*[tiab] OR expend*[tiab] OR 
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OR "Egyptian ophthalmia" OR (chlamydia W/3 conjunctiv*) OR dracuncul* OR 
draconti* OR filari* OR philar* OR wucher* OR brugia* OR elephantias* OR 
onchocerc* OR (river W/1 blindness))) AND  ((((economic* OR financ* OR cost* OR 
pharmacoeconomic* OR expend* OR expens*) W/3 (patient* OR individual* OR 
personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) W/3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* OR 
disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR reduct* 
OR input*)) OR (work* W/1 (time OR week* OR day* OR load*)) OR workweek* OR 
workday* OR ((caregiver* OR illness* OR disease*) W/3 burden) OR (distan* W/3 
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OR ((leishmania OR trypanosom* OR schizotrypanum OR worm* OR hookworm* OR 
whipworm* OR ancylostoma* OR Euglenoz* OR kinetoplast*) AND (infect* OR 
infestat* OR disease* OR transmiss*)) OR "black fever" OR "kala azar" OR lepros* OR 
lepra* OR helminth* OR ascari* OR trichuria* OR trichocephal* OR bunostomias* OR 
schistosom* OR bilharzi* OR "Katayama fever" OR Trachoma* OR "Egyptian 
ophthalmia" OR (chlamydia N3 conjunctiv*) OR dracuncul* OR draconti* OR filari* 
OR philar* OR wucher* OR brugia* OR elephantias* OR onchocerc* OR (river N1 
blindness))) AND  (MH "Psychology, Occupational+" OR MH absenteeism+ OR MH 
 
 
"Task Performance and Analysis+" OR MH "Job Re-Entry+" OR MH "Job 
Performance" OR MH "Work Capacity Evaluation+" OR MH "Economic Aspects of 
Illness+" OR MH "Transportation of Patients+" OR MH income+ OR MH workload+ 
OR MH retirement+ OR MH employment+ OR MH unemployment+ OR MH "Health 
Services Accessibility+" OR (((economic* OR financ* OR cost* OR 
pharmacoeconomic* OR expend* OR expens*) N3 (patient* OR individual* OR 
personal* OR household)) OR fee OR fees OR productivit* OR unproductivit* OR 
absenteeis* OR presenteeis* OR ((job OR work* OR profession* OR occupation* OR 
labour) N3 (perform* OR efficien* OR return* OR back OR capacit* OR abilit* OR 
disabilit* OR unab* OR limit* OR impair* OR loss OR losing OR restrict* OR reduct* 
OR input*)) OR (work* N1 (time OR week* OR day* OR load*)) OR workweek* OR 
workday* OR ((caregiver* OR illness* OR disease*) N3 burden) OR (distan* N3 
(hospital* OR facilit* OR doctor* OR physician* OR "health care")) OR "patient 
transport" OR "health shock" OR income* OR salary OR salaries OR payment* OR 
((medical OR sick) N1 leave) OR workload* OR "time off work" OR retire* OR 
employment* OR employed* OR unemploy* OR "societal perspective" OR "human 
capital" OR "friction cost" OR "lost time"))  NOT (MH animals+ NOT humans+) 
PubMed publisher  
((((sleeping[tiab] OR Hansen*[tiab] OR neglected[tiab] OR Robles[tiab]) AND 
(disease*[tiab] OR sickness[tiab])) OR ((NTD*[tiab] OR GWD[tiab]) AND 
disease*[tiab]) OR Chagas*[tiab] OR leishmaniasis[tiab] OR trypanosomiasis[tiab] OR 
((leishmania[tiab] OR trypanosom*[tiab] OR schizotrypanum[tiab] OR worm*[tiab] OR 
hookworm*[tiab] OR whipworm*[tiab] OR ancylostoma*[tiab] OR Euglenoz*[tiab] OR 
kinetoplast*[tiab]) AND (infect*[tiab] OR infestat*[tiab] OR disease*[tiab] OR 
transmiss*[tiab])) OR black fever[tiab] OR kala azar[tiab] OR lepros*[tiab] OR 
lepra*[tiab] OR helminth*[tiab] OR ascari*[tiab] OR trichuria*[tiab] OR 
trichocephal*[tiab] OR bunostomias*[tiab] OR schistosom*[tiab] OR bilharzi*[tiab] OR 
Katayama fever[tiab] OR Trachoma*[tiab] OR Egyptian ophthalmia[tiab] OR 
(chlamydia[tiab] AND conjunctiv*[tiab]) OR dracuncul*[tiab] OR draconti*[tiab] OR 
filari*[tiab] OR philar*[tiab] OR wucher*[tiab] OR brugia*[tiab] OR elephantias*[tiab] 
OR onchocerc*[tiab] OR (river blindness[tiab]))) AND  ((((economic*[tiab] OR 
financ*[tiab] OR cost*[tiab] OR pharmacoeconomic*[tiab] OR expend*[tiab] OR 







expens*[tiab]) AND (patient*[tiab] OR individual*[tiab] OR personal*[tiab] OR 
household[tiab])) OR fee[tiab] OR fees[tiab] OR productivit*[tiab] OR 
unproductivit*[tiab] OR absenteeis*[tiab] OR presenteeis*[tiab] OR ((job[tiab] OR 
work*[tiab] OR profession*[tiab] OR occupation*[tiab] OR labour[tiab]) AND 
(perform*[tiab] OR efficien*[tiab] OR return*[tiab] OR back[tiab] OR capacit*[tiab] OR 
abilit*[tiab] OR disabilit*[tiab] OR unab*[tiab] OR limit*[tiab] OR impair*[tiab] OR 
loss[tiab] OR losing[tiab] OR restrict*[tiab] OR reduct*[tiab] OR input*[tiab])) OR 
working time*[tiab] OR work week*[tiab] OR work day*[tiab] OR work load*[tiab] OR 
workweek*[tiab] OR workday*[tiab] OR ((caregiver*[tiab] OR illness*[tiab] OR 
disease*[tiab]) AND burden[tiab]) OR (distan*[tiab] AND (hospital*[tiab] OR 
facilit*[tiab] OR doctor*[tiab] OR physician*[tiab] OR health care[tiab])) OR patient 
transport[tiab] OR health shock[tiab] OR income*[tiab] OR salary[tiab] OR salaries[tiab] 
OR payment*[tiab] OR medical leave[tiab] OR sick leave[tiab] OR workload*[tiab] OR 
time off work[tiab] OR retire*[tiab] OR employment*[tiab] OR employed*[tiab] OR 
unemploy*[tiab] OR societal perspective[tiab] OR human capital[tiab] OR friction 
cost[tiab] OR lost time[tiab]))  AND publisher[sb] 
Google Scholar  
(trypanosomiasis|Chagas|leprosy|Helminthiasis|Ascariasis|Trichuriasis|Hookworm|
Schistosomiasis|Trachoma|Chlamydiasis|Dracunculiasis|filariasis|Onchocerciasis|"n
eglected disease") "(individual|personal|household) 
(cost|costs|economic|expenses|financial)" 
Popline / Lilacs / Scielo  
(trypanosomiasis OR Chagas OR leprosy OR Helminthiasis OR Ascariasis OR 
Trichuriasis OR Hookworm OR Schistosomiasis OR Trachoma OR Chlamydiasis OR 
Dracunculiasis OR filariasis OR Onchocerciasis OR "neglected disease") (productivity 
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household[tiab])) OR fee[tiab] OR fees[tiab] OR productivit*[tiab] OR 
unproductivit*[tiab] OR absenteeis*[tiab] OR presenteeis*[tiab] OR ((job[tiab] OR 
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workweek*[tiab] OR workday*[tiab] OR ((caregiver*[tiab] OR illness*[tiab] OR 
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time off work[tiab] OR retire*[tiab] OR employment*[tiab] OR employed*[tiab] OR 
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cost[tiab] OR lost time[tiab]))  AND publisher[sb] 
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S1 Fig. Flowchart describing the literature search for lymphatic 
filariasis 
 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S1 Fig. Flowchart describing the literature search for lymphatic 
filariasis 
 












S3 Fig. Flowchart describing the literature search for 
schistosomiasis 
 












S3 Fig. Flowchart describing the literature search for 
schistosomiasis 
 













S5 Fig. Flowchart describing the literature search for trachoma 













S5 Fig. Flowchart describing the literature search for trachoma 
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Lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminths 
(STH) and trachoma represent the five most prevalent neglected tropical diseases 
(NTDs). They can be controlled or eliminated by means of safe and cost-effective 
interventions delivered through programs of Mass Drug Administration (MDA)—also 
named Preventive Chemotherapy (PCT). The WHO defined targets for NTD 
control/elimination by 2020, reinforced by the 2012 London Declaration, which, if 
achieved, would result in dramatic health gains. We estimated the potential economic 
benefit of achieving these targets, focusing specifically on productivity and out-of-pocket 
payments. 
Methods 
Productivity loss was calculated by combining disease frequency with productivity loss 
from the disease, from the perspective of affected individuals. Productivity gain was 
calculated by deducting the total loss expected in the target achievement scenario from 
the loss in a counterfactual scenario where it was assumed the pre-intervention situation 
in 1990 regarding NTDs would continue unabated until 2030. Economic benefits from 
out-of-pocket payments (OPPs) were calculated similarly. Benefits are reported in 2005 
US$ (purchasing power parity-adjusted and discounted at 3% per annum from 2010). 
Sensitivity analyses were used to assess the influence of changes in input parameters. 
Results 
The economic benefit from productivity gain was estimated to be I$251 billion in 2011–
2020 and I$313 billion in 2021–2030, considerably greater than the total OPPs averted 
of I$0.72 billion and I$0.96 billion in the same periods. The net benefit is expected to be 
US$ 27.4 and US$ 42.8 for every dollar invested during the same periods. Impact varies 
between NTDs and regions, since it is determined by disease prevalence and extent of 
disease-related productivity loss. 
Conclusion 
Achieving the PCT-NTD targets for 2020 will yield significant economic benefits to 
affected individuals. Despite large uncertainty, these benefits far exceed the investment 
required by governments and their development partners within all reasonable scenarios. 
 
 
Given the concentration of the NTDs among the poorest households, these investments 
represent good value for money in efforts to share the world’s prosperity and reduce 
inequity.  
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The five most prevalent neglected tropical diseases (NTDs) are lymphatic filariasis (LF), 
onchocerciasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma. They 
can be controlled or eliminated by means of safe and cost-effective interventions 
delivered through programs of Mass Drug Administration (MDA) - also named 
Preventive Chemotherapy (PCT).The WHO defined targets for NTD 
control/elimination by 2020, reinforced by the 2012 London Declaration, which, if 
achieved, would result in benefits not limited to health gains. We estimated the potential 
economic benefit of achieving these targets for these NTDs. Economic benefit was 
calculated by combining the estimated disease frequency with productivity loss resulting 
from the disease, from the perspective of a person affected by each of the NTDs. The 
same was done for the healthcare costs paid by the affected individuals. The economic 
benefit to individuals from productivity gain was estimated to be I$ 251 billion in 2011-
2020 (before achieving the targets) and I$ 313 billion in 2021-2030 (after achieving the 
targets). The estimated total healthcare costs averted are substantial though lower than 
productivity costs: $0.72 billion in 2011-2020, $0.96 billion in 2021-2030. This would 
mean a return of US$ 27.4 for each dollar spent between 2015-2020 to reach the targets 
and US$ 42.8 between 2021-2030. The economic impact varies between NTDs and 
regions, since it is determined by disease prevalence and the degree of productivity loss 




Neglected tropical diseases (NTDs) are a group of debilitating infectious diseases that 
can result in death, but are more often associated with chronic, disabling and disfiguring 
morbidity [1]. Most of them affect forgotten people, with little political or financial 
capital, living in slums or in rural areas (predominantly in low – and middle-income 
countries), away from cities where policymakers live and work. [2-5] 
Besides having devastating consequences for one’s health, NTDs also have an important 
effect on the economic welfare of patients and their families, imposing additional 
economic difficulties for populations struggling to live below the poverty line of 1US$ a 
day [2-4,7-11,59]. In this sense, NTDs are an additional obstacle to sustainable 
development, which can be achieved only in the absence of high prevalence of 
debilitating communicable and non-communicable diseases. [14]  
NTD control or elimination targets for the year 2020 were set out in  the WHO Roadmap 
of 2011 and endorsed by partners in the London Declaration of 2012 [15-17]. Among 
these 10 NTDs, the most prevalent globally are: onchocerciasis, lymphatic filariasis (LF), 
schistosomiasis, soil-transmitted helminths (STH), and trachoma. [9,18,19] Even though 
they can be controlled or eliminated by means of safe and cost-effective interventions 
delivered through programs of Mass Drug Administration (MDA) - also named 
Preventive Chemotherapy (PCT) - NTD programs still face many obstacles [7]. Some of 
them are closely related to the degree of awareness that policymakers and the global 
health communities have of the health and socioeconomic importance of NTDs [13]. To 
bring more light onto this issue, de Vlas et al. estimated the health gains of achieving the 
2020 targets. [16,17]. Their findings suggest that roughly 300 million disability-adjusted 
life-years (DALYs) can be averted for the five PCT-NTDs over the period 2010-2030. 
[20]  
An improved understanding of the economic impact that NTDs have on individuals, 
households, and countries would help in informing the scale-up of effective and equitable 
interventions to address them [59]. Therefore, robust and clear estimates of the cost of 
NTDs to patients, households and broader societal costs are needed. Combining these 
cost estimates with the already existing estimates of disease burden and comparing the 








The five most prevalent neglected tropical diseases (NTDs) are lymphatic filariasis (LF), 
onchocerciasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma. They 
can be controlled or eliminated by means of safe and cost-effective interventions 
delivered through programs of Mass Drug Administration (MDA) - also named 
Preventive Chemotherapy (PCT).The WHO defined targets for NTD 
control/elimination by 2020, reinforced by the 2012 London Declaration, which, if 
achieved, would result in benefits not limited to health gains. We estimated the potential 
economic benefit of achieving these targets for these NTDs. Economic benefit was 
calculated by combining the estimated disease frequency with productivity loss resulting 
from the disease, from the perspective of a person affected by each of the NTDs. The 
same was done for the healthcare costs paid by the affected individuals. The economic 
benefit to individuals from productivity gain was estimated to be I$ 251 billion in 2011-
2020 (before achieving the targets) and I$ 313 billion in 2021-2030 (after achieving the 
targets). The estimated total healthcare costs averted are substantial though lower than 
productivity costs: $0.72 billion in 2011-2020, $0.96 billion in 2021-2030. This would 
mean a return of US$ 27.4 for each dollar spent between 2015-2020 to reach the targets 
and US$ 42.8 between 2021-2030. The economic impact varies between NTDs and 
regions, since it is determined by disease prevalence and the degree of productivity loss 




Neglected tropical diseases (NTDs) are a group of debilitating infectious diseases that 
can result in death, but are more often associated with chronic, disabling and disfiguring 
morbidity [1]. Most of them affect forgotten people, with little political or financial 
capital, living in slums or in rural areas (predominantly in low – and middle-income 
countries), away from cities where policymakers live and work. [2-5] 
Besides having devastating consequences for one’s health, NTDs also have an important 
effect on the economic welfare of patients and their families, imposing additional 
economic difficulties for populations struggling to live below the poverty line of 1US$ a 
day [2-4,7-11,59]. In this sense, NTDs are an additional obstacle to sustainable 
development, which can be achieved only in the absence of high prevalence of 
debilitating communicable and non-communicable diseases. [14]  
NTD control or elimination targets for the year 2020 were set out in  the WHO Roadmap 
of 2011 and endorsed by partners in the London Declaration of 2012 [15-17]. Among 
these 10 NTDs, the most prevalent globally are: onchocerciasis, lymphatic filariasis (LF), 
schistosomiasis, soil-transmitted helminths (STH), and trachoma. [9,18,19] Even though 
they can be controlled or eliminated by means of safe and cost-effective interventions 
delivered through programs of Mass Drug Administration (MDA) - also named 
Preventive Chemotherapy (PCT) - NTD programs still face many obstacles [7]. Some of 
them are closely related to the degree of awareness that policymakers and the global 
health communities have of the health and socioeconomic importance of NTDs [13]. To 
bring more light onto this issue, de Vlas et al. estimated the health gains of achieving the 
2020 targets. [16,17]. Their findings suggest that roughly 300 million disability-adjusted 
life-years (DALYs) can be averted for the five PCT-NTDs over the period 2010-2030. 
[20]  
An improved understanding of the economic impact that NTDs have on individuals, 
households, and countries would help in informing the scale-up of effective and equitable 
interventions to address them [59]. Therefore, robust and clear estimates of the cost of 
NTDs to patients, households and broader societal costs are needed. Combining these 
cost estimates with the already existing estimates of disease burden and comparing the 







result to the estimated cost of intervention could bolster the case for increased 
investment.  
The aim of the study described in this article was to estimate the socioeconomic benefit 
(to individuals) of controlling or eliminating PCT-NTDs. More specifically, we examined 
the productivity loss and out-of-pocket payments (OPPs) that can be prevented globally, 




The estimate of economic benefit was based on the health benefit calculated by De Vlas 
et al.[20]  Briefly, De Vlas et al used 2010 GBD data of prevalent cases of the NTDs 
included in the London Declaration for the years 1990 and 2010 as the starting point in 
their calculations, with estimates for other years obtained by interpolating between 1990 
and 2010, and further extrapolated until 2030, under the assumption that the 2020 WHO 
Roadmap targets were met and sustained beyond 2020. They first created a 
“counterfactual scenario”, which assumed that the epidemiological situation from 1990 
regarding NTDs would continue unabated and that the number of cases would increase 
as a function of overall population growth. They estimated the numbers of disease cases 
that would be expected if the 2020 targets mentioned by the 2012 London Declaration 
and described by the WHO were to be achieved (target achievement scenario). Disease 
cases averted by achieving the targets were calculated for each GBD disease 
manifestation (or “sequela”), country, sex and age group. For a complete list of the GBD 
sequela per NTD, refer to Salomon et al (2012).[21]  Guinea worm (dracunculiasis) was 
not included in this study, since it was targeted to eradication in 2015. [22] 
De Vlas et al. used a time period of 2011-2030 that extended beyond 2020 since some of 
the benefits of achieving the targets will only arise after that year. That is, the benefits of 
preventing permanent sequelae like blindness will appear much later than the benefits of 
better treatment of other sequelae. [20] 
 
 
General Approach to Estimate the Economic Benefits  
This economic study builds on the approach used by de Vlas et al. to assess the health 
benefits of achieving the 2020 targets. Namely, for each GBD disease sequela a 
comparison is made between the counterfactual scenario and the target achievement 
scenario, calculating the benefit for the period between 2011 and 2030 (ten years before 
and then years after the target achievement) instead of the entire period from 1990 to 
2030. The economic benefit was calculated by subtracting the costs calculated for the 
target achievement scenario from the costs of the counterfactual scenario. [20]  
All economic benefit estimates were expressed in international dollars (constant 2005 I$), 
a hypothetical unit of currency that has the same purchasing power as the U.S. dollar has 
in the United States at a given point in time (in this case, 2005). It is calculated using 
purchasing power parity (PPP) exchange rate, defined as the amount of a country's 
currency required to buy the same amounts of goods and services in the domestic market 
as U.S. dollar would buy in the United States. It is regarded as a more valid measure to 
compare estimates between countries. [23,24] 
Economic benefits from productivity gain and out-of-pocket payments were reported 
separately, as recommended by the WHO. Intangible costs and leisure time were not 
included.[12,67,68] Discounting at 3% was applied using the base year of 2010. All 
calculations were performed using Microsoft Excel (version 2010). [28]   
Time frame  
The estimated economic benefits are presented for 2011-2020 and 2021-2030 separately 
to show how much of the benefits can be expected before the 2020 targets are met 
compared to after 2020.  
Perspective  
We used a microeconomic perspective to analyze the economic costs per GBD sequela, 
sex and country. Only the most important costs that individuals in low- and middle-
income countries incur during illness were included in the analysis, namely indirect costs 
due to lost productivity and the direct costs of obtaining health goods and services [25].  
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The countries included in the analysis were the ones with disease cases for each sequela 
according to the GBD study. The list of countries differs according to disease and 
sequela. The list of countries per disease can be accessed by using the open-access web-
based dissemination tool available here: 
https://erasmusmcmgz.shinyapps.io/dissemination/. [20] 
Productivity loss  
The annual productivity loss per NTD was calculated using the formula shown below 
(Fig.1). The costs per country and NTD were calculated independently for both 
counterfactual and target achievement scenarios. The economic benefit was obtained by 
comparing the target achievement scenario to the counterfactual scenario. Global and 
region-specific benefits were estimated by adding up the benefits of all countries or the 
countries within a specific region. 




TPC =  Total productivity costs (in US$ 2005) 
NTD = Neglected Tropical Disease 
c = Country 
y  =  Year 
PS1  =  Number of prevalent cases aged 15+ years with sequela 1 
PS2  =  Number of prevalent cases aged 15+ years with sequela 2 
PLs1  =  % productivity loss related to sequela 1 of NTD 
PLs2  =  % productivity loss related to sequela 2 of NTD 
I = GDP per capita in the lowest quintile 
D = Annual discount rate (%) 





The number of prevalent cases refers to the average number of cases per country, age 
group, and sex with a specific disease sequela in any particular moment in a year. The 
numbers of disease cases of each year in the period 2011-2030 for both the counterfactual 
and the target achievement scenarios were calculated by de Vlas et al. and used in our 
analyses [20].  
Only individuals older than 15 years were included in the calculation of productivity loss. 
The lower age limit of 15 was chosen since it is often used by the International Labour 
Organization (ILO) [29], even though we know that a significant percentage of children 
aged 5-14 years works in developing countries (sometimes as high as 27%), especially in 
rural settings. [30,31] All cases older than 65 years were included in the calculations, 
assuming they would continue to work after this age,  since only a small proportion of 
people effectively receive a pension in developing countries (median: 7%); people living 
below the US$ 2/day poverty line are even considered not to have any effective basic 
social protection. [32,33].    
 
Productivity loss associated with disease  
Productivity loss refers to the amount of time spent on economic activity that is lost due 
to a specific disease sequela. Economic activity includes time spent in the formal labor 
market but also time spent on self-sufficient farming, time spent on domestic chores or 
other unpaid activities. [34,35] 
Estimates of the productive time lost due to a specific NTD sequela were not easily 
obtained, since published literature of population-based studies on this topic is scarce. 
[36] To address this issue, previous studies have used disability weights as a proxy for 
extent of productivity loss, assuming a linear relationship between productivity and the 
disability weight [37,38]. However, there are many reasons to believe that disability 
weights are not appropriate indicators for productivity loss, since a variety of different 
health states have almost the same disability weights even though they may result in 
differing degrees of productivity loss. For example, in the most recent set of disability 
weights (GBD 2010), blindness has a weight of 0.195, severe anemia has a weight of 
0.164 and disfigurement (level 2 with itch or pain) has a weight of (0.187). [21] It seems 
rather implausible that these various health states lead to the same amount of productivity 
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loss. Perhaps more importantly, the latest published disability weights from 2010 
sometimes differ dramatically from previous values. For instance, the most recent weight 
for blindness is 0.195, much lower than the previous weight of 0.60 [39].  
We therefore performed a comprehensive search of the literature to determine the most 
appropriate estimates of productivity loss related to NTDs. [36] Results were translated 
into annual proportions of productivity loss per sequela, assuming 300 working days per 
year [40]. If several estimates of productivity loss were identified in the literature review, 
we used the lowest value found as the base-case value to keep the estimates conservative. 
One exception was lymphatic filariasis, where we chose to use the values reported by an 
earlier review [40]. If no estimates of productivity losses were available in the literature, 
assumptions were made based on the productivity loss of similar sequelae caused by other 
diseases. 
Table 1 shows the percentage of annual productivity loss per sequela, which ranges from 
0% for sequela like mild onchocerciasis skin disease to 79% for blindness. The table 
shows additional information for onchocerciasis and trachoma since the GBD study only 
reported the number of cases per disease sequela and not the number in each level of 
severity. For example, for vision loss due to onchocerciasis, only the numbers of cases 
with vision loss were reported and not the numbers with blindness, severe vision loss 
and moderate vision loss. Therefore, in order to calculate an overall estimate of 
productivity loss, we had to combine our estimates of productivity loss per severity level 
with the estimated frequencies of the different severity levels (i.e., the ‘case mix’). Table 
1 therefore shows the productivity loss according to severity and case mix regarding 
severity for onchocerciasis and trachoma. The minimum and maximum estimates of 
productivity loss are shown in the sensitivity analysis section. 
Productivity losses associated with long-term cognitive impairment due to helminthic 
infections and productivity compensation mechanisms were not calculated in our 
analyses. This is discussed later in the Discussion section. 
Income 
In this study, income refers to annual income losses to patients as a consequence of NTD 
sequela. As in earlier economic impact studies of NTDs, productivity loss was calculated 
 
 
by using the human capital approach, which uses income to place monetary terms on 
healthy time [25,40,41]. The human capital approach has been criticized for its use in the 
estimation of productivity losses experienced by society as a whole, in part because it 
assumes full employment (i.e. that there are no unemployed individuals to replace the 
sick ones). [25] We limit our analysis to the productivity loss of affected individuals.  
Estimating the income of individuals with NTDs is difficult, since these diseases are 
mainly prevalent in rural areas where self-sufficient farming is one of the most – and 
sometimes the most - important sources of revenue [9]. Previous economic analyses of 
NTDs have applied different methods to estimate the rural wage, including use of GDP 
per capita, average agricultural value added per worker and the lowest wage estimate from 
different predefined wage sources [37,38,40].  
We compared the GDP per capita of the lowest quintile with the minimum nominal 
annual wage (both 2010 PPP), for the endemic countries with the highest number of 
prevalent cases (which would have the highest impact on the final results), showing that 
the minimum wage would still be higher. Since NTDs are generally known as diseases of 
the poorest, we decided to use the GDP per capita of the lowest income quintile for the 
calculations of this study, and use only one data source for income instead of several (this 
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Out-of-Pocket Payments  
We used one general formula to estimate the total out-of-pocket payments (OPPs) 
(Figure 2). This formula was applied for each country and NTD separately, for both the 
counterfactual and the target achievement scenarios (Fig.2). The economic benefit was 
calculated by taking the difference between the results using the target achievement 
scenario and the results using the counterfactual scenario. Global and region-specific 
benefits were estimated by adding up the benefits of all countries or the countries within 
a specific region. In contrast to the estimation of the productivity loss that was calculated 
for individuals older than 15 years, OPPs were calculated for all prevalent cases, including 
children, since these costs are unrelated to the ability to work. 




TDC =  Total Direct Costs (in US$ 2005) 
NTD = Neglected Tropical Disease 
c = Country 
y  =  Year 
PS1  =  Number of prevalent cases with sequela 1 
PS2  =  Number of prevalent cases with sequela 2 
DCS1 =  Annual direct costs sequela 1  
DCS2 =  Annual direct costs sequela 2  
H = percentage of individuals seeking health care 
D = Annual discount rate (%) 
t = Time (years beyond 2010) 
 
Socioeconomic Benefit for Five PCT NTDs
103
3
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Prevalence of NTDs and their sequelae 
The same prevalence estimates used to calculate the productivity loss were used to 
calculate the OPPs. 
Annual direct costs 
Direct costs for health care refer to the costs that arise from seeking treatment to enhance 
or restore health and are paid for by the patient himself (e.g. payments made to health 
practitioners or suppliers of pharmaceuticals) [25]. Our literature review showed that 
relatively few studies have quantified direct costs for the five PCT diseases. This is not 
surprising considering that many drugs to cure these five diseases are donated for free by 
several international partnerships. [16,17] In this case, costs to the individual were 
assumed to be zero (except for LF, as explained below) even though individuals receiving 
free treatment might bear travel, escort, accommodation, food and other costs 
themselves. Another reason for the scarcity of information on direct costs is that initial 
complaints are often not considered important enough to seek health care, and once 
chronic sequelae have developed, only palliative measures can be taken, for instance 
onchocerciasis, trachoma, or lymphatic filariasis. [43-50,55] 
 
We assumed that blindness and skin disease due to onchocerciasis do not lead to any 
substantial out-of-pocket payments. First, there is no treatment for blindness, which is 
irreversible. Second, in the absence of a control program, skin disease is often not 
considered important enough for patients to seek health care. [66] We therefore ignored 
any additional costs since we did not expect any substantial additional costs for skin 
disease and since no publications describe additional OSD-related OPPs.  
Soil-transmitted helminthiasis and schistosomiasis were assumed to be cured with the 
anti-parasitic medication, resulting in minimal chronic sequelae and costs. [67,68] 
Just as with blindness due to onchocerciasis, blindness and low vision due to trachoma 
were assumed not to lead to any OPPs. This is not to say that no OPPs are expected, 
since previous studies have shown that patients with trichiasis can be treated surgically, 
which can result in additional spending for patients despite the fact that surgery is often 
provided for free.[98-103] However, since prevalence estimates of trichiasis were not 
 
 
included in the GBD database, trichiasis-related OPPs (and productivity costs) could not 
be included in this study.  
Previous studies on lymphatic filariasis have shown that the expenditures of patients 
seeking treatment due to LF sequelae are not negligible, even after they are treated with 
anti-parasitic drugs. [40,43,44,46,47,52,75-83] Therefore, we calculated the direct costs 
arising from lymphedema and hydrocele. Annual out-of-pocket payment costs were 
calculated for each WHO region separately since treatment type and costs can vary 
between regions. Table 2 shows the values used to estimate the OPPs for LF, which were 
kept constant over time. These values, used in the study by Chu et al., included costs for 
medicines, consultation fees, transport, food, accommodation and others. They were not 
only divided according to sequela, but also by WHO region, with the exception of India, 
for which country-specific estimates were available. [40] 
Percentage of patients seeking care 
Percentage of patients seeking care refers to the percentage of patients who seek 
treatment for that NTD sequela (shown in Table 2). 
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Productivity gain of premature mortality averted 
The number of productive years lost due to NTD-related premature mortality was 
estimated using country-, age-, and sex-specific mortality data for every year in the 1990-
2030 period. The number of lost work-years was determined for the two scenarios 
(counterfactual scenario and target achievement scenario). The productive years lost per 
person were estimated by comparing the year in which the person died due to an NTD 
(e.g., ascariasis) and the year in which the person would otherwise have died according 
to country-specific life expectancies. The difference between these two years reflected 
the total number of productive years lost due to an NTD. We then restricted these lost 
productive years to the time period used in our analyses (i.e., 2011-2030). Economic 
benefit in the 2011-2030 period was calculated by combining the lost productive years 
with income per person. 
Sensitivity analysis 
Economic benefit was calculated by combining various base-case values for disease 
prevalence, income, and productivity loss. This raised the question of how much the 
estimate of benefit would change if the values of the different input parameters were to 
change. Probabilistic sensitivity analyses were therefore performed to determine how 
much the statistical uncertainty about the values of input parameters influenced the 
estimated economic impact. In these analyses the values of three input parameters were 
allowed to vary simultaneously, assuming that there was no correlation between the 
values of the different parameters. 
The input parameters in our analysis included: 1) the GBD estimates of disease 
prevalence in 2010; 2) percentage of productivity loss and OPP per individual, and 3) 
income. The values of these parameters were varied using a beta PERT distribution in 
combination with the point estimate and the upper and lower limits for each input 
parameter. The limits used were based on different data sources or unavoidable 
assumptions. Table 3 shows the upper and lower limits used for the uncertainty regarding 
prevalence, productivity loss and income, per disease, while table 2 shows the upper and 
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The importance of uncertainty about the prevalence in 2010 and the years thereafter was 
examined by applying the country-specific upper and lower confidence intervals of the 
GBD estimates for 2010 to all the years in the 2010-2030 period.  
Uncertainty about the actual productivity loss and OPP from having one of the five 
diseases was addressed by using the highest and lowest values from studies with sufficient 
quality found through the literature review and estimating a frequency-weighted estimate 
of productivity loss and OPP per disease. 
The variation in the income estimates was based on the variation of income of the 
country with the highest number of prevalent cases for each disease. The lower limit was 
the average income in the lowest decile, while the upper limit was the average income in 
the second-highest quintile of these countries. The ratio between the income in the 
lowest quintile (point estimate) and the income in the lowest decile and second-highest 
quintile (limits) in these countries was then applied to the general income variation.  
Since the sensitivity analysis was performed varying these three variables simultaneously, 
the actual lower and upper limits in the sensitivity analysis were broader than the 
individual ones shown by Table 3. 
 
Return on Investment 
We calculated a rough estimate of the net return on investment (ROI) from 1990 to 2020 
(NTD Roadmap targets) and to 2030 (the SDG target). Net ROI is the present value of 
the benefit to affected individuals minus the present value of the cost to public and 
philanthropic funders, divided by the present value of the cost to public and 
philanthropic funders. We used the economic benefit to affected individuals of averted 
OPP and productivity loss calculated in this study, and the investment costs based on 
recent WHO estimates from the Third Report on Neglected Tropical Diseases. [22]  
We converted the I$ 2010 benefits to US$ 2015, for direct comparison to the investment 
targets. Evidently, part of these benefits is attributable to investments made before 2011; 
in calculating benefits net of costs we therefore had to estimate investments in the period 
1990-2010. We conservatively assumed that investments in the period 1990-2010 were at 
 
 
the same level of those in 2011 (in real terms). 1990 is assumed to mark the beginning of 
concerted global efforts to control most NTDs and 2011 is assumed to mark the 
beginning of the recent scale-up in investment to eliminate them. In reality, investments 
before 2011 were probably lower than this in most countries. Investments in improving 
housing and water and sanitation that occurred over the same period were not 
considered, since these were not targeted at the NTDs but nonetheless contributed to 
their control. We did not estimate the ROI for middle and low income settings separately 
due to lack of the necessary data on investments. We applied a discount rate of 3% per 
annum for both costs and benefits. [84] 
 
Results 
Timing of economic benefits 
Figure 3 shows the pattern of the global productivity loss over time (1990-2030) of 
onchocerciasis skin disease. Onchocerciasis skin disease serves as an example; however 
for other diseases similar patterns can be seen.  
Total global loss per year in the counterfactual scenario (blue) and target achievement 
scenario (orange). The economic benefit is the difference between both scenarios. 
The blue bars in Figure 3 represent the total global loss per year in the counterfactual 
scenario. The increase in loss over time is simply a result of population growth. The 
orange bars represent the global loss in the target achievement scenario, which gradually 
reduces over time. The difference between the blue and the orange bars is the economic 
benefit.  
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Figure 3: Productivity loss due to skin disease from onchocerciasis according to 
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As a result of fewer cases after the targets are achieved in 2020, the benefits for the period 
2021-2030 will be higher than for the period 2011-2020 (table 4). For some disease 
sequelae the differences between the two periods will be significant (e.g. trachoma-related 
blindness) whereas for other diseases the difference is small (e.g. onchocerciasis skin 
disease).  This can partly be explained by the differences in the targets between the 
diseases, which will affect the numbers of cases expected in 2020 when the targets are 
achieved. [16,17] More importantly, some disease sequelae are reversible whereas others 
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Figure 4. Global economic benefit (productivity loss prevented) for the period 













































Global economic benefit from reaching the targets for 5 PCT diseases, lower and upper 
estimates from sensitivity analysis.  
The disease that is responsible for the largest economic benefits is clearly STH, especially 
the anemia sequela (Figures 4 and 5), accounting for almost 60% of the benefits from 
reaching the targets for STH. Even though it causes a relatively low productivity loss, 
this finding can be explained by the widespread distribution of STH. 
 
 
Figure 5. Global economic benefit or reaching the targets for STH (point 
estimates), per disease sequela for the period 2011-2030 (billions I$ - international 
dollars) 
 
STH is the disease responsible for the largest economic impact, especially the anemia 
sequela. The 2.5 and 97.5 percentiles calculated in the sensitivity analysis are shown in 
the diagram.  
Figure 6 highlights the regional variation in the economic benefit, per WHO region. [85] 
Unsurprisingly, when China is included, the Western Pacific region clearly outweighs the 
benefits of all the other regions, mainly due to the control of STH. The South East Asia 
region has the highest benefits when China is not included, which is due to the impact in 
India.  
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Figure 6. Economic benefit of reaching the PCT targets per WHO region, with 
and without China 



















































WHO Region  
Regional variation in the economic benefit, per WHO region, where the Western Pacific 
region outweighs the benefits of all the other regions when China is included, mainly due 
to the control of STH. The South East Asia region has the highest benefits when China 
is not included, due to the impact in India. 
Out-of-Pocket Payments versus productivity loss 
Economic benefit due to prevention of lost working time is considerably higher 
compared to the benefit due to the prevention of direct OPP (I$ 31 billion vs I$ 0.72 
billion in 2011-2020 and I$ 40 billion vs I$ 0.96 billion in 2021-2030, corresponding to 
US$ 11 billion vs US$ 0.25 billion and US$ 14 billion vs US$ 0.33 billion in the same 




Economic benefit of averted premature mortality  
The economic benefit from averted premature mortality was rather small compared to 
the benefit of averted morbidity, amounting to just 0.48% of the total economic benefit 
for the period 2011-2030. Within the diseases that presented death cases, it corresponded 
to 0.03% of the STH benefit and 6.41% of the schistosomiasis benefit.  
Return on Investment 
The ROI was calculated considering a benefit to individuals of US$ 119.7 billion in the 
period 2015-2020 and US$ 399 billion in the period 2015-2030, if the 2020 targets for 
PCT diseases were to be met and considering costs to funders of US$ 2.8 billion and US$ 
6.2 billion in the same periods. 
The net benefit is US$ 27.4 for every dollar invested during the period 1990-2020 and 
US$ 42.8 for every dollar invested in the period 1990-2030 (best estimates). More detailed 
information on the ROI and the internal rate of return per WHO region, as well as other 
considerations on the investment case of ending/controlling NTD can be found in a 
forthcoming publication. [113] 
The health benefits calculated by De Vlas et al and the economic benefits shown here 




This is the first study estimating the global economic benefits of achieving WHO 
Roadmap targets endorsed by the London Declaration for the five PCT diseases. 
Prevalence estimates based on the GBD study, productivity loss and OPP values based 
on published literature and income estimates based on World Development Indicators 
data were used. The productivity costs were calculated using the human capital approach 
and reported separately from the OPPs [25]. Averted costs were calculated by comparing 
expected costs of the target achievement scenario with a counterfactual scenario.   
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Our findings suggest that by averting the five PCT disease, a total of I$ 563 billion (US$ 
229 billion) of productivity loss and I$1.7 billion (US$ 0.58 billion) OPPs can be averted 
over the 20 year time period 2010-2030. This implies that roughly I$ 28 billion (US$ 11 
billion) on productivity loss only can be averted annually.  
General Approach 
We used the human capital approach to calculate the productivity loss. Although this 
method is generally used and therefore increases comparability with previous studies, 
some would argue that it overestimates the actual productivity loss from the societal 
perspective [86]. Since we focused on the economic loss to individuals affected by NTDs, 
the alternative approach of the friction cost method (which focuses only on the lost 
productivity until a replacement can be found) was not considered. The consequences of 
the five PCT diseases are often chronic in nature, which mostly leads to reduced 
productivity while working (presenteeism) rather than lost work days (absenteeism). For 
instance, someone with itching due to onchocerciasis will still be able to work but will be 
less productive at work due to the distracting itching and constant scratching, or a tea 
plucker with hookworm anemia will not be absent from work, but will earn less due to 
fewer kilograms of tea plucked. [87,88] While these workers could also be replaced with 
healthier workers, this is less likely since they are still showing up for work. Therefore, 
use of the friction method is not expected to have a substantial effect on the estimated 
economic benefit. This means that the aggregation of individual costs does not exactly 
represent the total societal cost, since individuals’ productivity losses are still 
compensated by a variety of mechanisms in the societal level. Some of these mechanisms, 
for instance household coping strategies and work compensation will be discussed later 
in this section. 
The link between income and productivity depends on more factors than only labor. In 
the systematic literature review we performed for this study [36], most publications 
reported productivity in terms of days/hours of work although some publications 
reported it in terms of output (as kilograms of tea plucked a day, or square meters of 
constructed road a day). A linear relationship between health and productivity was not 
always seen and most of the time there was not enough information on this issue. 
Therefore, and also because of using conservative values for productivity loss, we 
 
 
assumed that average productivity gain would equal marginal productivity gain. The lack 
of information in the literature prevents us from knowing if this would have under- or 
overestimated the results. 
The impact of NTDs on productivity amongst agricultural families is worth commenting 
on in more detail since NTDs can lead to productivity loss in different ways. To start 
with, affected families might own less land than unaffected families as a direct result of 
NTD-related productivity loss. Oladepo et al reported that ‘farmers with OSD 
(Onchocercal Skin Disease) had significantly less farmland under cultivation (9,117 m2) 
than those with no OSD (13,850 m2)’. But even with a fixed amount of land, healthy 
farmers could be able to increase their productivity in different ways, including: 
harvesting more than once a year (enabling them to quickly harvest one crop and plant 
another); investing more energy in site preparation, which requires more physical 
strength (e.g., to remove stones and dead trees); working in steep areas that would 
otherwise be underutilized; and being capable of investing more energy in ameliorating 
compaction, aeration, soil moisture status, and weeding. It is worth noting that land 
preparation is by far the most time-consuming activity for the farmer and family, and 
that weeding accounts for more than 60 percent of the time a peasant farmer spends on 
the land.  [89-92]  
Household coping strategies and social security were not included in the calculations. 
However, household coping strategies can have several effects on the total costs that the 
illness of a family member can cause for the household. Coping strategies can reduce the 
impact of lost productivity because another household member can take over the work. 
For the individual patient these costs are still onerous and may lead to overwhelming 
effects. Patients may need to borrow money to pay for the treatment or forgo treatment 
if they cannot afford it. [40] On the other hand, when, for example, children step in and 
take over the work of their ill parents, they cannot go to school and may therefore have 
more limited career opportunities later in life. [25]  
Productivity loss due to subtle morbidities (for schistosomiasis and STH) as well as 
productivity loss by informal care were not included in this analysis. The reason for not 
including the subtle morbidities is that these are not part of the GBD study. However, 
previous research has shown that subtle morbidity affects people later in life since they 
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may often become trapped in poverty due to low-salary jobs and poorer school 
performance. [93-96] The productivity loss of caregivers of the blind due to trachoma or 
onchocerciasis or the severely affected by lymphedema or hydrocele is also not negligible 
although very little data is currently available.[97] Excluding the effects of subtle 
morbidity and informal care on productivity loss leads to an underestimation of the 
economic benefit. 
Large differences in economic benefit can be seen between diseases and 
countries/regions, since economic benefit clearly depends on disease prevalence in a 
country, the impact that the disease has on productivity and OPPs and income. 
Comparisons between diseases can only be made with caution. For one, the data 
limitations and potential biases in the methodology affect the different diseases 
differently. Furthermore, when multiple diseases can be treated in one single visit, it does 
not make sense to look at the economic returns from just one disease at a time.  
Integrated delivery of medicines and preventive efforts means that these returns are in 
fact complementary. The economic returns from investments in NTDs also depend on 
how productivity is valued in monetary terms, but the gains are not restricted to them. 
Physical and mental health of billions of people will be gained with the 
control/elimination and eradication of NTDs, and attributing exclusively monetary value 
to these domains in terms of productivity gain underestimates this much bigger gain, of 
which increased productivity is only a by-product. Therefore, the economic benefit of 
controlling NTDs (as calculated here) should not be the only argument driving 
policymaking.  
Productivity loss is often minimized by compensating mechanisms, which from the 
perspective of the individual could be for instance cancelling or postponing work, 
working extra hours to compensate, or having colleagues compensate for the lost 
productivity. [98,99] To our knowledge, there is no description in the literature of 
compensating mechanisms in Low- and Middle-Income Countries (LMIC), and the ones 
described for firms in developed countries do not necessarily reflect the reality of 
agricultural families/workers in developing countries. [100] Also, the more chronic 
nature of sequelae of NTDs leaves less room for work compensation, and some do not 
even enable people to work due to their severity, such as hepatomegaly or splenomegaly 
in schistosomiasis, heart failure in Chagas disease, blindness in onchocerciasis and others. 
 
 
Therefore, we do not know the extent to which work compensating mechanisms would 
have changed the results, but for the reasons just mentioned, probably the results would 
not change much. [101-103] 
 
Technical validity 
R scripts were written to construct technical validity/calibration of our Excel 
calculations. The R scripts are completely independent of the Excel calculations and use 
the same original data (GBD, UNPOP, GDP, productivity loss) as the Excel sheets 
(though transformed). The few differences we found lead to the improvement of the 
formulae for some of the diseases and later matching of the results, but the general 
programming in Excel did not change. R scripts and example Excel sheets can be found 




The numbers of prevalent cases were drawn from the 1990 and 2010 GBD estimates and 
the calculations made by De Vlas et al. [20] The GBD data on which prevalence estimates 
were based already contained uncertainty ranges, varying in relative terms from 10% less 
to 40% more compared to the mean (Table 3), depending on availability of country and 
disease-specific epidemiological data. [20] This uncertainty increased as the GBD 
numbers were extrapolated over time to estimate the annual prevalence estimates for the 
period 2010-2030.  
In this sense, the extrapolation of the counterfactual estimates may be questioned for 
several countries that have experienced rapid and large economic growth since 1990, and 
consequently have not maintained the same epidemiological situation for NTDs as in 
1990, as De Vlas et al. have argued. [20] This would mean that the difference between 
the prevalent cases of the two scenarios would be somewhat smaller. If we take the 
disease with the biggest economic impact, STH, we would see that more than half of the 
STH benefits are gained in China due to the possibly overestimated difference between 
the two scenarios [104]. Nevertheless, if we present the economic benefits excluding the 
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results for China, we would have a lower but still substantial total productivity gain of I$ 
126.1 billion for 2011-2020 and I$ 195.8 billion for 2021-2030.  
Productivity loss and Out-of-Pocket Payments 
Literature on productivity loss and out-of-pocket payments was scarce and not available 
at all for some diseases. [36] As a result, a general global estimate of productivity loss was 
used for each sequela, which was sometimes based on only one study. When no OPP or 
productivity loss values were available, other methods were required to estimate 
productivity loss (e.g. use studies of other diseases with similar sequelae). The few 
available studies were also often liable to several types of risk of bias, generating large 
uncertainty around the productivity loss estimates. [36] For instance, the productivity loss 
estimate used for four schistosomiasis disease sequelae was derived from one article by 
Fenwick and Figenschou published in 1972, who assessed the difference in productivity 
of cane cutters uninfected and infected with Schistosoma mansoni in Tanzania. [105] In fact, 
the values of productivity loss used were based on studies performed in very specific 
contexts, i.e. with tea pluckers, road workers, rubber tappers, farmers, in different 
countries. The generalizability of these studies to all persons with an NTD may be 
limited. First, by measuring the productivity loss in working populations, the results will 
suffer from the ‘healthy worker effect’, since the productivity loss was measured in 
affected persons that are still able to work, not considering the ones too sick to work 
[106]. This would underestimate the productivity loss each disease would cause. Second, 
the productivity loss estimated in the specific regional and working contexts is not 
necessarily the same for other professions (more or less strenuous, for instance) or for 
other contexts. Extrapolation of the data from one specific context to others was done 
due to lack of data, and, depending on the disease sequela, the profession and the working 
environment, it might have over- or underestimated the extent of productivity loss. 
The same productivity loss estimate was used for men and women, despite the fact that 
this might not always be the case. First, cultural factors may restrict women’s activities to 
domestic ones, which differ from farming and other occupations that men might have in 
the same culture; these differences could lead to different productivity losses. 
[44,46,48,96,107] Second, when performing the same tasks, women can perform 
differently from men. [64] Third, the same sequela can affect men and women differently. 
One example is anemia, which might be more frequent and even more severe in women, 
 
 
aggravated by menstrual and birth blood loss, breastfeeding depletion, [62] but might 
impact the productivity of men even more, since they have more muscle mass and may 
perform more strenuous tasks than women and are therefore more affected by less 
efficient blood oxygen transport. Many of the studies investigating productivity loss due 
to hookworm anemia in men found higher values (18.7–20%) than the ones investigating 
women (5.4-6.32%). Others showed a bigger impact of anemia on people who perform 
heavy work compared to those who do light work, so both the difference in severity and 
the different nature of the jobs could lead to different estimates in productivity loss due 
to anemia for both women and men.[59-64,108-110] At the same time, a recent 
systematic review on the impact of hookworm infection and deworming on anemia did 
also not report gender differences regarding this subject. [111] 
As described in the methods, we assumed out-of-pocket payments for onchocerciasis, 
schistosomiasis, STH, and trachoma to be zero. We know that there are other costs that 
individuals would have to bear besides transportation costs, such as food, 
accommodation, escort, diagnostic investigations or procedures (i.e. laboratory) and 
treatment. Since we did not have enough information on all of these different costs for 
all PCT diseases and countries included in this study, we assigned a zero value to the 
direct costs of PCTs (except for LF, as explained before), which led to a conservative 
estimate of the OPPs. 
Income 
We used the GDP per capita of the lowest income quintile as a proxy for income for the 
calculations of this study. Compared to the data sources used by other authors described 
above, the GDP per capita of the lowest quintile seems to be the most conservative 
estimate without having to combine multiple data sources for income. For instance, when 
comparing the GDP per capita of the lowest quintile with the minimum nominal annual 
wage (both 2010 PPP) we would have $ 1592 versus $3453 for China, and $ 1333 versus 
$2288 for India. [112-113] One could argue that the lowest quintile can refer either to 
the share of income or of consumption, and that the lower quintile of the population is 
likely the recipient of considerable transfers, so only part of the income would be earned, 
and therefore dependent on the worker's productivity. Hence, since NTDs are generally 
known as diseases of the poorest, using the GDP per capita of the lowest quintile would 
still overestimate the annual productivity loss of the affected populations. We therefore 
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allowed income to vary to the GDP per capita of the lowest decile in the sensitivity 
analysis.  
Comparisons with the literature  
To our knowledge only a small number of other studies have assessed economic benefits 
of preventing or treating NTDs. However, these studies did not include all five PCT 
diseases but examined one specific NTD per study, and most of them one specific 
country. Comprehensive global assessments were not identified so far. 
Frick et al. examined the economic impact of trachomatous visual loss in the year 2000. 
They estimated an annual productivity cost of $2.9 billion (US$ 1995). This significantly 
differs from our findings, with an annual average of $620 million for trachoma in the 
period 2011-2030. Frick used a productivity loss based on disability weights (0.40 for low 
vision and 0.60 for blindness). We used 79% for blindness but split low vision into severe 
visual impairment with 35% productivity loss and moderate visual impairment 0% 
productivity loss. Since trachomatous moderate impairment (55%) is far more common 
than severe impairment (10%) this together resulted in a much lower productivity loss 
for low vision compared to what Frick used, namely 6%.  
Chu et al. (2010) examined the economic benefits resulting from a global program to 
eliminate LF. Chu et al. estimated productivity costs and OPP, but they used a different 
approach to estimate the benefits. They quantified the clinical manifestations that would 
be averted, while we used GBD sequelae; the health system, was included in their costs 
calculations, while our approach was focused on the costs of the disease paid by the 
individual; they calculated the economic benefit for a fixed cohort population, which led 
to lifetime economic benefits that cannot be compared with our results for a 20-year 
period.  
Limitations 
The comprehensiveness of this economic analysis is limited by the paucity of 
country/regional data regarding productivity loss and OPPs related to the different 
NTDs and their sequelae, as well as the characteristics of the affected populations (e.g. 
income). In addition, assumptions had to be made regarding the predictions of the 
prevalent cases of each NTD. Even though sensitivity analyses were performed to 
 
 
estimate lower and upper limits of economic benefit, better knowledge and 
understanding about the abovementioned parameters would improve the estimates. 
Further research is needed to derive more accurate measures of productivity loss due to 
NTDs. Furthermore, studies that provide a more accurate characterization of the 
affected populations would allow a more realistic calculation of economic benefits, due 
to better information on their socioeconomic context (i.e., details about income, 
professions, and type of work performed). Future research should also be performed in 
as many affected countries as possible to shed more light on the socioeconomic 
differences between the different affected populations in the different countries and 
enable the consideration of each particular setting in future economic calculations. 
Considering that the 2020 targets for the 10 London Declaration NTDs described by the 
WHO [16,17] will be met of course implies a natural uncertainty about the future. The 
actual economic benefit will evidently depend on the extent that each country will reach 
those targets. In this sense, our results do advocate in favor of directing policies that 
invest in reaching these goals, but our results cannot help deciding on the instruments to 
reach them. 
Conclusions 
The robust findings of our study show that investing in achieving the 2020 WHO targets 
for the London Declaration NTDs will certainly result in substantial economic gain. The 
economic benefit to individuals from productivity gain was estimated to be I$ 251 (I$ 
187 – I$ 346) billion in 2011-2020 and I$ 313 (I$ 233 – I$ 432) billion in 2021-2030, 
corresponding to US$ 102 (US$ 76 – US$141) and US$ 127 (US$ 86 – US$ 203) 
respectively (2.5th and 97.5th percentiles from sensitivity analyses between brackets). Total 
OPPs averted were I$0.72 (US$ 0.25) billion and I$0.96 (US$ 0.33) billion in the same 
periods. The best estimates for the net benefit (return on investment) is US$ 27.4 for 
every dollar invested during the period 1990-2020 and US$ 42.8 for every dollar invested 
in the period 1990-2030. The impact varies between NTDs and regions, since it is 
determined by disease prevalence and productivity loss caused by each disease 
manifestation. 
Although the results of this study should be interpreted with care because of the different 
factors of uncertainty discussed above, we can conclude that economic benefits to 
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those targets. In this sense, our results do advocate in favor of directing policies that 
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reach them. 
Conclusions 
The robust findings of our study show that investing in achieving the 2020 WHO targets 
for the London Declaration NTDs will certainly result in substantial economic gain. The 
economic benefit to individuals from productivity gain was estimated to be I$ 251 (I$ 
187 – I$ 346) billion in 2011-2020 and I$ 313 (I$ 233 – I$ 432) billion in 2021-2030, 
corresponding to US$ 102 (US$ 76 – US$141) and US$ 127 (US$ 86 – US$ 203) 
respectively (2.5th and 97.5th percentiles from sensitivity analyses between brackets). Total 
OPPs averted were I$0.72 (US$ 0.25) billion and I$0.96 (US$ 0.33) billion in the same 
periods. The best estimates for the net benefit (return on investment) is US$ 27.4 for 
every dollar invested during the period 1990-2020 and US$ 42.8 for every dollar invested 
in the period 1990-2030. The impact varies between NTDs and regions, since it is 
determined by disease prevalence and productivity loss caused by each disease 
manifestation. 
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individuals will greatly exceed the investments required in interventions. We hope that 
these results help advocating in favor of addressing the social and environmental 
determinants of health, especially for the poor and vulnerable, aiming at more equity, 
inclusion, productivity and health in societies. 
Initiatives for joint collection of better socioeconomic and epidemiological data would 
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The control or elimination of neglected tropical diseases (NTDs) has targets defined by 
the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the 
economic impact to individuals of meeting these targets for human African 
trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or 
eliminated by innovative and intensified disease management (IDM). 
Methods  
A systematic literature review identified information on productivity loss and out-of-
pocket payments (OPPs) related to these NTDs, which were combined with projections 
of the number of people suffering from each NTD, country and year for 2011–2020 and 
2021–2030. The ideal scenario in which the WHO’s 2020 targets are met was compared 
with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. 
Economic benefit equaled the difference between the two scenarios. Values are reported 
in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. 
Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around 
the base-case impact estimate. 
Results  
The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 –I$ 
34.0) billion in 2011–2020 and I$ 35.9 (I$ 25.0 –I$ 51.9) billion in 2021–2030 (2.5th and 
97.5th percentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 –US$ 15.7) 
and US$ 16.6 billion (US$ 11.6 –US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 
6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods. 
Conclusion  
We faced important limitations to our work, such as finding no OPPs for leprosy. We 
had to combine limited data from various sources, heterogeneous background, and of 
variable quality. Nevertheless, based on conservative assumptions and subsequent 
uncertainty analyses, we estimate that the benefits of achieving the targets are 
considerable. Under plausible scenarios, the economic benefits far exceed the necessary 
investments by endemic country governments and their development partners. Given 
the higher frequency of NTDs among the poorest households, these investments 
 
 
represent good value for money in the effort to improve well-being, distribute the world’s 
prosperity more equitably and reduce inequity.  
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Human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease are 
neglected tropical diseases (NTDs) controlled or eliminated by innovative and intensified 
disease management (IDM). We estimated the economic impact of meeting the 2020 
targets defined by the WHO for NTD control/elimination, reinforced by the 2012 
London Declaration. A systematic literature review identified information on 
productivity loss and out-of-pocket payments (OPPs) relating to these NTDs. The 
economic benefit was calculated by combining the estimated disease cases with estimated 
productivity losses and OPPs resulting from the diseases, from the perspective of 
affected individuals. Very little information about OPPs and productivity loss due to 
NTDs was found in the literature. The total global productivity gained by reaching the 
goals for the four IDM-NTDs was I$ 23.1 billion in the period 2011-2020 and I$ 35.9 
billion in the period 2021-2030. The reduction in OPPs was I$ 14 billion and I$ 18 billion 
for the same periods. In order to estimate the economic impact of meeting the London 
declaration targets regarding four IDM-NTDs, we had to combine data from various 
sources, heterogeneous background, and variable quality. Nevertheless, based on 
conservative assumptions and subsequent uncertainty analyses, we estimate that the 
benefits of achieving the targets are nearly double the required investments by endemic 




Disadvantaged populations from low- and middle-income countries (LMICs) often have 
to deal with the health and economic consequences of neglected tropical diseases 
(NTDs), which can often aggravate their struggles to avoid poverty.[1-12] Chagas disease, 
human African trypanosomiasis (HAT), leprosy and visceral leishmaniasis (VL) are still 
difficult and costly to manage and available tools are unsuitable for use in large-scale 
preventive control programmes. They should be controlled or eliminated by “innovative 
and intensified disease management” (IDM), as promoted by the World Health 
Organization (WHO). [13,14] The populations affected by them frequently live in rural 
or remote areas, thereby limiting access to diagnosis and treatment of both the disease as 
well as the disabilities they cause.[15] 
Efforts of many private and public sector organizations have aimed at increasing the 
attention, as well as research and funding, given to NTDs. One of the results was the 
2012 London Declaration, based on targets set out in the WHO Roadmap for the control 
and elimination of 10 NTDs by the year 2020.[15-17] 
Compared to studies of the epidemiology and health consequences of NTDs, relatively 
few studies have examined the impact of NTDs on the productivity and out-of-pocket 
payments (OPPs) of individuals, households, communities and countries.[13,57] There 
is clear evidence that health improvements positively influence economic welfare and 
vice-versa. In this sense, apart from addressing the human fundamental right to the 
highest attainable standard of health, controlling and eliminating NTDs would also have 
a direct and sustainable effect on the economic growth and financial welfare of the 
affected populations, and consequently lead to greater national and global 
prosperity.[9,12,20-22] 
Advances in understanding the economic consequences of NTDs could help to further 
encourage prevention and control actions, assuring funders and policymakers that 
resources committed to these efforts are a good investment, or at least resulting in 
increased health policy dialogue.[18,23] 
We estimated the economic benefits of reaching the 2020 WHO targets for four IDM 
diseases: Chagas disease, human African trypanosomiasis, leprosy and visceral 
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leishmaniasis, which meant estimating how much of the economic loss faced by affected 
individuals due to productivity loss and out-of-pocket payments secondary to these 
diseases would be avoided by reaching these targets. 
 
Methods 
General approach and study design 
The general approach to estimate the economic benefits is the same as the one used to 
calculate the benefits of achieving the 2020 WHO targets for NTDs controlled or 
eliminated by preventive chemotherapy (PCT) described by Redekop et al. [140] This 
approach follows the concepts used by Chu et al., and a conceptual framework can be 
seen as Supporting Information 1 (S1 Figure. Conceptual framework). [25]  
The Global Burden of Disease Study (GBD) is the most extensive worldwide 
observational epidemiological study up to now. Mortality and morbidity from major 
diseases, injuries and risk factors to health are described at the global, national and 
regional levels. The GBD-2010 data of prevalent cases of the NTDs included in the 
London Declaration for the years 1990 and 2010 were used as starting points for the 
calculation of the estimates for other years. They were obtained by interpolating between 
1990 and 2010, as presented by de Vlas et al. The prevalent cases until 2030 were 
estimated by extrapolation under the assumption that the 2020 WHO Roadmap targets 
would be met and sustained beyond 2020. For each GBD disease sequela, a comparison 
is made between a counterfactual scenario (which assumed that the epidemiological 
situation from 1990 regarding NTDs would continue unabated and that the number of 
cases would increase as a function of overall population growth) and a target achievement 
scenario (that considers the 2020 targets described in the 2012 London Declaration and 
described by the WHO being achieved). [26]  
We calculated the base case estimates of the benefit for the period between 2011 and 
2030 (i.e., the period between ten years before and ten years after the target achievement) 
instead of the entire period from 1990 to 2030. The economic benefit was calculated by 
subtracting the costs for the target achievement scenario from the costs of the 
 
 
counterfactual scenario. The economic benefit of each country was combined in order 
to provide region and global estimates of the economic benefit. 
International US$ (constant 2005 dollars) were used to express all estimates in this study. 
It is a hypothetical unit of currency that has the same purchasing power as the U.S. dollar 
has in the United States at a given point in time (in this case 2005). It is estimated using 
purchasing power parity (PPP) exchange rate, defined as the amount of a country's 
currency needed to purchase the same amounts of goods and services in the domestic 
market as one U.S. dollar would buy in the United States. It is a valid measure frequently 
used to compare estimates between countries. [27,28]  
Constant discounting at 3% was applied to both productivity loss and OPPs, using the 
base year of 2010. Discounting is a mathematical operation to adjust future costs and 
effects of health-care interventions to the “present value”. When calculating for 
discounting, for each year (n) in the future the value of costs or benefits is multiplied by 
(1/(1 + D) n), D being the discount rate. [24,29,30]  
Following WHO’s recommendations, the economic benefits from prevented 
productivity loss and out-of-pocket payments were reported separately. [12] All 
calculations were performed using Microsoft Excel (version 2010). [31]  
 
Perspective 
Like previous NTD economic impact studies, we used the human capital approach in 
our study with the perspective of the individual affected by an NTD to analyze the 
economic costs per GBD sequela, sex and country.  
The WHO Guide to Identifying the Economic Consequences of Disease and Injury 
distinguishes the following cost categories when calculating the microeconomic impact 
of disease and injury: expenditures on health; labour and productivity losses; effects on 
human, physical and financial capital formation; non-market impacts such as leisure or 
caregiver time. We only included the first two in our analyses, incurred by affected 
individuals during illness in low- and middle-income countries. [23,32-35] 
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All countries referred by the GBD study as endemic for IDM NTDs were included in 
the analyses [23]. The list of countries per disease can be found using the open-access 
web-based dissemination tool available at 
https://erasmusmcmgz.shinyapps.io/dissemination/. 
Literature review  
We performed a systematic review of the literature to identify general and country-
specific information on productivity loss (indirect labor costs resulting from reduced 
working hours and economic activity attributable to morbidity) and direct costs incurred 
by individuals (such as consultation fees, medication, transport, food, assistance, 
accommodation) due to the 10 NTDs included in the London Declaration. Although in 
this paper we report on four IDM NTDs, we combined the 10 NTDs in the review, since 
many papers often refer to several NTDs and describe the economic impact of the related 
sequelae. Details about the methodology applied to all NTDs and the results regarding 
the findings on productivity loss related to the NTDs eligible for PC can be found in the 
review by Lenk et al.[36] In summary, the searched databases included Embase, Medline 
(OvidSp), Web of Science, Scopus, CINAHL, PubMed publisher, Cochrane, Popline, 
Lilacs, Scielo and Google Scholar. Websites of relevant organizations (i.e. World Health 
Organization, the Centre for Neglected Tropical Diseases, the Carter Center) were also 
screened for relevant grey literature. The search syntax used for each database can be 
found in the Supporting Information (S1 File. Literature Search Syntax), and the 
complete list of institutions searched for grey literature can be found in Supporting 
Information 3 (S2 File. Grey Literature Search). A total of 11,449 articles concerning all 
10 NTDs were identified using the database searches. Of these, 5,316 articles remained 
after duplicates were removed (S1 Table. Results of database searches). We sorted the 
articles that were related to each particular disease and screened the abstract and title of 
all papers, examining the full-text version of all articles that provided information on 
productivity loss or indirect costs. The paucity of studies that provide quantitative 
estimates of productivity loss and OPPs from NTDs can be seen in Supporting 




The formula below was used to calculate the annual productivity loss for each NTD and 
country, using the prevalence estimates for the counterfactual and target achievement 
scenarios independently (Fig.1).  
Figure 1. General formula for calculating productivity loss 
 
 
TPC =  Total productivity costs (in US$ 2005) 
NTD = Neglected Tropical Disease 
c = Country 
y  =  Year 
PS1  =  Number of prevalent cases aged 15+ years with sequela 1 
PS2  =  Number of prevalent cases aged 15+ years with sequela 2 
PLs1  =  % productivity loss related to sequela 1 of NTD 
PLs2  =  % productivity loss related to sequela 2 of NTD 
I = GDP per capita in the lowest quintile 
D = Annual discount rate  
t = Time (years beyond 2010) 
 
Prevalent cases 
We used the estimates relative to both the counterfactual and the target achievement 
scenarios calculated by de Vlas et al, as described in the general approach. [26] The 
population older than 15 years was used for the calculation of productivity loss. [24] 
Productivity loss from disease manifestations 
Disease can lead to productivity loss in many ways, including reduced productivity at 
work (presenteeism), absence from work (absenteeism) or even job loss, which were 
translated into each infected individual’s annual loss of income due to the effects of each 
NTD sequela. [23,25] 
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the analyses [23]. The list of countries per disease can be found using the open-access 
web-based dissemination tool available at 
https://erasmusmcmgz.shinyapps.io/dissemination/. 
Literature review  
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The formula below was used to calculate the annual productivity loss for each NTD and 
country, using the prevalence estimates for the counterfactual and target achievement 
scenarios independently (Fig.1).  
Figure 1. General formula for calculating productivity loss 
 
 
TPC =  Total productivity costs (in US$ 2005) 
NTD = Neglected Tropical Disease 
c = Country 
y  =  Year 
PS1  =  Number of prevalent cases aged 15+ years with sequela 1 
PS2  =  Number of prevalent cases aged 15+ years with sequela 2 
PLs1  =  % productivity loss related to sequela 1 of NTD 
PLs2  =  % productivity loss related to sequela 2 of NTD 
I = GDP per capita in the lowest quintile 
D = Annual discount rate  
t = Time (years beyond 2010) 
 
Prevalent cases 
We used the estimates relative to both the counterfactual and the target achievement 
scenarios calculated by de Vlas et al, as described in the general approach. [26] The 
population older than 15 years was used for the calculation of productivity loss. [24] 
Productivity loss from disease manifestations 
Disease can lead to productivity loss in many ways, including reduced productivity at 
work (presenteeism), absence from work (absenteeism) or even job loss, which were 
translated into each infected individual’s annual loss of income due to the effects of each 
NTD sequela. [23,25] 







Unless otherwise specified, we converted the least biased value of productivity loss found 
in the literature into annual percentages per sequela, assuming 300 working days per year, 
as seen in Table1. [25] In every year of the interval we assumed that there were no 
differences in productivity loss between men and women, between younger and older 
persons, and between countries. We also assumed that all persons older than 15 years are 
equally productive. If no estimates for productivity loss were found in the literature, 
assumptions were made as described in Table 1. 
Table 1 shows the estimates of annual productivity loss for each sequela included in the 
GBD study for IDM NTDs. Sequelae related to poor mental illness due to IDM diseases 
were not included in the GBD study and cutaneous leishmaniasis is not included in the 
London Declaration. Please refer to S3 Table. Publications reporting productivity loss 
for Chagas Disease and S4 Table. Publications reporting productivity loss for Visceral 
Leishmaniasis for a more detailed description of the sources. It shows mostly the 
productivity loss from absenteeism, due to lack of data on presenteeism. The table also 
shows additional information for chronic digestive disease and heart failure due to 
Chagas disease since the GBD study only reported the number of cases per disease 
sequela and not according to severity level. For example, regarding heart disease, only the 
numbers of cases with heart disease were reported and not the numbers per severity level 
(i.e. mild, moderate, severe). Therefore, in order to calculate an overall estimate of 
productivity loss, we had to combine our estimates of productivity loss per severity level 
with the estimated frequencies of the different severity levels (i.e., the ‘case mix’). Table 
1 therefore shows the productivity loss according to severity and case mix regarding 
severity for chronic digestive disease and heart failure. Upper and lower limits for the 
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Productivity loss due to premature mortality 
The number of productive years lost due to NTD-related premature mortality per person 
was estimated using the country-, age-, and sex-specific data on years-of-life lost (YLL) 
as provided by the GBD study. The GBD calculations used uniform Japanese life-
expectancies attributed to the year of death, but for our study we preferred to use 
country-specific life expectancies and only for the study period 1990-2030. We have 
therefore divided the YLL values by the Japanese age-specific life-expectancies to arrive 
at the number of deaths per country, age and sex, and treated them as incident cases for 
'absent persons' due to death by an NTD (e.g., visceral leishmaniasis). The prevalence of 
such 'absent persons' was then calculated similar to the procedure for irreversible disease 
manifestations. Work-years lost were now calculated by the difference between the 
number of absent persons for the counterfactual scenario and target achievement 
scenario over the 1990-2030 period. Economic benefit from averted premature mortality 
in the 2011-2030 period was calculated by combining the lost productive years with 
income per person, for the 15+ age group. Discounting at 3% was applied to the results 
using the base year of 2010. [24]  
Income 
IDM-NTDs are highly prevalent in countries that are no longer regarded as low-income 
countries. Nevertheless, most NTDs continue to affect poor populations that do not 
experience the welfare and health benefits of the economic growth seen in these 
countries. [47,48] 
Different methods were applied in previous economic analyses of NTDs to estimate the 
rural wage, including use of GDP per capita, average agricultural value added per worker 
and the lowest wage estimate from distinct predefined wage sources. [37,38,40] 
We compared the GDP per capita of the lowest income quintile with the minimum 
nominal annual wage (both 2010 PPP) for the endemic countries with the highest number 
of prevalent cases (which would have the highest impact on the final results) and found 
that the minimum wage was higher than the GDP per capita of the lowest income 
quintile. Considering the characteristics of the populations affected by NTDs regarding 
welfare mentioned above, we decided to use the GDP per capita of the lowest income 
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nominal annual wage (both 2010 PPP) for the endemic countries with the highest number 
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quintile as a proxy for income when calculating the base-case impact estimate, and use 
only one data source for income instead of several.  
GDP per capita for each country (purchase power parity-PPP, 2005 international $) and 
income shares of the five income quintiles were obtained from the World Development 
Indicators of the World Bank’s website.[49] In the rare cases where information about 
GDP per capita or income shares of the year 2010 for a country was lacking, we used 
data from previous years; if no information from any year was available, we used the 
average of surrounding countries.  
Since many of the countries included in this study have shown an increase in the GDP 
per capita of the lowest quintile in the last decade, we assumed that the income shares 
and the GDP per capita remained constant over the assessed period of 2011-2030, to 
keep estimates conservative. Income was not adjusted for labor force participation 
(people employed or actively looking for work) or age-related income patterns. 
Out-of-pocket payments (OPPs) 
The annual economic burden related to out-of-pocket payments was calculated using the 
formula below for each country and NTD independently (Fig.2). Despite the limited 
number of studies of OPPs from IDM-NTDs, it was possible to use country-specific 
values for Brazil, Argentina and Mexico, currently the countries with the highest 
prevalence of Chagas disease (based on GBD estimates). Their values for OPPs and 
productivity loss were therefore calculated separately. They serve as examples of how the 
economic impact of Chagas disease could be calculated for each country, if sufficient 
country-specific data are available. 
Costs were calculated by multiplying four values: the total number of cases in each year; 
annual direct costs per sequela; percentage of cases treated each year, and percentage of 
patients paying for treatment each year. Since OPPs are not related to the ability to work, 
they were calculated for all prevalent cases, including children. We assumed no change in 
prices for the period 2011-2030 to keep estimates conservative. 
 
 
Figure 2. General formula for calculating out-of-pocket payments 
 
TDC =  Total out-of-pocket payments (in US$ 2005) 
NTD = Neglected tropical disease 
c = Country 
y  =  Year 
PS1  =  Number of persons with sequela 1 of NTD 
PS2  =  Number of persons with sequela 2 of NTD 
DCS1 =  Annual out-of-pocket payments relating to sequela 1 (per WHO 
region or country) 
DCS2 =  Annual out-of-pocket payments relating to sequela 2 (per WHO 
region or country) 
PT =  Percentage of patients treated 
PP = Percentage of patients paying for the treatment 
D = Annual discount rate 
t = Time (years) 
 
Prevalence estimates 
The same prevalence estimates used to calculate the productivity loss were used to 
calculate the OPPs. 
Annual out-of-pocket payments 
OPPs relate to expenses usually incurred by an affected individual due to the illness, 
including consultation fees, medication, diagnostic tests, travel and escort costs, food, 
accommodation, etc. Whenever the information was available, the cost of the drug was 
excluded from the OPPs in case it is donated for free or reimbursed, as well as 
consultation or laboratory exams if they are also covered by the local health system. 
Depending on the data identified in the literature, country- or region-specific values were 
used. The same treatment value per sequela was used for all individuals in each country 
and sequela, and prices were adjusted to 2005 values using Consumer Price Index (CPI) 
and purchase power parity (PPP).[49] 
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In our calculations, the amount paid by patients varied depending on which direct costs 
patients have to pay per disease sequela and country. OPPs for HAT, for instance, 
included consultation fees, cost of travel, laboratory costs, all expenses for hospitalization 
as well as food for the patient and the caregiver. If the OPP described in the literature 
did not include non-medical payments, since estimates for these costs were lacking in the 
literature, we opted not to include them, also to keep our results conservative. If the 
medication was not included in the list of reimbursed drugs or the NTD was not included 
in the health insurance package, we assumed that all patients had to pay for treatment. 
This was the case for the three countries for which we could find specific information in 
the literature about Chagas disease.  [38,50-68] 
Percentage of cases treated and paying for treatment 
The Sustainable Development Goals (SDGs) emphasize the need to address inequity and 
provide health for all. The goal of universal health coverage (UHC) means financial risk 
protection, access to quality healthcare services, and access to safe, effective, quality, and 
affordable essential medicines and vaccines for all. [69] In line with these concepts, a joint 
WHO/World Bank framework for monitoring progress towards UHC proposed a target 
of a minimum of 80% essential health services coverage and 100% financial protection 
from out-of-pocket payments in 2030, which would mean 100% of the population at risk 
protected against out-of-pocket payments due to NTDs by 2030. [70] 
Parallel to the assumption that the London Declaration targets would be met, we 
therefore assumed a scenario where 80% of health coverage and 100% of financial 
protection would be achieved in 2030, instead of only assuming that people seeking care 
‘do not suffer financial hardship when using health services.’ [71] We assumed that the 
percentage of patients currently paying for the treatment corresponds to the percentage 
of persons not covered by health systems or insurance, since, by definition, out-of-pocket 
payments are direct payments made by individuals to healthcare providers at the time of 
service use. [72] 
In the counterfactual scenario, the percentage of cases that were treated in 2010 was kept 
constant at that level until 2030, to simulate a situation where nothing would be done. 
Similarly, the percentage of cases that paid for their treatment in 2010 was kept constant 
until 2030. In the target achievement scenario, we assumed that the percentage of cases 
 
 
treated in 2010 would linearly increase to 80% in 2030, and we assumed that the 
percentage of patients who paid for their treatment in 2010 would linearly decrease to 
0% in 2030.  
For these percentages, the literature review provided country-specific data for the three 
most prevalent countries for Chagas disease: Argentina, Brazil and Mexico. 
[145,156,159,161,163-168,175-177] A general average price for Latin America from 
Wilson et al was used for all other endemic countries, after correction for PPP for each 
endemic country (Table 2). [51]  
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Like Chagas, some country-specific OPPs for visceral leishmaniasis were found for India, 
Bangladesh, Nepal, and Sudan, which were used to calculate the annual OPPs for these 
countries (sources listed in S5 Table. Publications reporting Out-of-Pocket Payments for 
Chagas disease and S6 Table. Publications reporting Out-of-Pocket Payments for 
Visceral Leishmaniasis). A general average price available from the literature was used for 
all other endemic countries. Percentages for treated patients (successfully and 
unsuccessfully), untreated patients and patients paying for treatment were also derived 
from the literature and were assumed to linearly reach 80% treatment (keeping the same 
proportion between the three treatment categories) and 100% not paying for treatment 
in 2030, considering UHC as previously mentioned (Table3).  
Table 3. Values used to calculate Out-of-pocket payments (OPPs) for visceral 
leishmaniasis (I$ - international dollars) 
Out-of-pocket payments Reference 
India  $ 354.75  [43] 
Sudan  $ 488.89  [43,83,84] 
Bangladesh  $ 286.84  [45] 
Nepal  $ 364.00  [42] 
General  $ 160.00  [84,85] 
Percentage being treated  
India  80% [86-88] 
Sudan 
treated successfully 50% 
[89] treated unsuccessfully 5% 
untreated (undetected) 45% 
Nepal/Bangladesh 80% [87,90] 
 
All drugs currently used for the treatment of human African trypanosomiasis are donated 
to WHO for free distribution by the manufacturers (Sanofi and Bayer). Nevertheless, 
individuals affected by HAT still bear other costs than medication costs when seeking 
treatment, which is one of the reasons for many of them either not to seek treatment, or 
only do so long after their diagnosis or when their symptoms become more acute. [193] 
The OPPs described for HAT in the study by Lutumba et al. included these costs, i.e 
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consultation fees, cost of travel, laboratory/diagnostic costs, food for the patient and 
caregiver during hospitalization, and material such as syringes and needles. These costs 
were used for all endemic countries, after correction (Consumer Price Index – CPI and 
purchase power parity – PPP (Table 4). [27,91-93]  
We assumed no OPPs for leprosy since no information was available from the literature 
at the time the literature review was performed and to keep the estimates of OPP 
conservative. This assumption is supported by the fact that multidrug therapy (MDT) 
has been made available free of charge through the WHO for the past 20 years. The costs 
of palliative treatment of the incurable sequelae were not included for the same 
reasons.[70]  
 
Table 4. Values used to calculate Out-of-Pocket Payments (OPPs) for human 




Annual prices per HAT 
case 
 $ 156.77  [193] 
Percentage being treated 
 
General 24% [195] (7,200 reported, 30,000 estimated) 
Patients paying 
  
General 100% Assumption  
 
Return on Investment  
We calculated the net return on investment (ROI) by obtaining a crude estimate of the 
relationship between the economic benefit and the necessary investments to reach the 
2020 NTD Roadmap targets and the 2030 SDG targets. The net ROI is the current value 
of the benefit to affected individuals minus the current value of the cost to public and 
philanthropic funders, divided by the current value of the cost to public and 
philanthropic funders. The economic benefit to affected individuals of averted OPP and 
productivity loss calculated in this study and the investment costs based on recent WHO 
estimates published in the Third Report on Neglected Tropical Diseases were used in 
these calculations.  
 
 
In the case of IDM NTDs, only investments in individual management of HAT, leprosy, 
and visceral leishmaniasis were included, as well as active case finding for HAT, leprosy 
and VL, and vector control for VL (only in areas of the Indian subcontinent that are not 
co-endemic with malaria), plus the cost of integrated surveillance in HAT-endemic areas. 
Investments and benefits related to Chagas disease were not included. [70]  
For comparison to the disease-specific investment targets published by WHO in the 
Third Report on Neglected Tropical Diseases, the I$ 2010 benefits were converted to 
US$ 2015. Since part of these benefits can clearly be credited to investments made before 
2011, we conservatively assumed the investments to be equal to those in 2011 (adjusted 
for inflation).  We assumed 1990 to mark the beginning of concerted global efforts to 
control most NTDs and 2011 to mark the beginning of the recent scale-up in investment 
to eliminate them. In reality, investments before 2011 were probably lower than this in 
most countries. We did not consider investments in improving housing and water and 
sanitation that occurred over the same period, since these were not targeted at the NTDs 
but contributed to their control nonetheless. The ROI for middle and low income 
settings was not calculated separately due to lack of the necessary data on investments. 
Since investments estimates are given in US$, ROI is presented in US$ only. A discount 
rate of 3% per annum was applied for both costs and benefits. More detailed information 
on the ROI and the internal rate of return per WHO region, as well as other 
considerations on the investment case of ending/controlling NTD, can be found in the 
recently published DCP3/World Bank volume on infectious diseases by Fitzpatrick et al. 
[95] 
Sensitivity analysis 
The economic benefit was calculated using base-case values for the components of the 
formulae described above. We examined how much effect changes in four input 
parameters used in our calculations had on the estimated economic benefit: 1) the 
prevalence estimates, 2) the productivity loss percentages and out-of-pocket payments, 
3) income, and 4) percentage of patients seeking and paying for treatment.  
We performed a probabilistic sensitivity analysis, where the values of all input parameters 
are varied simultaneously to obtain the overall uncertainty regarding the economic 
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benefit. Beta PERT distributions were used in combination with values shown in table 
5; the values of the different parameters were assumed to be independent of each other.  
By applying the country-specific upper and lower confidence limits of the GBD - 2010 
estimates, we examined the relevance of uncertainty about the prevalence in all the years 
in the 2010–2030 period. Productivity loss and OPP values were varied by using the 
highest and lowest values found in articles with sufficient quality retrieved in the literature 
review. If no estimates were available from the literature, assumptions were made, as 
described in Table 1. For each disease, we varied income using data from the country 
with the most prevalent cases in the world. The lower limit of income equalled the 
average income in the lowest income decile in that country, while the upper limit equalled 
the average income in the second-lowest income quintile. For OPPs, we varied the 
uncertainty regarding out-of-pocket payments (per person) by a factor of 2 (i.e., from 
50% to 200%). [24] 
The rough estimates of the return on investment calculated in this study were not subject 
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R scripts were written to examine the technical validity of our Excel-based calculations. 
They used the same original data (GBD, UNPOP (United Nations Population Division), 
GDP, productivity loss) as the Excel files (though transformed), but were completely 
independent of the Excel calculations. The small number of differences were found led 
to the improvement of the formulae for some of the diseases and subsequent matching 
(or calibration) of the results, although the general programming in Excel did not change. 
R scripts and sample Excel sheets can be found in the Supporting Information section. 
The health benefits calculated by De Vlas et al. and the economic benefits shown here 





Figure 3 provides a graphical demonstration of the different cost estimates and their 
trend over time in the counterfactual and target achievement scenarios. The difference 
between the rising productivity costs in the counterfactual scenario and the decreasing 
costs in the target achievement scenario represents the total economic benefit of 
achieving the targets, which is highly dependent on the estimated prevalence of the IDM-
NTDs over time. Since the same pattern can be seen for all IDM diseases and related 
sequelae, we provide the example of productivity costs from the Chagas chronic heart 
disease sequela (the sequela with the biggest impact). 
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Figure 3: Productivity loss due to Chagas chronic heart disease according to the 




































Chagas chronic heart disease (undiscounted) 
Counterfactual scenario Target achievement scenario  
 Total global loss per year in the counterfactual scenario (blue) and target 
achievement scenario (orange). The economic benefit is the difference between 
both scenarios. 
 
Overview of the global estimates of the economic benefit from averted 
productivity loss 
Table 6 shows the total economic benefits in productivity gain for each of the IDM-
NTDs and their sequelae. The total benefits of achieving the targets for all four IDM 
diseases were estimated at I$ 23.1 billion (I$ 15.9 – 34.0 billion) or US$ 10.7 billion (US$ 
7.4 – 15.7 billion) in 2011-2020 and I$ 35.9 billion (I$ 25.0 – 51.9 billion) or US$ 16.6 
billion (US$ 11.6 – 24.0 billion) dollars in 2021-2030 (base case estimates and 2.5th and 
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Figure 4 shows the total values per disease (in I$) together with the sensitivity analysis 
diagram of the calculations of the total economic benefit of achieving the 2020 targets 
for the IDM diseases. The total economic benefit calculated for the entire period was 
$59.0 billion, with the 2.5th and 97.5th percentile values of I$ 40.9 and I$ 85.9 billion 
calculated in the sensitivity analysis. 
Figure 4. Global economic benefit (productivity loss averted) for IDM NTDs, for 
the period 2011-2030 (billions I$ - international dollars).  
 
Global economic benefit from reaching the targets for IDM NTDs, lower and upper 
estimates from sensitivity analysis. Global economic benefit per disease. 
Figure 5 shows the regional variation in the economic benefit, with the Americas and 
South-East Asia outweighing over the other regions due to Chagas disease and visceral 
leishmaniasis, respectively. More productivity loss prevented can be expected in the 




Figure 5. Regional economic benefit (productivity loss averted) for IDM NTDs, 
for the period 2011-2030 (billions I$ - international dollars) per WHO region.  
 
Regional economic benefit from reaching the targets for IDM NTDs, for the period 
2011-2030 per WHO region.  
Out-of-Pocket Payments  
IDM-NTDs impose a considerable burden on patients, mostly due to their incurable 
sequelae, and often compel patients to seek and pay for treatment. [13,96] Table 7 shows 
the economic gains regarding out-of-pocket payments that could be expected by reaching 
the 2020 targets for IDM-NTDs. Chagas chronic heart disease is the main reason for the 
OPPs among all sequelae. 
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Figure 6 shows the total values per disease together with the sensitivity analysis diagram. 
The total economic benefit calculated for the entire period was I$ 33 billion, with the 
2.5th and 97.5th percentile values of I$ 5 and I$ 90 billion calculated in the sensitivity 
analysis. 
Figure 6. Global economic benefit (out-of-pocket payments averted) for IDM 
NTDs, for the period 2011-2030 (billions I$ - international dollars). 
 
Total economic benefit from out-of-pocket payments averted, base case estimates and 
2.5th and 97.5th percentiles (billions I$ - international dollars), discounting 3% from 
2010. 
Return on Investment 
The ROI was calculated based on an estimated benefit of US$ 5.4 billion (in 2015-2020) 
and US$ 20.9 billion (in 2015-2030), assuming the 2020 targets for IDM diseases were to 
be met, and considering costs to funders of US$ 1.1 billion and US$ 2.2 billion in 2015-
2020 and 2015-2030, respectively. 
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The net benefit was estimated to be US$ 0.9 [0.62 – 1.32] for every dollar invested during 
the period 1990-2020 and US$ 2.8 [1.94 – 4.05] for every dollar invested in the period 
1990-2030 (best estimates and 2.5th and 97.5th percentiles related only to the benefits). A 
net benefit of US$ 0.9 per dollar means every dollar invested yielded US$ 1.9 in benefits, 
or benefits nearly double the investment in the period 1990-2020. [95] 
 
Discussion 
This study is a first attempt to estimate the global economic benefits of achieving the 
London declaration targets for four IDM NTDs (Chagas disease, human African 
trypanosomiasis, leprosy, and visceral leishmaniasis).   
General approach 
Scarce and heterogeneous data available on country- or regional-specific productivity loss 
and OPPs related to the different NTDs and their sequelae limits the comprehensiveness 
of this economic analysis to some extent. The same can be said about the paucity of 
information regarding the characteristics of the affected populations (e.g. income) and 
the impact of assumptions regarding the future frequencies of each NTD. More accurate 
measures of productivity loss caused by NTDs and better descriptions of the affected 
populations (e.g., type of work, income) in the different affected countries would greatly 
improve the quality of any estimates of the economic burden of NTDs and the economic 
benefits of controlling NTDs.  
The economic benefits of reaching the 2020 targets for IDM-NTDs were estimated using 
the human capital approach, which increases comparability with other studies. However, 
critics may argue that it overestimates the extent of productivity loss from the societal 
perspective. [97] Nevertheless, the perspective from the individuals affected by these 
diseases, rather than a societal one, was chosen for this study. The first reason for this 
choice was to maintain comparability with the recently published results regarding the 
economic benefit of reaching the 2020 London Declaration targets for PCT NTDs (i.e., 
the ones controlled or eliminated through preventive chemotherapy).[24] Secondly, the 
friction cost method focuses only on lost productivity until a replacement can be found. 
 
 
Use of the friction cost method is likely to have a limited effect on the results for leprosy 
and Chagas since these diseases can lead to reduced productivity while working 
(presenteeism) rather than simply lost work days (absenteeism) and presenteeism will not 
necessarily lead to replacement of the worker. Therefore, the use of the friction method 
is not expected to have a substantial effect on the estimated economic benefit for these 
diseases. In contrast, the biggest economic impact for HAT and VL is through avoiding 
premature deaths. Therefore, the friction cost method might have been a better choice, 
since premature death would lead to worker replacement. We also acknowledge that the 
aggregation of individual costs does not exactly correspond to the total societal cost, 
since individuals’ productivity losses can be compensated by a variety of mechanisms at 
the societal level. Some of these mechanisms are discussed later in this section (e.g., 
household coping strategies). 
Labor is not the only factor that influences the link between income and productivity. In 
all retrieved papers there was not enough information on whether there is a linear 
relationship between health and productivity. Therefore, and also because of using 
conservative values for productivity loss, we assumed that average productivity gain 
would equal marginal productivity gain. The lack of information in the literature prevents 
us from knowing if this would have under- or overestimated the results. 
Household coping strategies, social security, productivity loss of caregivers of people 
with IDM-NTDs, and work compensation mechanisms were not included in the 
calculations. However, household coping strategies can mediate the effects that an illness 
of a family member can have on household finances in several ways; for example, another 
member might start working to reduce the loss of household income. However, even if 
coping strategies are able to maintain the household income, they may reduce future 
opportunities for children who suspend their education and start working. [23] The 
productivity loss due to psychosocial consequences of the diseases (i.e.stigma and 
discrimination) was also not included, since these types of sequelae are not included in 
the GBD study; their omission may have led to an underestimation of the economic 
benefit.  
The basis for the diseases (and their sequelae) included in the GBD study was a set of 
brief lay descriptions emphasizing the main functional consequences and symptoms 
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productivity loss due to psychosocial consequences of the diseases (i.e.stigma and 
discrimination) was also not included, since these types of sequelae are not included in 
the GBD study; their omission may have led to an underestimation of the economic 
benefit.  
The basis for the diseases (and their sequelae) included in the GBD study was a set of 
brief lay descriptions emphasizing the main functional consequences and symptoms 







associated with each health state. For the sake of simplicity, comprehensibility, and 
feasibility, some aspects of health states were inevitably omitted in the GBD study, which 
means that it might not encompass all disease consequences. [40] For instance, erythema 
nodosum leprosum, a complication of leprosy that is known to result in direct costs by 
affected individuals, was not included. [197] Inclusion of other health states would lead 
to a higher estimate of the productivity loss and OPPs, and consequently, of the 
economic benefit. 
The large differences in the magnitude of the economic gain between the different 
diseases and sequelae and the affected countries/regions are a direct consequence of the 
prevalence of each disease in each country, the consequences of each sequela, the chosen 
proxy for income and the percentages of patients being treated and paying for treatment 
for these diseases in each country or region.[34] One should be careful when making 
comparisons between diseases. First, the results for each disease are affected differently 
by the data limitations and potential biases in the methodology mentioned in the 
‘Limitations’ section. The estimated economic benefit from investments in NTDs also 
relies on the way productivity is valued in monetary terms. Assigning exclusively 
monetary value to these domains in terms of productivity gain undervalues the much 
bigger gain in physical and mental health that will lead to the increase in productivity. 
Therefore, policymaking should consider the health impact of controlling NTDs and not 
simply the economic benefit (as calculated here). 
The expected benefits in 2021-2030 are greater than that in 2011-2020, which is not 
surprising, since the difference in disease frequency between the counterfactual scenario 
and target achievement scenario will be greater in 2021-2030 (after the targets are met).  
The gains of achieving the 2020 targets for IDM diseases are not restricted to the 
economic benefits, with billions of people gaining physical and mental health, increased 
mobility, improved performance in school, access to care, structural improvement of 
health care services, community participation, and democracy with the 
control/elimination and eradication of NTDs. [198] Therefore the economic benefits 
estimated in this study represent just one part of the benefits that society could experience 




Comparisons with the literature 
As far as we are aware of, this is the first reported attempt to estimate the economic 
burden of IDM diseases per endemic country and globally, from an individual’s 
perspective. We know of only one other global cost-of-illness study of an IDM disease. 
Specifically, Lee at al. estimated a global annual burden from Chagas disease of US$ 0.5 
($0.2 – 1) billion in healthcare costs (corrected to US$2005 values for comparison) and 
US$ 6 (4 - 8) billion including lost productivity for Latin America related to disease-
induced early mortality, using a societal perspective. Their estimate of healthcare costs is 
approximately 30% less than our estimate of annual OPPs of US$ 0.85 (0.1 – 2.4) billion 
(2011-2030) while their estimate of lost productivity related to mortality is two times 
greater than our annual general productivity loss average of US$ 1.4 (0.9 – 2.0) billion 
using an individual’s perspective. However, it is difficult to make meaningful 
comparisons between our estimates and their estimates because of differences in 
methodology. For example, Lee et al grouped countries into quartiles based on GDP per 
capita (low/low-middle/high-middle/high income) and estimated the healthcare costs 
by quartile, assuming a linear correlation between costs and GDP per capita. With the 
exception of the three most prevalent countries (for which we had country-specific 
estimates), we converted one general Latin American estimate to local currencies of each 
of the other endemic countries. Lee et al included treatment-seeking probability in their 
model that was much higher than the percentage that we used (78% versus 35%). Also, 
they did not mention what they used regarding percentage of people paying for the 
treatment. [100]  
NTDs and poverty 
Paying for treatment – especially for IDM-NTDs treatment – can be catastrophic for 
individuals and even for households.[35] This is one of the reasons why the Sustainable 
Development Goals (SDGs) are more difficult to achieve without addressing NTDs (and 
vice-versa). This is especially true for goal 3.3: ‘By 2030, end the epidemics of AIDS, 
tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne 
diseases and other communicable diseases.’ [7,101] Furthermore, NTDs constitute an 
obstacle to achieving wider human development outcomes (for instance, food and 
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nutritional security, and improved maternal and child health). So, undoubtedly, achieving 
universal health coverage for NTDs will support progress in various interdependent 
development areas, such as poverty, education, sanitation, nutrition, water and gender 




Due to the scarcity of data on NTD spread and control, the prevalence estimates from 
the GBD study show very wide confidence intervals. These wide CIs affect the 
predictions by De Vlas et al. of the health impact of achieving the targets described in 
the London Declaration. Substantial uncertainty regarding the frequency of IDM diseases 
also existed, where the variation ranged from five times less to up to three times greater 
than the mean values (Table 7), dependent on availability of country and disease-specific 
epidemiological data [26]. This uncertainty only increased as the GBD numbers were 
extrapolated to estimate the prevalence in the period of 2010-2030. Given the influence 
of disease frequency on our estimates of economic impact, we included uncertainty about 
disease frequency in our sensitivity analyses. The results of these analyses show that even 
if the true prevalence values were close to the lower limits of the ranges used in our 
analyses, the economic impact would still be substantial. 
Productivity loss and Out-of-Pocket Payments 
In general, limited data was found on productivity loss and out-of-pocket payments, as 
well as the percentages of patients getting treatment or having to pay for it. As described 
in the Methods section, the OPP estimates available in the literature regarding IDM-
NTDs varied, partly because some sources included only drugs, while others included 
other medical and non-medical costs. This means that the values used might have been 
overestimated for some diseases but underestimated for other diseases. For instance, the 
variability in OPP prices for Chagas disease between Argentina and Brazil is due to their 
differences regarding the organization of the health system, the approaches to treating 
Chagas disease and its manifestations, and the infrastructure to treat Chagas 
manifestations. As an example, the digestive form of Chagas disease frequently needs 
 
 
surgery, but the direct costs related to it depend on access to hospital care and whether 
treatment is insured. [38,50-68] 
We also assumed that the percentage of patients paying for treatment equals the 
percentage of uninsured persons. This could lead to an overestimation of the costs, since 
not all individuals affected by NTDs might want treatment or be able to pay for it. 
However, it could also be an underestimation of the costs, since in many countries 
insured patients pay for treatment out-of-pocket in order to be treated faster. 
When no OPP or productivity loss values could be found, assumptions were made. In 
some cases, data from other diseases with similar sequelae were used. For instance, the 
productivity loss from disfigurement due to HAT was estimated using the estimate for 
onchocerciasis moderate scriot disease since they have the same GBD sequela category. 
[102]   
Most of the studies described lost productivity in working days missed because of the 
disease sequelae (absenteeism), especially for visceral leishmaniasis and Chagas digestive 
disease, where treatment itself requires a long hospitalization.[41-43,88,103-106] Only a 
few studies provided quantitative estimates of the decreased productivity loss at work 
due to presenteeism, something that can occur because of problems such as 
disfigurement or the early stages of Chagas disease.[38,62] 
Several assumptions regarding the generalizability of data had to be made due to lack of 
data. First, the same estimate for productivity loss was applied to men and women, even 
though the degree of productivity loss may differ between the two. [107-112] Secondly, 
for each sequela, the same estimate for productivity loss was applied to all individuals 
and countries, even though it differs between professions and settings. A similar situation 
was seen with OPPs, since sometimes only one estimate for one country was available 
(i.e. HAT), although the values used in the different countries were adjusted using CPI 
and PPP. Transferring the data from one country to another might have led to over- or 
underestimates of productivity loss estimates, as well as OPPs, depending on the disease 
sequela, the profession and the working environment, and the characteristics of each 
health care system.[34,113] 
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The achievement of 80% essential health services coverage and 100% financial 
protection from out-of-pocket payments in 2030, will surely happen in various ways and 
paces in the 191 countries included in this study. Most countries might want to invest 
sooner to gain more efficiency by reducing the vectors and prevalent cases and thereby 
reducing the number of infected individuals and disease transmission. This approach 
would probably follow a curve of ‘economies of scale’, which would mean more 
investments than the linear approach we followed. This would probably result in less 
economic benefit, but it would be difficult to estimate how much less, given the many 
possibilities and scenarios each country faces. In this sense, we calculated an ideal 
scenario that included reaching both the London Declaration targets and the 
WHO/World Bank recommendations for universal coverage and financial protection 
regarding NTDs aiming to provide extra arguments in favor of pursuing them. 
Income 
Different methods have been used in previous economic analyses of NTDs to 
approximate the rural adult wage, including use of GDP per capita, average agricultural 
value added per worker and the lowest wage rate from different predefined wage 
sources.[25,114,115] 
The GDP per capita of the lowest income quintile was used as a proxy for income for 
our calculations, since it provided the lowest - and therefore most conservative - 
estimates possible without having to combine multiple data sources. This approach could 
be criticized as an overestimation of the annual productivity loss of the affected 
populations, since NTDs are typically known as diseases of the poorest. We consequently 
varied income to the GDP per capita of the lowest decile in the sensitivity analysis.  
Sensitivity analyses 
A good estimate of the uncertainty around the economic impact shown in this paper is 
an impossible task, since the uncertainty regarding the impact on prevalence over the 
years cannot be reliably estimated Although sensitivity analyses were carried out to 
estimate the degree of uncertainty surrounding our estimates of economic benefit, greater 
knowledge of the variables used would improve the quality of the analyses.  
 
 
Despite the effort to account for many of the differences between diseases (sequela, 
productivity loss, OPP per disease, etc), our analyses represent a simplification of reality. 
In case more empirical data become available, more detailed studies could be done for 
each disease. Moreover, individual countries are encouraged to perform similar analyses 
to gather and use local data wherever possible to derive better local estimates of 
economic benefit. 
Reaching the 2020 targets for the 10 London Declaration NTDs described by the WHO 
[15,17] will depend on continued and sufficient efforts to achieve them, so especulating 
that they will be met of course implies a natural uncertainty about the future. The real 
economic benefit will certainly depend on local data, local circumstances, and the degree 
that each country will reach those targets. In this sense, our results support the 
implementation of efforts to reach these goals, but our results cannot help in deciding 
on how to reach them. 
Conclusions 
While the different factors of uncertainty described in the Discussion suggest that the 
results of this study should be interpreted with care, we can safely conclude that the 
economic benefits to individuals are at least equal to the investments required by 
governments and their development partners to reach the London Declaration 2020 
targets. It is more likely that the economic benefits will far exceed the necessary 
investments. Given the higher frequency of NTDs among the poorest households, these 
investments represent good value for money in efforts to increase human well-being and 
freedom, to better share the world’s prosperity and reduce inequity. We hope that these 
results can help policymakers in affected countries to choose to add NTDs to their public 
health, medical and scientific priority lists. A concerted effort is needed to collect better 
epidemiological and economic data to enable more accurate and complete estimates, 
which can be a better basis for planning and decision making. 
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Severe adverse events (SAEs) after treatment with ivermectin in individuals with high 
levels of Loa loa microfilariae in the blood preclude onchocerciasis elimination through 
Community-Directed Treatment with Ivermectin (CDTI) in Central Africa. We 
measured the cost of a community-based pilot using a test-and-not-treat (TaNT) strategy 
in the Soa health district in Cameroon. 
Methods 
Based on actual expenditures, we empirically estimated the economic cost of the Soa 
TaNT campaign, including financial costs and opportunity costs that will likely be borne 
by control programmes and stakeholders in the future. In addition to the empirical 
analyses, we estimated base-case, less and more intensive resource use scenarios to 
explore how costs might differ if TaNT were implemented programmatically. 
Results 
The total costs of US$ 283,938 divided by total population, people tested and people 
treated with 42% coverage were US$4.0, US$9.2, and US$9.5, respectively. In 
programmatic implementation, these costs (base-case estimates with less and more 
intensive scenarios) could be US$ 2.2 ($1.9 – $3.6), US$ 5.2 ($4.5 – $8.3), and US$ 5.4 
($4.6 – $8.6), respectively. 
Conclusions 
TaNT clearly provides a safe strategy for large-scale ivermectin treatment and overcomes 
a major obstacle to the elimination of onchocerciasis in areas co-endemic for Loa loa. 
Although it is more expensive than standard CDTI, costs vary depending on the setting, 
the implementation choices made by the institutions involved, and the community 
participation rate. Research on the required duration of TaNT is needed to improve the 
affordability assessment, and more experience is needed to understand how to implement 




Community-Directed Treatment with Ivermectin (CDTI) has been used since 1999 as 
the main strategy to combat onchocerciasis in Africa.[1,2] While generally considered 
safe, ivermectin has been associated with severe adverse events (SAEs) in individuals 
with high levels of circulating microfilariae (mf) of Loa loa (another filarial parasite 
endemic in Central Africa).[3,4] CDTI has been implemented in coendemic areas where 
the proportion of individuals with O. volvulus nodules exceeds 20% (hyperendemic and 
mesoendemic areas), albeit with enhanced adverse events (AEs) surveillance. However, 
fear of SAEs has caused individuals in such areas to refuse treatment, leading to 
suboptimal drug coverage and continued O. volvulus transmission. Moreover, CDTI is not 
recommended in Loa-coendemic areas where O. volvulus is hypoendemic (nodule 
prevalence <20%), as the risk of SAEs is thought to outweigh the benefits of CDTI. This 
jeopardizes onchocerciasis elimination in Africa.[5,6]  
A test-and-not-treat (TaNT) strategy using a smartphone-based videomicroscope 
(LoaScope) enabled the safe implementation of ivermectin treatment in a pilot study in 
the Okola health district (HD) in Cameroon where all individuals ≥5 years of age [7,8] 
were included. Of 16,259 tested individuals, only 340 (2.1%) were excluded from 
ivermectin treatment because of microfilarial counts >20,000 mf/mL; whereas 15,522 
(95.5%) were treated without the occurrence of SAEs.[7] A second TaNT study in Soa 
HD also had no postivermectin SAEs and further demonstrated that TaNT could be 
performed by local health workers and community members under the supervision of 
the research team.[9] Additional information about this TaNT round in the Soa HD can 
be found in Supplementary Appendix 1.  
Although TaNT is a promising strategy for onchocerciasis elimination in loiasis-
coendemic areas, its implementation is expected to be costlier than that of CDTI. 
Consequently, there are affordability concerns at a wider scale. Thus, we measured the 
cost of community-based TaNT in the above-mentioned Soa pilot study [9]. In addition, 
we estimated the cost for three programmatic implementation scenarios (base-case, less 
and more intensive), to obtain a range of plausible estimates under different assumptions 
of resource use. 
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A micro-costing approach [10] was used to empirically assess the cost of a community-
based TaNT in the Soa HD.[9] The empirical costing study reflects the costs borne by 
the organizations involved in implementing and executing the program in this specific 
pilot. A future program would likely be run by the Cameroonian Ministry of Health 
(MoH) in partnership with nongovernmental development organizations (NGDOs). We 
aimed to reflect this future situation in our cost calculations and therefore calculated the 
economic costs of the pilot, including financial costs (explicit cash expenditures on 
project activities) and added relevant opportunity costs (resources that could be used in 
other projects, if not used in this one).[11] We designed the protocol, data collection 
instruments and cost calculation sheets following standard guidelines and reported input 
quantities and costs to maximize comparability with other studies and recently published 
mass drug administration (MDA) benchmarks. [11,12]  
Study area and population 
The Soa HD in Cameroon (Figure 1) is an ivermectin-naive district that is hypo-endemic 
for onchocerciasis and co-endemic for loiasis.[13] It is located 17 km from Yaoundé 
(Cameroon’s capital) and is easily accessible. Soa HD consists of 6 health areas (3 rural, 
2 semiurban, 1 urban) and its population was estimated at 71,643 inhabitants, according 
to the census performed as part of the TaNT pilot. 
 
 
Figure 1. Map of Soa health district in Cameroon, showing the rural/urban 
characterization, number of communities and population size by health area 

















C: Number of communities
Pop: Total population
 
Time window  
The census, testing/treating and monitoring of SAEs in the TaNT round took place 
from September 2017 to February 2018. Costs were collected beginning with the 
preparation of the round in August 2017 until the last payments in March 2018.  
Cost calculation components 
The ‘supplies’ category includes (but is not restricted to) fuel, car maintenance, food, 
transportation, office materials, field materials, and drugs to treat AEs. The ‘personnel’ 
category includes per diems of community drug distributors (CDDs) and other staff, 
project staff salaries, and fringe costs for study personnel, when applicable. Overhead 
costs were not explicitly measured, but were assumed to be 15% of direct costs, as 
reported in the project budget. Supplementary Appendices 1 and 2 (Tables 1,2 and 4) 
provide additional information. We excluded the following costs: ivermectin costs (as 
the drug was donated); bank tariffs; management/administrative costs incurred outside 
the country; costs incurred by households to be treated; opportunity cost of time spent 
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by school staff; opportunity costs of buildings used by MoH staff and of capital items 
purchased for previous projects.  
 
Costs of LoaScopes and capillaries were provided in US dollars (US$); all other costs 
were reported in Central African francs (XAF) and converted to US$ using the US 
Treasury Reporting Rates of Exchange of December 31st, 2017 (1 US$ = $ 568 
XAF).[14]  
Data collection  
Costs were based on actual payments or booked transfers collected from all invoices and 
bank transactions provided by project managers. External MoH staff working in the 
project and CDDs were interviewed using structured questionnaires to obtain 
information about their time spent on the project and opportunity cost of their salaries. 
A summary of the design, structure and dissemination protocol for each questionnaire 
and English versions of these can be found in Supplementary Appendix 3 (Table 6 and 
Questionnaires 1 - 3).  
Data entry, cleaning and analysis 
The invoices were analysed and compared to the data provided by monthly financial 
reports and bank transactions for consistency and quality checks. The value of each 
invoice or bank transaction was labeled according to the input category, the health area 
in which the cost was incurred (using the label “district costs” if costs were not specific 
to any health area, but relative to the project as a whole), and the activity to which the 
cost could be attributed (advocacy, census, planning and budgeting, procurement, 
training, health education in the community and mobilization [HECM], delivery and 
distribution of interventions to target populations, AE surveillance and management, 
monitoring and evaluation, and general management). Data from invoices and 
questionnaires were entered into a Microsoft Excel spreadsheet for further analysis. 





To assess the effect of different implementation strategies on the overall cost of TaNT, 
costs were calculated using three hypothetical alternative TaNT implementation 
scenarios: “base-case”, “less intensive resource use” and “more intensive resource use”. 
The scenarios were designed based on the literature and our own expertise in conducting 
CDTI in Cameroon, using the same HD for context (eg, applying the same rural/urban 
distribution, same distances to the capital, same mode of delivery). [2,15] Table 1 
describes the main differences between the scenarios and the pilot. See Supplementary 
Appendix 4 (Tables 7 - 9) for a more detailed description. 
Table 1. Summarized description of alternative scenarios  
Cost Category Cost scenario 
 








Smaller teams and 
fewer days than pilot 
<<< pilot 
Same team and fewer days 
than base-case 
< pilot 
Bigger team and 
more days than 
base-case 






= pilot << pilot (50% less than 
pilot) 
= pilot 
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CDDs < pilot (CDDs only 
paid for training days) 
< pilot (CDDs only paid 
for training days) 
>> pilot (CDDs 





income of an 
eight-hour work 
day (to account 




> pilot (were paid a 
higher transport fee per 
field day, to account for 
more distant 
communities - based on 
responses of 
questionnaires) 





None None 100 workers 
Supplies 
Fuel > pilot (extra fuel 
allowance for MoH and 
NGDO cars) 






< pilot (assumed large-
scale prices) 





< pilot (30% less than 
pilot) 
< pilot (50% less than 
pilot) 
= pilot 
Abbreviations: <, less than; <<, lesser than; <<<, much lesser than; >, more than; >>, much 
more than; AE, adverse events; CDD, community drug distributors; HECM, health education in 
the community and mobilization; M&E, monitoring and evaluation; MoH, Ministry of Health; 
NGDO, nongovernmental development organization. 




The population size and numbers of individuals tested, treated or excluded, as well as 
the occurrence of AEs, per health area are given in Table 2. Only 0.8% of the tested 
population was excluded from treatment. The overall coverage was relatively low (42%).  
The costs of the pilot, disaggregated by programmatic activity, are presented in Table 3. 
The costliest activities were related to the actual delivery of the intervention (31%) and 
HECM (11%), although general management costs (not related to a specific activity) also 
formed a large part of the total costs (19%). The supplies input categories that were 
responsible for the highest shares of the total costs (from highest to lowest), are 
capillaries and information, education and communication materials leading with 12% 
and 10% of the total pilot costs, respectively (Supplementary Appendix 2: Table 3). 
Supplementary Appendix 5: Table 10 shows volumes and prices of supplies per input 
category.
table continues
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more than; AE, adverse events; CDD, community drug distributors; HECM, health education in 
the community and mobilization; M&E, monitoring and evaluation; MoH, Ministry of Health; 
NGDO, nongovernmental development organization. 




The population size and numbers of individuals tested, treated or excluded, as well as 
the occurrence of AEs, per health area are given in Table 2. Only 0.8% of the tested 
population was excluded from treatment. The overall coverage was relatively low (42%).  
The costs of the pilot, disaggregated by programmatic activity, are presented in Table 3. 
The costliest activities were related to the actual delivery of the intervention (31%) and 
HECM (11%), although general management costs (not related to a specific activity) also 
formed a large part of the total costs (19%). The supplies input categories that were 
responsible for the highest shares of the total costs (from highest to lowest), are 
capillaries and information, education and communication materials leading with 12% 
and 10% of the total pilot costs, respectively (Supplementary Appendix 2: Table 3). 
Supplementary Appendix 5: Table 10 shows volumes and prices of supplies per input 
category.
table continues



























































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Total costs of pilot per activity (US$) 
Programme  
Activity 
Supplies Personnel Total Percentage of 
total pilot 
costs 
1) Advocacy 6,020 843 6,864 2% 
2) Census 741 18,975 19,715 7% 
3) Planning and 
budgeting 
100 8,071 8,170 3% 
4) Procurement 30 9 39 0.01% 
5) Training 2,537 13,542 16,078 6% 
6) HECM 21,442 8,979 30,421 11% 
7) Delivery 
intervention 
46,527 42,137 90,115 31% 
8) AE surveillance 
and management 
2,048 10,253 12,300 4% 
9) M&E 107 11,606 11,712 4% 
10) General 
management a 
18,280 34,613 52,892 19% 
Subtotal Activities 97,830 149,027 248,308 87% 
Overhead Costs b b 37,253b 13% 
Total 112,504 171,381 283,885 100% 
Abbreviations: AE, adverse event; HECM, health education in the community and 
mobilization; M&E, monitoring and evaluation. 
a Includes all inputs related to the project as a whole and that could not be attributed to 
a specific activity (eg, electricity, some office supplies, communication, some of the fuel 
and car maintenance costs). 
b Calculated as 15% of the activities subtotal. 
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The majority of the personnel costs were not related to a specific activity but to actions 
related to the implementation of the round as a whole. The same holds true for district 
and health area level MoH personnel. The main costs of all other categories were related 
to the delivery of the intervention (Supplementary Appendix 2: Table 5). 
The total cost for the entire pilot was US$ 283,938 (Table 4), with a cost per person 
treated of US$ 9.5. The cost per person treated was reduced to US$ 5.4 for the base-case 
and to US$ 4.6 and US$ 8.6 for the less and more intensive scenarios, respectively.  
The absolute costs of the Soa pilot and each of the implementation scenarios 
disaggregated by programmatic activity, as well as the percentages of each activity are 
given in Figure 2. The empirical study was more expensive than the scenarios, mainly 
due to the census, HECM, general management costs (for instance car maintenance and 
field materials) and the costs of LoaScopes and capillaries. Costs of delivering the 
intervention formed the largest share of the total costs, mainly due to the costs of 
capillaries, field material and per diems, which showed a reduction in the base-case and 
less intensive scenarios mostly due to less supervision and less expensive materials. Costs 
increased considerably in the more intensive scenario, due to the payment of higher per 
diems to CDDs to account for income loss. Even though general management costs 
were also reduced by less expensive materials in the scenarios, the percentage of the total 
costs did not change much. Costs of HECM were lower in the scenarios because of the 
exclusion of the costs of the megaphone-equipped car and the reduction of prices of 
materials.
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This study provides both empirical cost estimates of a pilot and projected costs based on 
scenario analyses using the new TaNT strategy in regions co-endemic for O. volvulus and 
L. loa. Based on actual expenditure during the pilot, this strategy cost US$ 4.0 per person 
in the population, US$ 9.2 for each person tested, and US$ 9.5 for each person treated. 
In the alternative implementation scenarios, these costs (shown as base-case estimates 
with less and more intensive scenarios) were estimated to be US$ 2.2 ($1.9 – $3.6), US$ 
5.2 ($4.5 – $8.3), and US$ 5.4 ($4.6 – $8.6), assuming that population participation 
remained unchanged. 
Several limitations apply to the internal validity of our study. Despite the careful 
collection of available data from invoices, bank transfers and questionnaires, we had to 
adapt to the system usually used by financial managers of the implementing institution, 
without explicit reporting of the cost of previously acquired capital items or building 
rental. Using a retrospective questionnaire investigating opportunity costs of MoH staff 
was also not ideal, since it allows recall bias. Opportunity costs of time spent by school 
staff when helping during the treatment phase and of vehicles and furniture acquired for 
other projects were not included in this study, leading to a slight underestimation of the 
costs of the pilot. These limitations should be addressed in future studies to increase the 
accuracy of cost estimates and enable policymakers to anticipate their costs more reliably. 
This would also allow economic costs to be presented separated from financial costs. 
Because we measured costs in a study setting, alongside a pilot implementation of 
community-based TaNT, our results may not be fully representative of a programmatic 
setting, limiting the external validity. Some costs may have been higher than expected 
under programmatic implementation (eg, all personnel received intensive training and 
supervision and CDDs received payment). Further, best implementation practice still 
remains to be determined, and future programs may be implemented somewhat 
differently. The programmatic operationalization scenarios were designed to address the 
external validity limitations. They still do not cover all possible variations in 
implementation choices. We built the base-case scenario aiming to reflect Cameroonian 
reality as much as possible. As shown in the scenario analyses, costs heavily depend on 




reductions in supervisory personnel, health education and sensitization, surveillance and 
management of AEs and purchase prices of the LoaScopes and capillaries. The last two 
categories can be further reduced by implementing NGDOs/MoH if external funding 
agencies opt to donate these supplies to countries choosing to implement the TaNT 
strategy, as already done with the donation of ivermectin. 
Overall study coverage was relatively low, particularly in the semi-urban and urban areas. 
Higher coverage is essential to onchocerciasis elimination. Achieving high coverage in 
urban areas is a known problem, even in standard CDTI, due to lack of trust in public 
programs, migrant populations, and disorganized poor urban settlements.[16,17] Yet, it 
may be even more difficult to achieve in TaNT programs, as blood sampling needs to be 
done during regular school/work hours; requires the involvement of additional people 
(blood drawers and “loascopists”), and is best done with a mobile station rather than 
house-to-house. Additional measures are needed to increase coverage, including 
continuous and improved health education/mobilization and alternative ways to offer 
testing and treatment, such as mobile stations at schools and in commercial/industrial 
areas. However, since it is difficult to predict the cost and impact of these measures on 
coverage, we have not considered increases in coverage in our implementation scenarios. 
Although there will be some economies of scale (fixed costs divided over a larger 
population), other costs are likely to increase with the number of people covered (eg 
personnel costs for delivering the intervention), resulting in a higher cost per person. 
Our estimates, derived from a community-based single study, are not directly transferable 
to other settings due to many factors, such as variations in local prices, organization and 
availability of healthcare, and geographic characteristics such as remoteness, accessibility 
and level of “urbanness”.[18,19]  
To eliminate onchocerciasis, treatment would have to be repeated yearly (or more 
frequently) for many years with sufficient treatment coverage (ie, 80% of the eligible 
population per WHO guidance).[20] The costs of future rounds are likely to be 
significantly lower than the initial round for a number of reasons, including the absence 
of start-up costs, shared fixed costs (over multiple rounds within a given year), more 
efficient implementation (from the experience and structure provided by the first round), 
lower intensity of HECM (communities would already be aware of the strategy), and less 
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MoH advocacy and AE surveillance (since fewer cases would need to be followed). 
Further, as L. loa microfilarial densities remain low after treatment for at least 18 months, 
people proven to be treated in the previous round (using re-identification methods) 
would not need to be re-tested [21]. Capillary and LoaScope costs would only remain for 
the individuals not previously tested and treated, making costs much more comparable 
to those of standard CDTI. 
To date, there are no studies of the costs of alternative strategies of measuring L. loa 
microfilarial densities before treating for onchocerciasis to which we could compare our 
results. We cannot directly estimate the difference in costs between TaNT and CDTI 
without empirical comparisons, as it is impossible to disentangle costs of treatment from 
those of testing in the TaNT strategy. A unit cost benchmarking study by Fitzpatrick et 
al. [11] showed that the unit cost of mass drug administration is highly variable, 
depending very much on the use of volunteers and economies of scale. This variation 
complicates a direct comparison of our results with any previously published figures. A 
web-based tool [11] that provides unit cost benchmarks for different settings allowed us 
to estimate the expected cost of a first round of standard CDTI in Soa, using the 
corresponding population and characteristics of the area (which the tool allows), and the 
resulting cost estimates were US$ 18.3 (95% confidence interval [CI], $6.9 – $35.6) per 
person treated using paid community health workers. The observed cost of TaNT for 
the pilot and more intensive scenario are closer to the lower end of the range despite the 
cost of testing. The benchmark unit cost of standard CDTI is considerably lower when 
implemented by unpaid community volunteers, US$ 3.9 [95% CI, $2.2 – $5.7], and the 
cost of our base-case and low-intensity implementation scenario comes quite close to 
this. Details on the use of the benchmark tool are provided in Supplementary Appendix 
6. 
Through TaNT, community treatment with ivermectin can be expanded into the many 
areas in central Africa that are hypoendemic for onchocerciasis and co-endemic for 
loiasis, where standard CDTI cannot be applied for safety reasons. Implementing 
treatment in these regions is crucial for the continent-wide elimination of onchocerciasis, 
with associated health and socio-economic benefits estimated at more than US$ 6 
billion.[22] The populations concerned will not only benefit from the control and 




anthelmintic drug - also from the effects of treatment of other parasitic diseases including 
scabies and soil-transmitted helminthiases.  
Conclusion 
Costs of TaNT are higher than costs of standard CDTI. How much higher will depend 
on how subsequent treatment rounds will be implemented and the required program 
duration. The duration will not be much longer than in Loa-free areas if the coverage is 
sufficiently high and the proportion of the population excluded from treatment (because 
of high-density loiasis) is as low as observed in Soa and Okola (1% on average). The 
effect of excluding people from treatment may be more important where the proportion 
of people excluded due to loiasis is higher, but this can be mitigated by offering 
alternative treatment for onchocerciasis, such as a course of doxycycline. Although we 
did not assess the costs associated with such treatment, these should be weighed against 
the impact on program duration and success.  
Even though TaNT is undoubtedly more expensive than MDA, onchocerciasis 
elimination will not be reached without a strategy that can be safely used in areas co-
endemic for L. loa. Our empirical study shows that TaNT using LoaScopes remains 
affordable, given the enormous potential economic benefits of reaching elimination of 
onchocerciasis in Cameroon and in other countries where L. loa is co-endemic with O. 
volvulus. Various implementation scenarios show that costs could be further reduced. 
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Appendix 1. Summarized description of the TaNT pilot in Soa HD 
Cameroon participated in the African Programme for Onchocerciasis Control (APOC) 
between 1995 and 2015, adopting CDTI as its main strategy to control onchocerciasis 
morbidity in meso- and hyperendemic areas.[227,228] During this period, Cameroon 
reported 471 SAEs following ivermectin treatment (~34% of all reported cases in the 
Mectizan Donation Program). Encephalopathy was reported in 221 cases, mostly (90%) 
in individuals taking ivermectin for the first time.[229] 
This pilot was implemented in the Soa Health District (HD) by the Centre de Recherche 
sur les Filarioses et autres Maladies Tropicales (CRFilMT), Cameroon in partnership with 
Institut Bouisson-Bertrand, France and was funded by the Bill and Melinda Gates 
Foundation (BMGF). 
The round started with advocacy meetings, followed by health education and community 
mobilization about the importance and the dates of the upcoming TaNT-related 
activities. Community-directed distributors (CDDs) were selected within their own 
villages (approximately 1/100 inhabitants), whereas blood drawers and loascopists (those 
responsible for handling the LoaScope) were selected at the level of the health area. All 
three categories were trained by professionals from the implementing institution and the 
Ministry of Public Health (MoH). After the training, CDDs conducted village censuses 
and reported the population numbers to the implementing institution. 
After completion of the training, the community teams spent several days in each village 
to test and treat the population. Inhabitants were invited to come to a central location in 
the village between 10am and 4pm (because of the diurnal periodicity of Loa loa mf in 
peripheral blood), where the team assessed whether they met the participation criteria 
(age ≥ 5 years, non-pregnant and without severe chronic diseases) and tested those 
eligible for participation. The entire eligible population was offered blood screening using 
a smartphone-based microscope called LoaScope, which provides an accurate estimate 
of L. loa mf counts within 2 minutes.[212] Tested individuals with a count lower than 
20,000 Loa mf/mL were treated with ivermectin. Those with ≥20,000 Loa mf/mL - 




spectrum anthelmintic drug that has no direct effect on L. loa mf). The threshold used 
was lower than the 30,000 mf/mL suggested by the WHO to ensure the prevention of 
marked adverse events that could raise concern and reduce participation rates.[208,211] 
Additional testing and treating was performed in schools as a means to increase the 
coverage among children who were unable to attend the centralized treatment conducted 
in their communities. A team from the implementing institution (1 physician, 1 
pharmacist, 1 nurse, 1 driver) supervised AE surveillance. The surveillance period 
comprised the first three consecutive days, and day 7 after treatment of each individual. 
A more detailed description of all activities undertaken for the pilot of community-based 
TaNT in Soa HD is provided in Table S1, with comparison to standard CDTI and the 
implementation of a TaNT base case scenario. The scenarios are described in more detail 
in Appendix 4.  
Table S1. Comparison between the activities usually carried out in a standard CDTI 
round in Cameroon, the pilot of community-based TaNT in Soa HD, and the TaNT base 
case implementation scenario.[206,219]









Appendix 1. Summarized description of the TaNT pilot in Soa HD 
Cameroon participated in the African Programme for Onchocerciasis Control (APOC) 
between 1995 and 2015, adopting CDTI as its main strategy to control onchocerciasis 
morbidity in meso- and hyperendemic areas.[227,228] During this period, Cameroon 
reported 471 SAEs following ivermectin treatment (~34% of all reported cases in the 
Mectizan Donation Program). Encephalopathy was reported in 221 cases, mostly (90%) 
in individuals taking ivermectin for the first time.[229] 
This pilot was implemented in the Soa Health District (HD) by the Centre de Recherche 
sur les Filarioses et autres Maladies Tropicales (CRFilMT), Cameroon in partnership with 
Institut Bouisson-Bertrand, France and was funded by the Bill and Melinda Gates 
Foundation (BMGF). 
The round started with advocacy meetings, followed by health education and community 
mobilization about the importance and the dates of the upcoming TaNT-related 
activities. Community-directed distributors (CDDs) were selected within their own 
villages (approximately 1/100 inhabitants), whereas blood drawers and loascopists (those 
responsible for handling the LoaScope) were selected at the level of the health area. All 
three categories were trained by professionals from the implementing institution and the 
Ministry of Public Health (MoH). After the training, CDDs conducted village censuses 
and reported the population numbers to the implementing institution. 
After completion of the training, the community teams spent several days in each village 
to test and treat the population. Inhabitants were invited to come to a central location in 
the village between 10am and 4pm (because of the diurnal periodicity of Loa loa mf in 
peripheral blood), where the team assessed whether they met the participation criteria 
(age ≥ 5 years, non-pregnant and without severe chronic diseases) and tested those 
eligible for participation. The entire eligible population was offered blood screening using 
a smartphone-based microscope called LoaScope, which provides an accurate estimate 
of L. loa mf counts within 2 minutes.[212] Tested individuals with a count lower than 
20,000 Loa mf/mL were treated with ivermectin. Those with ≥20,000 Loa mf/mL - 




spectrum anthelmintic drug that has no direct effect on L. loa mf). The threshold used 
was lower than the 30,000 mf/mL suggested by the WHO to ensure the prevention of 
marked adverse events that could raise concern and reduce participation rates.[208,211] 
Additional testing and treating was performed in schools as a means to increase the 
coverage among children who were unable to attend the centralized treatment conducted 
in their communities. A team from the implementing institution (1 physician, 1 
pharmacist, 1 nurse, 1 driver) supervised AE surveillance. The surveillance period 
comprised the first three consecutive days, and day 7 after treatment of each individual. 
A more detailed description of all activities undertaken for the pilot of community-based 
TaNT in Soa HD is provided in Table S1, with comparison to standard CDTI and the 
implementation of a TaNT base case scenario. The scenarios are described in more detail 
in Appendix 4.  
Table S1. Comparison between the activities usually carried out in a standard CDTI 
round in Cameroon, the pilot of community-based TaNT in Soa HD, and the TaNT base 
case implementation scenario.[206,219]






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Personnel were paid per diems for days of work outside their working place 
(receiving/giving training or any days of field work). To the costs of the per diems were 
added the costs of the daily salaries of each professional, to account for the opportunity 
cost of their time not spent in other projects. The structure needed for the use of the 
LoaScope still does not allow a house-to-house strategy, so we kept the costs of using 
mobile stations. 
 
Overhead costs were included to capture the shares of the salaries of the administrative 
and financial managers (general administration), and the coordinator, building rental, 
cleaning and security services attributable to this project. Capital items are here defined 
as having a life expectancy of more than 5 years. Capital items such as vehicles, 
computers, software, office furniture, communication or audiovisual equipment used in 
the Soa campaign had already been paid by previous projects (except for the LoaScopes, 
no capital items were purchased specifically for this project) and were not included in the 
cost calculations. The variable running costs related to such capital items were explicitly 
included in the micro-costing study. Overhead costs were billed to the funding source 
(Bill and Melinda Gates Foundation via Institut Bouisson-Bertrand) as 15% of all actual 
expenditures of the entire round (of all costs of supplies and personnel). This seems to 
be a reasonable estimate of the overhead costs, considering that the TaNT campaign is 
not the only project to fund these expenses. These resources are jointly used by more 
programmes run by CRFilMT. A higher percentage bears the risk of double counting. 
Costs exclusively related to research (research protocol driven costs) were not included 
in this study. They include costs related to travelling to and attending research meetings, 
congresses, research visits from international researchers for the development of data 








Appendix 3. Questionnaires 
Questionnaires were adapted from those used in the DOLF project.[216]  
A prospective questionnaire with a user-friendly design with tables, tick boxes and 
expected short answers was chosen based on feedback from the CDDs. This was used 
to investigate the number of hours CDDs spent on transportation, training, census-
taking, treatment and reporting. It was also used to collect information about their 
occupation and income, capture their opportunity costs and enable the use of real 
information instead of arbitrary valuation systems such as Gross National Income (GNI) 
or rural wage as a proxy for an 8-hour day of volunteer labor.[230]  
The English versions of the French questionnaires are included below. 
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The English versions of the French questionnaires are included below. 
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Retrospective questionnaire for people involved in TNT 
 
To be completed by a CRFilMT interviewer for each  staff of the Ministry of Health and NGOs 
involved in the TNT strategy.  This does not include permanent CRFilMT staff.  Please note that all 
questions refer to time spent during one year. 
 
In 2017, did you spend time on TNT Loa loa project in Soa ?. 
  Yes       No 
If yes, continue with questions below ; if else, stop interview. 
 
 
1. Please allocate an estimate of your time spent on the TNT project for Loa loa in Soa across the 
following activities: (Note: total must equal 100%) 
 
Activity codes Nr days Percentage of time 
allocated 
(1)  Advocacy   
(2)  Supervision of census   
(3)  Planning and budgeting   
(4)  Procurement   
(5)  Training   
(6)  Supervision of health education/community 
mobilization  
  
(7)  Delivery of interventions (treatment) to target 
populations  
  
(8)  Adverse event surveillance and management   
(9)  Monitoring and evaluation   





2. What is your monthly salary? ______________________ 
 
 
3. Did you receive per diems for the days you spent on TNT Soa? Yes ____ No ____ 
 If yes, for how many days?  ________ 
 How much did you receive per day? _______ CFA francs /per day 
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Fuel and drivers. CRFilMT transported blood drawers and loascopists from their 
villages to the villages they were going to work at. In a CDTI round organized by the 
health district this would not be possible and it also decreases the efficiency of the work, 
since it delays the starting time in the field. To account for this, we added a transportation 
fee of 600 XAF to the per diems paid to blood drawers and loascopists in the base case 
scenario, using the average transportation cost paid by CDDs in our project to get to the 
trainings. They would still have to bring back LoaScopes to health centers at the end of 
each treatment day in order to recharge their batteries and check for any malfunction. 
Since personnel from the different levels would still need drivers to take them to training 
sites and to the field for supervision, we assigned one driver per person of the above-
mentioned supervision team, for each day of work, with a per diem of 20,000 XAF. Since 
it is more difficult to have available drivers for district level staff, a fuel fee of 10,000 
XAF was assigned to each of their days of work. Fuel allowance was also added to 
national and regional level personnel: 30,000 and 20,000 XAF, respectively. The sum of 
the per diem costs of drivers just mentioned replaced the costs of drivers’ per diems of 
the original TaNT pilot for census, training and delivery of intervention. Fuel costs were 
kept as the original round costs, added the costs of the fuel for the national, regional and 
district personnel. 
Since we are considering a first implementation round in the scenarios, health education 
and community mobilization costs would be similarly high. Unlike during the pilot, a 
sound car is not typical. Thus, we excluded all costs relative to its use in all scenarios.  
Personnel costs related to administrative authorities (180,000 XAF) were kept the same. 
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Appendix 5. Volumes of supplies input categories 
Supplementary Table 10. Volumes of supplies per input category. Prices specified 
in Communauté Financière Africaine (CFA, African Financial Community) 
francs (XAF). 
Item  Quantity Unit price Total price 
Personnel material (variable)  
Capillaries (receipt in Dec 2017)  66,274 1.1 72,901 
LoaScopes purchase  15 212,000 3,180,000 
Badges  566 263 149,000 
Bags for blood drawers  15 5,000 75,000 
T-shirts  700 1,800 1,260,000 
Drugs for AE management (variable) 
Aerius 5mg coated tablet/7  1 2,600 2,600 
Amoxicilline 500mg gel B/1000  1 29,000 29,000 
Artemether  9 650 5,850 
Arthemether+lumefantrin 
20/120mg tablet disp B/6  
10 1,121 11,210 
Arthemether+lumefantrin 
80mg/480mg B/6 tablet  
10 910 9,100 
Arthemether+lumefantrine 
20/120mg tablet B/24  
9 855 7,695 
B complex vitamin tablet B/1000  1 13,146 13,146 
Yellow Betadine dermatologic 
solution flacon /125ML  
1 1,550 1,550 
Chlorpheniramine B/10  60 500 30,000 
Cloxacilin  6 500 3,000 
Compress 40*40  1 1,450 1,450 




Diclofenac DENK 50 TABLET 
B/2x10  
50 794 39,700 
DIFENASOL flacon /5ML  10 680 6,800 
Dynapar 100mg  1 950 950 
Pregnancy test  1 500 500 
Gentamycin eyedrops 10mL  5 525 2,625 
GENTASOL CY flacon 5mL B/1  10 713 7,130 
Glove  3 100 300 
Glycaemia  1 1,000 1,000 
Health care visit ticket  1 300 300 
Ibuprofen 400 tablet B/10x10  5 1,050 5,250 
Ibuprofen 400mg B/100 tablet  5 1,350 6,750 
Iron sulfate 200mg+Folic acid 
0.25mg tablet B/1000  
2 22,000 44,000 
Laritem 80mg/480mg tablet/6  1 2,650 2,650 
Loratadine 10mg B/10 tablet 20 1,407 28,140 
Metronizadole 250mg tablet 
B/1000 (Flagyl)  
3 6,890 20,670 
Crepe band 4*7C  1 600 600 
Paracetamol 500mg tablet B/100  100 425 42,500 
Patient card  1 300 300 
Quinine sulfate 300mg tablet 
B/1000  
1 32,400 32,400 
Plaster 5x5cm  1 2,550 2,550 
Syringe  6 100 600 
Vitamin B complex tablet B/1000  2 13,146 26,292 
Voltaren emulgel 1% T 50G  1 1,875 1,875 
Hemoglobin test 1 500 500 
    
table continues
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Fuel and car maintenance (variable) 
Car maintenance (episodes) 47 98,584 4,633,429 
Fuel (Liters)  7,144 577 4,121,900 
IEC materials and registers (variable) 
IEC Leaflets 10,000 170 1,700,000 
IEC Posters  1,000 2,500 2,500,000 
Registers  900 2,777 2,499,000 
Field materials (variable) 
Alcohol 95% (liters)  200 1,500 300,000 
Bin bag 50Lx20  11 1,425 15,675 
Bleach water (1 liter)  1 950 950 
Bleach water 250ml  10 300 3,000 
Hydrophilic cotton (pack of 500g)  130 1,900 247,000 
Disposable cup  127 1,400 177,800 
Chalk (pack of 100)  23 1,614 37,129 
Gloves (pack of 20)  86 25,000 2,150,000 
Grapefruit anti-bac  10 1,000 10,000 
Hand washing gel 500ml  9 975 8,775 
Lancets (pack of 200)  120 3,000 360,000 
Paper towels  21 3,000 63,000 
Paper towels large size*2  5 1,500 7,500 
Paper towels large size*6  5 2,400 12,000 
Mineral water (10L)  5 1,250 6,250 
Recycle bin bags  20 1,750 35,000 
Trash bucket  1 1,500 1,500 




Wraps (pack of 72)  21 2,350 49,350 
Office supplies (fixed) 
Staple remover  1 500 500 
Paper (reams of 500 sheets)  117 2,250 263,250 
Pen (pack of 144)  4 40,750 163,000 
Pencil  60 50 3,000 
Pencil sharpener  20 150 3,000 
File with 40 plastic bags 1 1,600 1,600 
File with 40 plastic bags 1 1,850 1,850 
Printer cartridge  14 47,000 653,000 
Paper clips (1000)  1 2,000 2,000 
Air time (global)  70 5,000 348,000 
table continues
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Appendix 6. Benchmark tool use 
Fitzpatrick et al. (2016) developed a web-based software application that allows each user 
to calculate MDA round costs per person treated, varying different aspects according to 
each context.[215] We used the tool for the calculation of economic costs with a 
population of 71,643 (our censused total population), coverage rate of 42% (our final 
coverage rate), subnational, with no school-based delivery, no volunteers, 1 disease 
(stand-alone program), 1 round per year, first year of implementation, GDP per capita 
(2017) of US$ 1446.70 [231], and population density of 51.91/sq km [232] for the setting. 
We chose McFarland and Menzies (2005) for study-specific fixed effect, whose 
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The main aim of the research presented in this thesis was to study the socioeconomic 
effect of neglected tropical diseases (NTDs) on individuals and society. Different aspects 
were investigated, from the description of productivity loss due to NTDs, to the 
economic benefit of reaching the London Declaration targets, to the cost of a new 
strategy to reach the targets for onchocerciasis, and the assessment of illness-related 
impoverishment. In general, lack of available data imposed extra challenges in the 
fulfillment of these objectives. Nevertheless, the results contributed to filling the existing 
gap in scientific knowledge related to this topic. In this chapter, by answering the research 
questions, the results will be put in a larger context of the literature and recommendations 
for further research. Furthermore, some additional perspectives on NTD research, policy 
making and a personal view on research in Brazil are provided before summarizing the 
main conclusions of this work. 
 
7.1 Answering and discussing each research question 
a. How (far) has productivity loss related to NTDs / disease been 
described in the literature? 
It was logical to assume that the physical and psychological effects of NTDs affect 
productivity loss, and the results of the literature review described in Chapters 2 and 4 
confirmed it, but more importantly, they also showed a vast gap in in the literature 
regarding this topic. 
The focus of the literature on NTDs has been mostly epidemiological and clinical, so the 
impact of NTDs on productivity of affected men and women has been less frequently 
studied. The systematic literature review (Chapter 2) revealed a scarcity in studies on the 
productivity loss related NTDs, both those controlled by preventive chemotherapy 







 NTD Number of studies with any 


















Chagas disease 12 
Visceral leishmaniasis 10 
Leprosy 4 
 
There was a large variation in the definition of productivity loss used by the studies, and 
in the applied methodologies to quantify absolute and relative productivity loss. 
Furthermore, type and severity of the disease directly interfere on the actual impact, as 
well as the context where it occurs. Quality differed between studies for each disease, 
with 60% of the papers with an overall high risk of bias, mostly detection bias, selection 
bias, and attrition bias. No particular trend was observed, regarding over- or 
underestimation of results due to bias. 
As with most reviews regarding costs and cost-effectiveness evidence, this systematic 
literature review conducted in 2013 focused on peer reviewed publications in the English 
language. We found only few studies published after our review that specifically reported 
productivity loss due to NTDs. One study measured 10% productivity loss for 
onchocerciasis patients via a household (HH) survey in Nigeria [1], less than the results 
for onchocerciasis found in this review and less than the values used in the calculations 
of the economic benefit in Chapter 3. Another study described a productivity loss of 
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the results for onchocerciasis found in this review, but similar to the values used in 
Chapter 3. 
The general impression, also presented in Chapter 5, is that illness-related productivity 
loss related to low-income settings has not yet raised much academic interest. This might 
be explained from two angles. First, measuring productivity loss in low-income contexts 
might be more difficult than in high-income settings. Second, poor populations usually 
have little political voice and therefore might not be among the highest priorities of policy 
makers and research funds. Furthermore, the relation to poverty does not seem to be 
appealing to many scientists that aim to show societal impact of their research. Therefore, 
given the striking scarcity of peer reviewed evidence, we strongly recommend stimulation 
of research on productivity loss related to NTDs, but also to other diseases that have a 
high burden in low- and middle-income countries (LMICs). 
 
b. How much economic benefit can be expected from reaching the 
targets for the 10 London Declaration NTDs? 
There is an important economic benefit of reaching the 2020 NTD targets set by the 
WHO for PCT and IDM diseases, both in averted productivity loss and out-of-pocket 
payments (OPPs), as described by Chapters 3 and 4. 
The economic benefit of reaching these targets was calculated by subtracting the costs 
calculated for a target achievement scenario from the costs of the counterfactual scenario 
of having done nothing for each disease, for the period between 2011 and 2030 (ten years 
before and after target-achievement). For the calculation of the costs, the estimated 
disease frequency was combined with productivity loss resulting from the disease, from 
the perspective of a person affected by each of the NTDs. The same was done for the 
healthcare costs paid by the affected individuals. The results based on conservative 














NTDs 2011 - 2020 2021 - 2030 2011 - 2020 2021 - 2030 
Preventive 
Chemotherapy (PCT) 
251 billion 313 billion 0.72 billion 0.96 billion 
Intensified Disease 
Management (IDM)  
23.1 billion 35.9 billion 14 billion* 18 billion* 
 (I$) – International dollars (2005 purchasing power parity) 
* Already considering the latest WHO targets for 2030 (a minimum of 80% essential 
health services coverage and 100% of the population at risk protected against out-of-
pocket health payments due to NTDs by 2030).  
 
The economic impact varies between NTDs and regions, since it is determined by the 
prevalence, the OPPs and the degree of productivity loss caused by the sequelae of each 
NTD. 
For both Chapters 3 and 4, the same limitations apply, such as the many assumptions 
that had to be formulated due to lack of available data, the exclusion of coping strategies 
and the productivity loss from subtle morbidity, or the use of the human capital 
approach. As a consequence, we were not able to calculate specific economic impact of 
NTDs for individual countries.  
Since the publication of our estimates, there have not been other published results that 
could be compared to them. The lack of research on socioeconomic effects of NTDs is 
likely due to a higher priority in basic research towards building strategies to combat 
NTDs, which is understandable. For instance, the ability and feasibility of current 
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making still faces challenges for all London Declaration diseases (as also mentioned in 
point 7.1c) - except for LF, which faces minor delays/challenges. [3]  
Since the country-specific estimates that were provided were based on OPPs and 
productivity loss from only a few countries (sometimes only one), future research 
regarding these topics could be conducted or commissioned by each government, in 
order to provide a convincing case for the realism of the results. Furthermore, a more 
realistic country-specific estimate of the economic benefit of reaching the London 
Declaration targets for local endemic diseases might complete the advocacy package of 
a country. Despite the fact that the timeframe for the London Declarations 2020- targets 
is short, such insights might be relevant for future health care decision making. 
c. What are the costs and cost drivers related to new diagnostic 
strategies aimed at reaching the 2020 NTDs targets? The example 
of Loa loa 
Costs of a new and safe diagnostic point-of-care strategy developed to avoid severe 
adverse events due to MDA in areas where onchocerciasis and loiasis are coendemic were 
higher than costs for usual treatment, but nevertheless affordable, as shown in Chapter 
5. The main costs drivers were field material (capillaries especially developed for the 
diagnostic device) and salary costs of supervision personnel. 
A micro-costing approach was used to empirically assess the cost of a community-based 
test-and-not-treat strategy in the Soa health district in Cameroon. The empirical costing 
study reflected the costs borne by the organizations involved in implementing and 
executing the program in this specific pilot. The total costs of US$ 283,938 divided by 
total population, people tested and people treated with 42% coverage were US$4.0, 
US$9.2, and US$9.5, respectively. In programmatic implementation, these costs (base-
case estimates with less and more intensive scenarios) could be US$ 2.2 ($1.9 – $3.6), 
US$ 5.2 ($4.5 – $8.3), and US$ 5.4 ($4.6 – $8.6), respectively. Even though higher than 
standard mass treatment, affordability might increase with further reductions, for 
instance, once the purchase price of the tool and capillaries is reduced by large-scale 




Despite the use of a time-consuming micro-costing approach, for several items we were 
still not able to estimate costs, such as the cost of previously acquired capital items, 
building rental and opportunity costs of school staff when helping during the treatment 
phase. Furthermore, retrospective data collection might have introduced some recall bias. 
The recent literature shows other examples of cost and feasibility of new strategies. One 
studied the integration of a field deployable, rapid diagnostic tool (based on detection of 
anti-Ov16 antibodies) into ongoing onchocerciasis surveillance programs in endemic 
countries. In Senegal, the total cost per participant in the surveillance activity showed a 
difference of $0.23 per method ($16.57 for the rapid test and $16.34 for skin snip 
microscopy), with a far bigger willingness to take the rapid test compared to the skin snip 
test. In this case, transportation costs accounted for the higher costs of the new strategy. 
[4] 
Another example showed that swab tests for Chlamydia trachomatis infection can be 
applied in trachoma control to prevent further redundant MDA rounds and that in 
circumstances where an initial MDA round reduces infection below the decision 
threshold, this will save resources. When the swab test was included in the round, a $0.88 
increase per tested child was calculated. Main cost drivers were personnel costs, followed 
by supervision. [5] 
Regarding costing studies of new diagnostic strategies for targets in NTDs we have three 
recommendations. Firstly, a clear diagnostic strategy and the specific context of the 
health care system where it will be introduced need to be defined in order to collect the 
relevant surveillance data, including costing data. A clear diagnostic strategy and the 
implementation context might point out on forehand the main cost drivers and these 
should be measured prospectively in order to get unbiased cost estimates. In the case of 
point of care testing, for instance, cost might be mainly driven by field supervision of 
previously trained health care personnel when using the tests and effective supply chain, 
however, the cost-estimates will be specific to the local circumstances, giving 
effectiveness and fragility of health care systems due to shortage of human and other 
resources. [6] Secondly, since cost drivers might vary due to the local setting, for instance 
transportation and personal costs in areas with sparse population and difficult terrain, 
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information. [7] Thirdly, despite the undeniable importance of new diagnostic strategies, 
the third WHO global NTD report does not include extra costs for research and 
development of new diagnostic tests or strategies, let alone evaluation of their 
implementation. [8] Consequently, no specific funds are allocated for research and 
development of these strategies, so governments with the same challenges regarding 
NTDs endemic in their countries could join in the commissioning of studies on specific 
strategies according to their local demands. 
 
d. What are the effects of combining OPPs and productivity loss in 
the assessment of illness-related impoverishment? 
Combining the joint impact of OPPs and productivity loss to individuals affected by 
specific diseases might increase the likelihood of illness-related impoverishment, as 
shown in Chapter 6. 
The impact of combining both productivity loss and OPPs on the likelihood of illness-
related impoverishment was examined by looking at which moment the residual income 
of an individual affected by disease would cross the US$1.9 and US$3.2 poverty line (PL) 
thresholds: after deducting illness-related OPPs alone or after deducting OPPs combined 
with productivity loss. Analysing the joint impact, the percentage of countries where 
affected individuals were pushed below the poverty line clearly increased (from 0% to 
46% using the US$1.9 PL; from 5% to 80% using the US$3.2 PL).  
Again, despite the fact that we focused on one disease only, a limitation of our work is 
scarcity of available data: very little is known about OPPs, productivity loss and the 
characteristics and behavior of affected individuals. Furthermore, the individual 
perspective was used and we therefore did not consider other factors that could influence 
illness-related economic losses, including household coping, productivity loss of informal 
caregivers and intergenerational inequality. 
Contrasting to the little data is the great importance of disease and its economic 
consequences (large expenditures and productivity loss) as causes of poverty. Literature 




out-of-pocket payments (OPPs) and productivity loss jointly. Joint assessment provides 
a more complete picture of an important and well-known cause of poverty. Besides, 
improvements in the quantity and quality of data would greatly enhance the ability to 
assess illness-related impoverishment, regardless of the disease. Therefore, research on 
the corresponding adjustments of household surveys on the quantification of OPPs, 
productivity loss, on the measurements of health-status, on the intangible costs related 
to illness but also on the feasibility and efficiency challenges of these measurements 
would be needed. Combining OPPs and productivity loss would show a more complete 
picture of poverty in all its forms, supporting priority setting and improving decision-
making about policy instruments to reduce illness-related impoverishment and achieve 
the  main aim of the Sustainable Development Goals (SDGs): to end poverty by 2030.  
 
7.2 The larger perspective of this thesis 
So far, NTDs have been regarded as important diseases to be addressed from the 
perspective of the physical and psychological suffering they cause to affected individuals, 
but also the consequences to the household, such as harming children’s education and 
thus their future, and keeping families trapped into poverty. The work in this thesis shows 
that NTDs also deserve more attention because they might not only cause important 
economic consequences to affected individuals, but also to societies/nations. This 
section will discuss another aspect of the economic benefits of reaching the targets: 
return on investments. It will also approach the topic of transferability of research and 
data collection methods. 
Return on investment  
 An important argument to reach NTDs’ targets is that it would also have a direct and 
sustainable effect on the economic growth and financial welfare of the affected 
populations, and consequently lead to greater national and global prosperity.[9-11] This 
thesis provided the concrete economic estimates that were missing to be used in advocacy 
pro NTD control (see also 7.1b above). Moreover, these economic estimates were used 
to provide a very crude first calculation of the return on investment of reaching the 2020 
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* Net benefit per US dollar invested   
There is a considerable difference between the estimated return on investments from 
avoided PCT versus IDM diseases, which can be explained by the difference in the 
investments that need to be made to achieve the targets for each of them. On the one 
hand, MDA treatment is relatively cheap: MDA drugs are safe and effective; the 
treatment can be delivered by health agents or trained community drug distributors, 
saving the costs of pre-treatment diagnosis for PCT diseases; and treatment of PCT 
chronic disease symptoms does not involve costly procedures in a high proportion of 
cases. On the other hand, IDM diseases are relatively expensive: cases need to be 
diagnosed and treated in health services by specialized health care personnel, using 
specific tests; treatment might need hospitalizations due to the severity of disease 
symptoms and high toxicity of drugs; and treatment of chronic disease symptoms 
frequently involves high costs due to high drug costs and severity of disease 
consequences.[12,13] 
It was expected that showing the actual values of the economic benefit of productivity 
loss and OPPs averted would render a bigger interest from local governments to invest 
in reducing the NTD burden in each country, since the return on investment was shown 
to be big. But what was seen since the publication of these results in January 2017, is that 
investment is still one of the main priorities in the current NTD agenda. Healthcare 
financing is still rated as a high priority for Chagas disease, HAT, leprosy, LF, 
onchocerciasis, trachoma and VL, and as a critical priority for schistosomiasis and STH. 
The degree to which available funding is sufficient for program requirements is regarded 
as a critical priority for LF, onchocerciasis, schistosomiasis, STH and trachoma and as a 
high priority for Chagas disease, HAT, leprosy and VL. [3] A resource mobilization plan 
for meeting identified funding gaps is still a critical priority for HAT, leprosy, 
onchocerciasis, STH, trachoma and VL, and a high priority for Chagas disease, LF and 




for program requirements is referred to as presenting “moderate challenges/delays” for 
most of the London Declaration NTDs, except for schistosomiasis and trachoma, for 
which even substantial challenges/delays apply. [3] Apparently, high return on 
investments is still not reason enough to stimulate a higher commitment in combating 
NTDs.  
Our crude calculations of return on investment of reaching the targets for NTDs did not 
include big investments in local long-term improvements such as clean water, sanitation, 
health/hygiene education and in equipping and strengthening local health systems with 
trained health care workers and adequate infrastructure. These actions are as necessary 
to address NTDs as the drug treatments donated by the pharmaceutical industry. 
Furthermore, enabling access to health care is not only critical to reach the targets, but 
also to sustain them in the long run. Addressing the human fundamental right to the 
highest attainable standard of health is a logical justification to address NTDs. Still, 
adding the significant economic benefit of reaching NTDs’ targets to this argument did 
not exclude investment of the higher priorities’ list on the current NTD agenda.  
Globalize the framework, individualize the methods, localize the 
evidence 
The economic benefit of reaching the targets for NTDs (and consequently the return on 
investment) is absolutely dependent on local circumstances. As such, the work of this 
thesis is a reminder of the transferability limitations of using the same methods in all 
countries and, more importantly, generalize data across jurisdictions. [14]  Of course, 
global organizations such as the WHO and Uniting to Combat NTDs need standard 
indicators of the situation in each country, so they can act in the organization of general 
advocacy, strategies, and funding. As seen in the OPP literature and even more in that 
on productivity loss, as well as in our costing study of the test-and-not-treat (TaNT) 
strategy, the way information is collected should be individualized by each country and 
perhaps each region within a country, depending on the specific challenges they face. In 
short, the framing and choice of indicators (‘what’) should be ‘globalized’, defined by 
global organizations (to allow data comparison and data compilation), but the data 
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prospective collection of the context-specific evidence. Between both steps is the 
adaptation of the ‘how’: the data collection instruments that will be used, by changing 
existing ones or creating and validating new ones. This adaptation process would follow 
the global guidelines, to ensure that information on the globally defined indicators will 
be collected. The adjustments would not only consider literally translating the 
instruments to the local language, but figuratively to the local culture and socioeconomic 
reality, and to the local available structure that will be used in the data collection. 
Evidently, each instrument should comply with the current knowledge on data collection 
instruments.  
One example of the ‘localization’ of data collection was experienced in the development 
of the questionnaire to collect personal information from the community drug 
distributors (CDDs) working in the TaNT round. Three rounds of pilot tests took place, 
during which CDDs were individually assisted in reading, understanding and filling in the 
questionnaires. A user-friendly design with tables, tick boxes and expected short answers 
was adopted based on feedback from the CDDs, still providing all inputs requested by 
the data collection protocol.  
Another example is the output approach, described in more detail in the prospects on 
future research below. In short, to measure household productivity loss secondary to 
malaria, not only the questions were adapted to the local setting, but also the way they 
were asked, for instance alternating the questions on income, in order to avoid distrust 
by the interviewed.[15] 
 
7.3 Future prospects 
This thesis contributed to the scientific evidence base on productivity loss related to 
NTDs, as well as the economic benefit of reaching the London Declaration targets, cost 
of one alternative strategy to enable reaching the target for onchocerciasis, and the 
likelihood of being impoverished from illness-related productivity loss. There are, 
however, important challenges for future research, many of which have already been 
cited while answering to the research questions. This section will discuss some additional 




survey design, presenteeism, and the WHO recommended output approach. A more 
detailed data collection on the characteristics of the populations affected by NTDs and 
their intangible effects is also covered by this section. Furthermore, some considerations 
about how more detailed data collection relates to the results calculated in this thesis 
using data from the Global Burden of Disease study (GBD) are presented. This section 
concludes with an overview of prospects on policy making. 
Prospects on research 
First and foremost, more research is needed on how to better collect actual OPPs and 
productivity loss data from affected individuals and households and on how to measure 
the counterfactual (healthy individuals).   
The development of instruments to capture illness-related OPPs and productivity loss 
should consider that there is evidence that estimates captured by surveys are extremely 
sensitive to survey design, preventing comparisons between them. The development of 
questionnaires/surveys considering wording, framing, recall periods, and number of 
questions, culturally and contextually adaptable to the population to be applied to would 
be a first step to address this issue. [16,17] As mentioned above, indicators should be 
defined globally, but the operationalization of the data collection should be defined 
locally.  Ideally, questionnaires should ask for any health issue affecting an individual or 
the household, eventually adding extra questions, depending on the most prevalent or 
the diseases causing the highest burdens in each country. 
Regarding productivity loss specifically, most NTD studies report lost working days, 
describing only absenteeism. Presenteeism (decreased on-the-job performance due to the 
presence of health problems) is also very relevant, especially due to chronic diseases that 
do not prevent the person from going to work and in countries with little or no social 
security.[18] In developing countries, employment opportunities tend to depend more 
on physical endurance and strength, so questions on the ability to perform job tasks 
involving bodily strength, movement, endurance, coordination, and flexibility are needed, 
as well as on the ability to produce work output in a high-quality or timely manner.[19] 
As seen in some of the studies describing productivity loss of individuals affected by 
NTDs, the magnitude of the productivity loss depends of course on the disease 
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occupation and decreased work performance due to disease symptoms should also be 
included in future surveys/instruments. 
The output approach is the method of measuring productivity loss recommended by the 
WHO. It is especially aimed at low-income settings, or settings where work is not paid 
by a salary. Attanayake et al [15] applied it to measure the productivity loss of households 
related to malaria in Sri Lanka, using a definition of productive work as ‘involvement in 
any economic activity with the potential to add to the disposable income (in kind or cash) 
to the household’. Whenever illness had adversely affected the productive work of any 
household member, it was measured either in terms of output units or person days. Both 
completely and partially disabled days of the patients were considered and the valuation 
of indirect cost was based on actual loss of income attributable to illness. Loss of income 
could happen as the result of direct monetary loss, e.g. loss of daily wage of a casual 
labourer, or as a reduction in farm income or production ‘such as due to being unable to 
harvest tobacco leaves at the proper time (and hence receiving a lower price) or the 
destruction of crops by wild animals as ﬁelds were left unattended’. Referred changes in 
agricultural production (for commercial or subsistence purposes), were translated into 
the market prices of those products in the respective subdistrict to calculate their money 
value. The opportunity cost of the time of other household members to cover the loss 
of productive work of patients or the household members caring for the patient was 
calculated using the average wage rates (of males and females separately) of the respective 
subdistrict. ‘Complete disability period was deﬁned as the number of days in which the 
patient had to avoid the engagement in his/her main and subsidiary occupations due to 
physical and/or mental disability. Partial disability was the inability to engage in some of 
those activities.’ [15] The concepts used in the output approach could serve as basis for 
more encompassing and detailed surveys on productivity loss. With the standardization 
of the indicators and a clear definition of what each of them should be measuring, the 
comparison between them is possible, despite of the different methodology used to 
collect the data to generate them.   
A more detailed and elaborate design like the output approach was also missing in the 
studies describing the population affected by NTDs. There is no doubt that most of them 
affect poor individuals, but it was not clear how poor these populations were, to allow a 




information on their occupation, their income, or other sociodemographic variables was 
not collected. Furthermore, social consequences were also hardly included in economic 
assessments related to NTDs. People’s feelings, thoughts, wellbeing changed by the 
disease symptoms are mostly described as intangible, and therefore no monetary value is 
attached to them, as is was not in the work presented here. The same holds for potentially 
long-term consequences to a child being out of school, or a household member taking 
care of a sick person not having leisure activities: the impact on human/social capital 
formation is also not monetarily quantified. For these aspects to be included in future 
economic evaluations, they also have to be captured by data collection instruments. 
In summary, establishing new methods to assess OPPs, productivity loss, and 
characteristics of affected populations validly and reliable is an important topic for future 
research. 
Prospects on Global Burden of Disease 
The economic benefit of reaching the NTD targets was calculated based on the 2010 
Global Burden of Diseases, Injuries, and Risk Factors (GBD) study, which is a 
comprehensive study of health loss designed to capture complex patterns of disease and 
injury burden. The burden is reported in disability-adjusted life years (DALYs), calculated 
for each disease, considering both the years of life lost due to premature death caused by 
the disease and the years of life lost due to disability of living with the disease and 
enduring its consequences.[20,21] 
Some of the 2010 criticisms as discussed in the literature will be elaborated upon below, 
to allow for a more critical view of the work in this thesis. 
The GBD study uses disability weights to represent the severity of a disease/condition. 
These are standardized values that are assigned to non-fatal health outcomes to capture 
their severity on a scale between 0 (full health) and 1 (death), calculated by either a panel 
of experts or surveys not globally representative. The universal usage of these weights 
and their failure to account for both qualitative and cultural differences and differential 
access to resources around the world is still a cause for debate, since the same disease 
consequence can have more or less weight depending on the context of the affected 
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developed nations compared to LMIC. Also, diseases that affect the use of a person’s 
limbs will have a bigger negative impact in developing nations, where labor is frequently 
dependent on physical strength and mobility.[20,22] Disease weights have been used as 
a proxy for productivity loss when such an estimate was not available, which was the case 
for visual impairment caused by trachoma, for instance.[23-25] Better estimates on the 
productivity loss due to visual impairment from trachoma would lead to better estimates 
of the economic benefit of reaching the targets for trachoma. 
Still on the parameters used by GBD, data sources range from scientific literature to 
survey data to epidemiological surveillance data. Nations might provide less-than-
accurate surveillance data to inflate their progress, yielding results that are not always 
transparent and therefore questionable.[20,21] This would influence the prevalence and 
death estimates used to calculate the counterfactual scenarios for the comparison with 
the target reach scenario for each disease. If GBD used prevalence estimates with 
‘inflated progress’, there is a possibility that even more prevalent cases existed in the years 
prior to reaching the targets, which would mean that the difference between the 
counterfactual scenario and the target reach scenario is in reality bigger, leading to an 
underestimate of the economic benefit of reaching the targets. 
The use of single statistic metrics for evaluating health and for prioritizing resources has 
also been under ethical debate, since DALYs do not show who is being more 
affected.[22,26] This information would also have to be complemented with studies 
investigating the characteristics of people affected by each disease, as mentioned above. 
Ultimately, studies collecting better data on OPPs, productivity loss, income, occupation, 
intangible effects – only to name a few, as well as more reliable prevalence estimates, 
would also contribute to more accurate future GBD estimates. 
Since 2010, the GBD study has undergone many updates and changes in methodology 
and reporting, to account for several issues, including the above-listed ones.  Still, the 
debate on whether the use of ostensibly universal disability weights is possible, desirable 
or even useful for policy purposes continues. In this sense, future contextualized surveys 
could supplement indicators like the DALYs with local qualitative knowledge and 




Prospects on policy making 
Our studies suggest that the economic benefit of reaching the 2020 targets for NTDs is 
considerable, which might ultimately influence health policy agenda in favor of 
addressing NTDs. Independently from the economic argument, there are more reasons 
that justify an increase in attention by policy makers and ultimately investments related 
to NTDs and their control.  
First, countries are being called to invest more in combating NTDs and reaching the 
targets and to gradually depend less on foreign investments. The calculated economic 
benefit in this thesis could encourage countries to do so, as the investments would largely 
pay off. As mentioned previously, reaching the targets also depends on investments on 
instances linked not only to NTDs such as potable water supply, sanitation, education 
and health systems (including access to them). This should be done independently of 
reaching targets for NTDs and of the anticipated economic benefits. These are basic 
necessities that should be guaranteed to each individual by each government. Foreign 
investors could then still contribute with drug donations (which would gradually decrease 
with the decrease in the number of people needed to be treated) and with the research 
and development of the new strategies, specifically new diagnostic tools. The alignment 
of the local and global actions would be essential for the provision of real needs and to 
avoid waste of investments (double investments).   
Second, new diagnostic strategies are essential for monitoring progress and impact of 
interventions and guiding treatment strategies of control, interruptions of transmission, 
elimination and post-elimination surveillance (reaching the targets and sustaining them). 
The absence of clear diagnostic strategies has resulted in limited and unreliable 
surveillance data. Point-of-care technologies are needed, that can be used in remote 
settings, designed in a “sample-in answer-out format”, requiring minimal training and 
providing results in a relatively short time period. [6] As mentioned in the answer of 
question c above, financing of research and development of point-of care diagnostic tests 
is not included in the third WHO Global NTD report or in the London Declaration. 
[6,8] Ability and feasibility of current diagnostics to provide accurate view of disease 
epidemiology to inform decision making was ranked as a critical priority for HAT, leprosy 
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absence of the development of these new strategies in the London Declaration and in 
the investment costs makes it difficult to organize who should fund them. As suggested 
while answering question b, governments could jointly commission research on specific 
strategies that help them address common challenges to reach the targets for the same 
diseases. On the other hand, with the increase of investment of developing nations in 
many general instances, from basic potable water supply to sanitation and health care 
systems, international donors could commit to investing in the research and development 
of the new strategies needed to reach the London Declaration targets.  
Third, NTDs are now directly or indirectly linked to almost all SDGs. So in fact, each 
government would not only be looking at investing in reaching London Declaration 
targets, but also at reaching many SDGs (including eradication of poverty) with the 
actions required to address NTDs. [27-30] In this sense, the economic and social 
intertwined benefits would certainly outweigh the ones calculated for reaching only the 
targets for NTDs. Perhaps this argument outweighs the argument of the economic 
benefit and might now interfere positively in the many gaps delaying NTDs to be 
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• Combining OPPs and productivity loss offers a more comprehensive view 
on the likelihood of illness-related impoverishment. This information 
might support the development of policies to better address illness-related 
impoverishment and reach SDG 1. 
Paucity of evidence from the literature was the main challenge throughout the thesis. 
More research is needed, also aiming at improving research methods, in order to obtain 
more accurate estimates of illness-related socioeconomic consequences, especially OPPs 
and productivity loss. The economic impact of NTDs related to patients, their families 
and societies is substantial. Although this important information did (so far) not seem to 
interfere positively in the increase of investments from local governments in addressing 
NTDs, improved understanding of the economic effect of NTDs on individuals, 
households and countries, should at least increase health policy and research dialogue. 
New diagnostic strategies also deserve attention and dedicated research, especially on 
their costs, to allow for advocacy on their affordability and ultimately to provide missing 
epidemiological information needed to reach and sustain NTDs’ targets. Hopefully, these 
results can help advocating in favor of addressing the social and environmental 
determinants of health, especially for the poor and vulnerable, aiming at more equity, 
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Physical and mental suffering caused by disease is known to anyone, even when 
experiencing a mild cold. But disease also has economic consequences to individuals, 
households and societies that not everybody might be aware of. Depending on the 
disease and on the context of the affected individuals, these consequences might lead to 
economic hardship (forcing the reduction of basic expenditures such as food and shelter 
or children’s education) and even to impoverishment. Out-of-pocket payments (OPPs) 
can be described as the expenses attributable to a specific illness, directly related to 
medical costs or to non-medical costs, borne by an individual. Productivity loss refers to 
the short-term or long-term inability to work resulting from morbidity, disability and 
mortality related to a disease.   
Economic hardship and poverty (from disease and from other causes) are unfortunately 
still so relevant that two of the Sustainable Development Goals are devoted to these 
causes. The first SDG is ‘To end poverty in all its forms everywhere by 2030’ and SDG 
3 ‘Good health and well-being - Ensure healthy lives and promote well-being for all’ has 
a specific goal to ‘Achieve universal health coverage, including financial risk protection, 
access to quality essential health-care services and access to safe, effective, quality and 
affordable essential medicines and vaccines for all’. 
 
Neglected Tropical Diseases (NTDs) 
NTDs are a group of communicable diseases associated with chronic, disabling and 
disfiguring morbidity, but also death. Most of them affect extremely poor populations 
with little political capital, living in slums or in rural areas, frequently also affected by 
conflict, predominantly in low–and middle-income countries. Almost everyone in the 
poorest bottom billion in the world has at least one NTD, which also contributes to keep 
them trapped in poverty. 
In 2012, the World Health Organization (WHO) set targets for the year 2020 for 10 
NTDs. In the same year, these targets were endorsed by partners in the London 
Declaration: eradication of Guinea worm; elimination of lymphatic filariasis (LF), 
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control of schistosomiasis, soil-transmitted helminthiasis (STH), Chagas disease, visceral 
leishmaniasis (VL) and onchocerciasis (river blindness). The WHO recommends five 
interventions to reach the NTDs targets: preventive chemotherapy (PCT) by mass drug 
administration (MDA); innovative and intensified disease management (IDM); vector 
ecology and management; veterinary public health services; and the provision of safe 
water, sanitation, and hygiene. 
In addition to the disease burden, the economic burden that NTDs inflict on patients 
and their families is also heavy, but only a few studies have investigated the impact of 
NTDs on OPPs and productivity loss for individuals, households, and societies. 
 
This thesis 
By studying the socioeconomic eﬀ ect of NTDs on individuals and society, this thesis 
aimed at providing an improved understanding on this poorly investigated topic. First, a 
systematic literature review describes how NTDs impact productivity loss in affected 
adults. The subsequent two chapters report the estimation of economic benefit (to 
individuals) of meeting the 2020 WHO targets for PCT and IDM NTDs respectively. 
The next chapter presents cost assessments of a pilot round for a new tested diagnostic 
strategy to enable the treatment of onchocerciasis in areas co-endemic for Loa loa worm 
infections. Thereafter, the joint impact of OPPs and productivity loss on the likelihood 
of illness-related impoverishment is examined, using Chagas disease as an example. The 
final chapter contains a general discussion of the research findings, leading to the main 
conclusions and recommendations derived from this thesis. 
 
Productivity loss related to NTDs in the literature 
The focus of the literature on NTDs has been mostly epidemiological and clinical. The 
impact of NTDs on productivity of affected men and women has been less frequently 
studied. A comprehensive systematic literature review was performed in November 2013, 
relating all 10 London Declaration NTDs to economic impact. Eleven databases were 




described productivity loss: 13 related to LF, 10 on onchocerciasis, 11 on schistosomiasis, 
6 on STH, none for trachoma, 3 for human African trypanosomiasis (HAT), 12 for 
Chagas disease, 10 for VL and 4 for leprosy. 
There was much variation in the definition of productivity loss and, consequently, in the 
methodology to measure it. For instance, the annual productivity loss range for LF was 
10 – 23% for chronic and 0.9 – 9% for acute symptoms, looking mostly at lost working 
hours or days. Onchocerciasis studies looked at more specific effects, such as the 
difference in daily wages between individuals with and without the disease, or the 
difference in size of the farm that healthy men can keep satisfactorily weeded compared 
to affected ones, with onchocerciasis-related skin diseases causing productivity loss 
ranging from 10 – 34% and blindness assumed to be 100%. Studies looking at 
schistosomiasis measured absolute productivity loss in lost working days, but also 
comparing infected individuals with healthy ones, with a range of 8.7% – 23%, depending 
on the symptom. STH-related studies also investigated absolute and compared 
productivity loss, ranging from 0.1 – 35%. Quality also differed between studies for each 
disease, with 60% of the papers with an overall high risk of bias.  
This study showed that, despite the scarcity in publications and the variation caused by 
different research methods it is clear that NTDs do affect productivity loss. Type and 
severity of the disease directly interfere on the actual impact, as well as the context where 
it occurs. 
The economic benefit from reaching the targets for 9 London 
Declaration NTDs 
The WHO defined targets for NTD control/elimination by 2020, reinforced by the 2012 
London Declaration, which, if achieved, would result in benefits not limited to health 
gains. The economic benefit of reaching these targets was calculated by subtracting the 
costs calculated for a target achievement scenario from the costs of the counterfactual 
scenario of having done nothing for each disease, for the period between 2011 and 2030 
(ten years before and after target-achievement). For the calculation of the costs, the 
estimated disease frequency was combined with productivity loss resulting from the 
disease, from the perspective of a person affected by each of the NTDs. The same was 
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economic impact of meeting the London declaration targets, data from various sources, 
heterogeneous background, and variable quality had to be combined. The results based 
on conservative assumptions were: 




NTDs 2011 - 2020 2021 - 2030 2011 - 2020 2021 - 2030 
Preventive 
chemotherapy (PCT) 
251 billion 313 billion 0.72 billion 0.96 billion 
Intensified disease 
management (IDM) 
23.1 billion 35.9 billion 14 billion 18 billion 
 (I$) – International dollars (2005 purchasing power parity) 
The economic impact varied between NTDs and regions, since it was determined by 
disease prevalence, the OPPs and the degree of productivity loss caused by the sequelae 
of each NTD.  
Apart from addressing the human fundamental right to aim for the highest attainable 
standard of health, controlling and eliminating NTDs would also have a direct and 
sustainable effect on the economic growth and financial welfare of the affected 
populations, and consequently lead to greater national and global prosperity. Combining 
these arguments to the cost and return on investment estimates and the already existing 
estimates of disease burden might increase health policy dialogue and further encourage 
prevention and control actions, assuring funders and policymakers that resources 
committed to these efforts are a good investment. 
Costs and cost drivers related to a new diagnostic strategy aimed at 
reaching the target for onchocerciasis: the example of Loa loa 
Improved diagnostics are essential for monitoring progress and impact of interventions 
and guiding treatment strategies of control, interruption of transmission, elimination and 
post-elimination surveillance. Point-of-care technologies are needed, that can be used in 
remote settings, designed in a “sample-in answer-out format”, requiring minimal training 




One example is a point-of-care strategy to test-and-not-treat individuals with high levels 
of Loa loa microfilariae in their blood, in areas hypoendemic for onchocerciasis and 
coendemic for loiasis, since they have a high risk of severe adverse events. This study 
calculated the costs of a pilot implementation round based on actual expenditures, 
including financial costs and opportunity costs that will likely be borne by control 
programmes and stakeholders in the future. In addition to the empirical analyses, three 
scenarios (base-case, less and more intensive resource use) were estimated to explore how 
costs might differ if TaNT were implemented programmatically. This strategy cost US$ 
4.0 per person in the population, US$ 9.2 for each person tested, and US$ 9.5 for each 
person treated. In the alternative implementation scenarios, these costs were estimated 
to be US$ 2.2 [1.9–3.6], US$ 5.2 [4.5–8.3], and US$ 5.4 [4.6–8.6] (base-case estimates 
with less and more intensive scenarios in square brackets), assuming 42% programme 
coverage. These costs were higher than usual mass drug treatment, but still affordable 
and with room for further reduction, depending on the implementation choices made. 
For instance, the purchase price of the diagnostic tool and capillaries might be reduced 
by large-scale production and supervision personnel can be cut down.  
Effect of combining out-of-pocket payments and productivity loss 
in the assessment of illness-related impoverishment 
One important cause of poverty is disease and its economic consequences (large 
expenditures and productivity loss). Literature on economic hardship due to illness and 
its effect on poverty has hardly ever addressed out-of-pocket payments (OPPs) and 
productivity loss jointly.  
The impact of combining both productivity loss and OPPs on the likelihood of illness-
related impoverishment was examined by looking at which moment the residual income 
of an individual affected by disease would cross the US$ 1.9 and US$ 3.2 poverty line 
(PL) thresholds: after deducting illness-related OPPs alone or after deducting OPPs 
combined with productivity loss. The example used was heart failure due to Chagas 
disease in all countries endemic for Chagas disease. Analysing the joint impact, the 
percentage of countries where affected individuals were pushed below the poverty line 
clearly increased (from 0% to 46% using the US$ 1.9 PL; from 5% to 80% using the US$ 
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Including productivity loss in the assessment of illness-related impoverishment might 
provide a more complete picture of one of the causes of poverty, supporting the 
achievement of the main aim of the Sustainable Development Goals (SDGs): to end 
poverty by 2030.  
 
Future prospects 
Even though the fight against NTDs has seen huge progress, there are many challenges 
still to be faced before the targets can be met at a universal scale. Some of these challenges 
concern lack of available evidence on many aspects that might influence policy making. 
As shown in this thesis, there is a striking paucity of evidence on many aspects of illness-
related consequences of NTDs, from OPPs and productivity loss to intangible effects, 
characteristics and behavior of affected populations.  
This work also shows that the economic benefit of reaching the 2020 targets for nine 
NTDs mentioned in the London Declaration is estimated to be considerable, totaling 
several hundred billions of dollars world-wide over a 20 year period. Also, it is feasible 
to conduct studies to investigate costs of new diagnostic strategies to reach the London 
Declaration targets for NTDs, which is supported by the study on onchocerciasis and by 
the other studies cited from the literature.  
Furthermore, as seen in the OPP literature and even more in that on productivity loss, 
as well as in our costing study of the test-and-not-treat (TaNT) strategy, the way 
information is collected should be individualized by each country and perhaps each 
region within a country, depending on the specific challenges they face. In order to gather 
needed and reliable data for global socioeconomic indicators and concomitantly address 
transferability issues, our work suggests to globalize the scientific framework, 
individualize the methods, and localize the evidence. 
And finally, combining OPPs and productivity loss in the assessment of illness-related 
impoverishment offers a more comprehensive view on the likelihood of illness-related 
impoverishment. This information might support the development of policies to better 
address illness-related impoverishment and reach SDG 1. There is an undeniable link 




‘leave no one behind’ calls for global focus on reaching the most impoverished, excluded 
disadvantaged, who still face painful inequalities when accessing resources, services and 
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Het fysieke en mentale lijden wat ziekte met zich mee brengt is bij iedereen bekend, al 
gaat het maar om een milde verkoudheid. Wat wellicht niet iedereen zich realiseert is dat 
ziekte ook economische gevolgen kan hebben voor individuen, huishoudens en 
samenlevingen. Deze gevolgen kunnen, afhankelijk van de ziekte en de context waarin 
het individu zich bevindt, op hun beurt weer leiden tot verdere economisch tegenspoed 
(gedwongen vermindering van uitgaven ten behoeve van basale levensbehoeften zoals 
eten, onderdak en onderwijs van de kinderen) en zelfs tot armoede. Eigen bijdragen 
(ofwel out-of-pocket payments, OPPs) zijn medische of niet-medische kosten die direct zijn 
toe te schrijven aan een specifieke aandoening en die gedragen worden door een individu. 
Productiviteitsverliezen betreffen zowel de korte- als lange termijn beperkingen om te 
kunnen werken veroorzaakt door morbiditeit, chronische beperkingen en overlijden als 
gevolg van ziekten.  
Economische tegenspoed en armoede (als gevolg van ziekten en andere oorzaken) komt 
helaas nog steeds zo vaak voor dat twee duurzame ontwikkelingsdoelen, de zogeheten 
Sustainable Development Goals (SDGs), hieraan zijn gewijd. Het eerste SDG is 
‘Beëindigen vanarmoede, overal en in al zijn vormen tegen 2030’ en SDG 3 ‘Goede 
gezondheid en welzijn –Waarborgen van gezonde levens en bevorderen van welzijn voor 
iedereen’ met als specifiek doel ‘Bewerkstelligen van een zorgstelsel met universele 
dekking, inclusief bescherming tegen financiële risico’s, toegang tot essentiële 
gezondheidszorgdiensten van goede kwaliteit, en toegang tot veilige, effectieve, 
betaalbare essentiële medicijnen van goede kwaliteit en vaccinaties voor iedereen’.  
 
Vergeten tropische ziekten 
Vergeten tropische ziekten  (ofwel neglected tropical diseases, NTDs) zijn een groep 
overdraagbare ziekten die vaak samengaan met chronische beperkingen, invaliderende en 
verminkende klachten, en ook sterfte. NTDs komen het meest voor bij zeer arme 
populaties met weinig politieke zeggenschap,  vooral wonend in de sloppenwijken of op 




door langdurige conflicten. Bijna iedereen die behoort tot de armste miljard mensen van 
de wereld heeft een NTD, wat hen weer gevangen houdt in de armoedeval.  
In 2012 heeft de wereldgezondheidsorganisatie (WHO) voor 10 NTDs doelen opgesteld 
voor het jaar 2020. Deze doelen zijn in datzelfde jaar door partners onderschreven in het 
Verdrag van London: uitroeiing van de guineawormziekte; eliminatie van lymfatische 
filariasis (LF), lepra, slaapziekte (Afrikaanse trypanosomiasis) en het blind makend 
trachoom; en controle van schistosomiasis, via de grond overgedragen parasitaire 
worminfecties (soil-transmitted helminthiasis, STH), ziekte van Chagas, viscerale 
leishmaniasis (VL) en onchocerciasis (rivierblindheid). De WHO beveelt vijf interventies 
aan om deze NTD-doelen te bereiken: preventieve chemotherapie (PCT) door 
massabehandeling (MDA); innovatief en geïntensiveerd ziektemanagement (IDM); 
vectorecologie en -beheer; veterinaire volksgezondheidsdiensten; en de voorziening van 
veilig water, sanitaire voorzieningen en hygiëne. 
Naast de ziektelast is de economische last die NTDs toebrengen aan patiënten en hun 
families ook aanzienlijk. Opvallend is dat nog zo weinig onderzoek is gedaan naar de 
impact van NTDs op eigen bijdragen (OPPs) en productiviteitsverliezen voor individuen, 
huishoudens en samenlevingen. 
 
Dit proefschrift 
Het doel van dit proefschrift is een beter inzicht te verschaffen in het sociaal-
economische effect van vergeten tropische ziekten (NTDs) op individuen en de 
samenleving. Het proefschrift begint met een systematisch literatuuronderzoek over hoe 
NTDs van invloed zijn op productiviteitsverliezen bij volwassenen. In de 
daaropvolgende twee hoofdstukken wordt een schatting gemaakt van het economische 
nut (voor particulieren) van het behalen van de WHO-doelstellingen van 2020 voor 
respectievelijk PCT- en IDM NTDs. In het hoofdstuk daarna worden de kosten bepaald 
van een nieuw geteste diagnostische strategie voor de behandeling van onchocerciasis in 
gebieden die co-endemisch zijn voor Loa loa worminfecties. In het volgende hoofdstuk 
wordt gepresenteerd in welke mate OPPs en productiviteitsverliezen tezamen zouden 
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voorbeeld genomen. Het laatste hoofdstuk bevat een algemene bespreking van de 
onderzoeksresultaten, afgesloten met de belangrijkste conclusies en aanbevelingen uit dit 
proefschrift. 
Productiviteitsverliezen gerelateerd aan NTDs in de literatuur  
De bestaande literatuur over NTDs bleek voornamelijk epidemiologisch en klinisch van 
aard. De impact van NTDs op productiviteitsverliezen voor mannen en vrouwen met 
een dergelijk ziekte was minder vaak bestudeerd. In november 2013 werd een uitgebreid 
systematisch literatuuronderzoek gedaan naar de economische impact van alle 10 NTDs 
van het Verdrag van Londen. Elf databases werden doorzocht, en van de 5.316 gevonden 
artikelen over NTDs waren er maar weinig die productiviteitskosten op en kwantitatieve 
manier beschreven: 13 waren gerelateerd aan LF, 10 aan onchocerciasis, 11 aan 
schistosomiasis, 6 aan STH, er was geen enkele over trachoma, 3 waren er over 
slaapziekte, 12 over Chagas ziekte, 10 over VL en 4 over lepra.  
Er bleek veel variatie in de definitie van productiviteitsverliezen. Als gevolg hiervan 
verschilden ook de gebruikte meetmethoden. Bijvoorbeeld, wanneer gekeken werd naar 
het aantal verloren werkuren of dagen, dan varieerden de jaarlijkse 
productiviteitsverliezen van LF van 10 tot 23% voor chronische symptomen en van 0,9 
– 9% voor de acute symptomen. In studies over onchocerciasis werd met name gekeken 
naar specifieke effecten, zoals het verschil in het dagelijkse salaris van individuen met en 
zonder de ziekte of het verschil in oppervlakte gewasgrond dat mannen met en zonder 
onchocerciasis konden wieden. Op basis van deze studies varieerden de 
productiviteitsverliezen voor onchocerciasis-gerelateerde huidziekten van 10 - 34% met 
daarnaast de aanname dat blindheid tot 100% productiviteitsverlies leidde. In artikelen 
waarin gekeken werd naar schistosomiasis werd productiviteitsverlies gemeten in het 
aantal absolute verloren werkdagen, waar gezonde individuen met schistosomiasis 
patiënten vergeleken werden. De gevonden productiviteitsverliezen varieerden 
afhankelijk van de symptomen tussen 8,7 – 23%. STH-gerelateerde onderzoeken 
onderzochten ook absoluut en relatief productiviteitsverlies, met een variatie van 0,1 – 
35%. De kwaliteit verschilde ook tussen studies voor elke ziekte, met bij 60% van de 




Dit literatuuronderzoek toonde aan dat, ondanks het feit dat studies over 
productiviteitsverliezen schaars waren en dat verschillende manieren werden gehanteerd 
om productiviteitsverliezen te meten, NTDs duidelijk gerelateerd zijn aan 
productiviteitsverliezen. Er blijkt een relatie tussen het type en de ernst van de ziekte en 
de daadwerkelijke impact, waarbij ook de context waarin het gebeurt een rol speelt.  
Het economische voordeel van het bereiken van de doelen voor 9 
NTDs van het Verdrag van Londen  
De WHO heeft doelen gesteld om voor 2020 ofwel controle te hebben over de NTDs 
ofwel ze te hebben geëlimineerd. Deze doelen zijn versterkt in het Verdrag van Londen 
van 2012, en het nut van het bereiken ervan beperkt zich niet tot alleen de 
gezondheidswinst. Het economische nut van het bereiken van de doelen werd 
geanalyseerd door allereerst de kosten te berekenen van een scenario waarin de doelen 
bereikt werden. Deze kosten werden vervolgens afgetrokken van de kosten van een 
‘counterfactual’, ofwel een nulscenario waarbij per ziekte niets werd gedaan om de doelen 
te bereiken. Deze berekeningen werden gedaan voor de periode 2011 tot 2030 (tien jaar 
voor en na het bereiken van de doelen). Om de kosten te berekenen, werd de geschatte 
frequentie van de ziekte gecombineerd met de productiviteitsverliezen gerelateerd aan de 
verschillende ziekten, vanuit het perspectief van een persoon met de desbetreffende 
NTD. Hetzelfde werd gedaan voor de gezondheidszorgkosten betaald door de 
individuen zelf. Om de economische impact van het bereiken van de doelen uit het 
Verdrag van Londen te schatten moest informatie uit verschillende bronnen met elkaar 
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23,1 miljard 35,9 miljard 14 miljard 18 miljard 
 (I$) – Internationale dollars (2005 koopkrachtpariteit) 
De economische impact varieerde tussen NTDs en regio’s doordat deze impact bepaald 
werd door de prevalentie van de ziekte, de OPPs en de mate van productiviteitsverlies 
per ziekteverschijnsel van de NTDs.  
Naast het bevorderen van het fundamentele recht van de mens om te streven naar de 
hoogst haalbare  standaard voor gezondheid, zal het bedwingen of elimineren van NTDs 
ook een direct en blijvend effect hebben op de economische groei en het financiële 
welzijn van getroffen populaties. Dit leidt dan vervolgens weer tot een groter nationaal 
en wereldwijd welzijn. Deze argumenten, gecombineerd met de schattingen van de 
kosten en het rendement op investeringen en de al bestaande schattingen van de 
ziektelast, zouden het debat over gezondheidszorgbeleid en verdere preventieve 
maatregelen kunnen aanmoedigen. Hierdoor kunnen investeerders en beleidsmakers 
overtuigd worden dat de inzet van middelen voor zulke inspanningen een goede 
investering is.   
 
Kosten en kostenfactoren gerelateerd aan een nieuwe diagnostische 
strategie gericht op het bereiken van de doelstelling voor 
onchocerciasis: het voorbeeld van Loa loa 
Betere diagnostiek is essentieel voor het monitoren van vooruitgang en de impact van 
interventies en voor het bepalen van behandelingsstrategieën bij controle, onderbreking 
van transmissie, eliminatie en post-eliminatie surveillance. Point-of-care technologieën 
die gebruikt kunnen worden in afgelegen gebieden zijn nodig. Deze zouden  ontworpen 
moeten zijn volgens een “sample-in answer-out format”, waarbij weinig opleiding nodig 
is en testresultaten in korte tijd beschikbaar zijn.  
Een voorbeeld van een point-of-care strategie is de test-and-not-treat (TaNT) (wel testen 




het bloed, in gebieden die hoog-endemisch zijn voor onchocerciasis en co-endemisch 
voor loiasis, aangezien zulke mensen een hoog risico hebben op ernstige bijwerkingen.  
In deze studie werden de kosten van een pilot implementatieronde berekend op basis 
van daadwerkelijke uitgaven, inclusief financiële kosten en opportuniteitskosten die 
waarschijnlijk in de toekomst door bestrijdingsprogramma’s en belanghebbenden 
gedragen moeten worden. Naast de empirisch analyses, werden er drie scenario’s (basis, 
minder en meer intensief zorggebruik) geanalyseerd om uit te zoeken hoe kosten kunnen 
verschillen als TaNT programmatisch geïmplementeerd zou worden. Deze strategie 
kostte 4,0 US$ (Amerikaanse dollar) per persoon in de populatie, 9,2 US$ voor elk getest 
individu en 9,5 US$ voor elk individu dat behandeld werd. Bij de alternatieve 
implementatiescenario’s waren de geschatte kosten 2,2 US$ [1,9–3,6], 5,2 US$ [4,5–8,3] 
en 5,4 US$ [4,6–8,6] (basisscenario en schattingen met minder of meer intensieve 
scenario’s tussen vierkante haken). Hierbij werd uitgegaan van 42% dekking van het 
programma. Deze kosten waren hoger dan gangbaar bij massale medicinale behandeling 
maar nog steeds acceptabel en met ruimte voor eventuele vermindering van kosten, 
afhankelijk van verdere implementatiekeuzes. Bijvoorbeeld, de aankoopkosten van het 
nieuwe diagnostisch hulpmiddel en capillairen zouden kunnen worden verminderd door 
grootschalige productie. Daarnaast kan toezichthoudend personeel op termijn worden 
verminderd. 
 
Het effect van het combineren van eigen bijdragen en 
productiviteitsverlies bij de beoordeling van ziekte-gerelateerde 
verarming 
Een belangrijke oorzaak van armoede is ziekte en de economische consequenties hiervan 
(grote uitgaven en productiviteitsverliezen). Studies over ziekte-gerelateerde economisch 
tegenspoed en het effect daarvan op armoede nemen zelden het effect van eigen 
bijdragen (out-of-pocket payments, OPPs) en productiviteitsverliezen tezamen mee.  
Het effect van het combineren van zowel productiviteitsverliezen als eigen bijdragen op 
de kans dat iemand door ziekte in armoede geraakt werd onderzocht door te kijken naar 
het moment dat iemands resterende inkomen minder wordt dan de armoedegrens (AG) 
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OPPs of na aftrek van OPPs gecombineerd met productiviteitsverliezen. Hiervoor werd 
hartfalen door de ziekte van Chagas in alle landen endemisch voor deze ziekte als 
voorbeeld genomen. Bij analyse van het gecombineerde effect nam het percentage landen 
waar getroffen individuen onder de armoedegrens terecht zouden komen duidelijk toe 
(van 0% tot 46% bij gebruik van de 1,9 US$ AG; van 5% tot 80% bij de grens van 3,2 
US$ AG).   
Het meenemen van productiviteitsverliezen in de beoordeling van ziekte-gerelateerde 
verarming geeft mogelijkerwijs een completer beeld van een van de oorzaken van 
armoede. Dit ondersteunt daarmee het hoofddoel van de duurzame ontwikkelingsdoelen 
(SDGs): een einde maken aan armoede tegen 2030. 
 
Toekomst 
Ondanks de grote vooruitgang in de strijd tegen de vergeten tropische ziekten (NTDs), 
moeten nog vele obstakels overwonnen worden voordat de doelen op mondiale schaal 
bereikt kunnen worden. Een aantal van deze uitdagingen hebben te maken gebrek aan 
kennis over verscheidende aspecten die van invloed kunnen zijn op beleid. Zoals in dit 
proefschrift beschreven, is er een opvallend gebrek aan kennis over ziekte-gerelateerde 
gevolgen van NTDs, van eigen bijdragen en productiviteitsverliezen tot immateriële 
effecten, kenmerken en gedrag van getroffen populaties.  
Dit werk laat ook zien dat het bereiken van de 2020 doelen betreffende negen NTDs een 
aanzienlijke economische impact kan hebben, oplopend tot honderden miljarden dollars 
wereldwijd over een periode van 20 jaar. Daarnaast laat de studie over onchocerciasis, 
evenals andere geciteerde studies, zien dat het goed mogelijk is om onderzoek te doen 
naar de kosten van nieuwe diagnostische strategieën die worden ingezet om de in het 
verdrag van London gestelde doelen voor NTDs te bereiken. 
Daarnaast is het belangrijk dat, wanneer informatie verzameld wordt, deze 
geïndividualiseerd wordt naar land en misschien zelfsnaar regio’s binnen een land, 
afhankelijk van de specifieke uitdagingen waarmee landen worden geconfronteerd. Deze 
relevantie van individualisering van informatie bleek uit de literatuur over OPPs en 




behandelen’ (TaNT) strategie. Om de benodigde en betrouwbare gegevens voor 
mondiale sociaaleconomische indicatoren te verzamelen en tegelijkertijd problemen met 
de ‘transferability’ aan te pakken, suggereert ons werk het wetenschappelijk kader te 
globaliseren, de methoden te individualiseren en het bewijsmateriaal te lokaliseren. 
Tot slot biedt de combinatie van eigen bijdragen en productiviteitsverlies bij de 
beoordeling van ziekte-gerelateerde armoede een uitgebreider beeld van de 
waarschijnlijkheid van het optreden van ziekte-gerelateerde armoede. Deze informatie 
kan de ontwikkeling van beleid ondersteunen om ziekte-gerelateerde armoede beter aan 
te pakken en SDG 1 te bereiken. Er is een onmiskenbaar verband tussen het aanpakken 
van NTDs en het bereiken van de SDGs. De kernverplichting van ’de SDGs om 
'niemand achter te laten' vereist een wereldwijde focus op het bereiken van de allerarmste, 
uitgesloten kansarmen, die nog steeds met pijnlijke ongelijkheid worden geconfronteerd 
bij de toegang tot middelen, diensten en rechten. Focus op deze populaties betekent ook 
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É de conhecimento geral que doenças causam sofrimento físico e mental, até mesmo um 
simples resfriado. Mas doenças também têm consequências econômicas para indivíduos, 
famílias e sociedades, consequências essas das quais nem todos podem estar cientes. 
Dependendo da doença e do contexto dos indivíduos afetados, essas consequências 
podem levar a dificuldades econômicas (forçando a redução de gastos básicos, como 
alimentação e moradia ou educação das crianças) e até ao empobrecimento. Pagamentos 
diretos (OPP, sigla em inglês para out-of-pocket payment) podem ser descritos como as 
despesas atribuíveis a uma doença específica, diretamente relacionadas a custos médicos 
ou não médicos, pagos pelo indivíduo acometido. A perda de produtividade aqui se refere 
à incapacidade laboral a curto ou longo prazo, resultante de morbidade, incapacidade e 
mortalidade relacionadas a uma doença. 
Infelizmente, dificuldades econômicas e pobreza (por doenças e outras causas) ainda são 
tão relevantes que dois dos Objetivos de Desenvolvimento Sustentável (ODS) são 
dedicados a essas causas. O primeiro ODS é 'Acabar com a pobreza em todas as suas 
formas em todos os lugares até 2030' e ODS 3 'Boa saúde e bem-estar - Garantir vidas 
saudáveis e promover o bem-estar para todos' tem um objetivo específico de 'Alcançar a 
cobertura universal de saúde, incluindo proteção contra riscos financeiros, acesso a 
serviços essenciais de saúde de qualidade e acesso a medicamentos essenciais seguros, 
eficazes, de qualidade e vacinas para todos '. 
Doenças Tropicais Negligenciadas  
Doeças Tropicais Negligenciadas (DTN) são um grupo de doenças transmissíveis 
associadas a morbidade crônica, incapacitante e desfigurante, mas também à morte. A 
maioria afeta populações extremamente pobres com pouco capital político, vivendo em 
favelas ou em áreas rurais, freqüentemente também afetadas por conflitos, 
predominantemente em países de baixa e média renda. Quase todas as pessoas 
pertencentes ao bilhão de pessoas mais pobres do mundo têm pelo menos uma DTN, o 
que também contribui para mantê-las presas na pobreza. 
Em 2012, a Organização Mundial da Saúde (OMS) estabeleceu metas para o ano 2020 




Declaração de Londres: erradicação da doença do verme-da-Guiné; eliminação da 
filariose linfática (FL), hanseníase, doença do sono (tripanossomíase humana africana – 
HAT, sigla em inglês) e tracoma (conjuntivite granulomatosa); e controle da 
esquistossomose, geo-helmintíases, doença de Chagas, leishmaniose visceral (LV) e 
oncocercose (cegueira do rio). A OMS recomenda cinco intervenções para alcançar os 
objetivos das DTN: quimioterapia preventiva (PCT, sigla em inglês) por administração 
de medicamentos em massa (MDA, sigla em inglês); gestão inovadora e intensificada de 
doenças (IDM, sigla em inglês); ecologia e gerenciamento de vetores; serviços de saúde 
pública veterinária; e o fornecimento de água potável, saneamento e higiene. 
Além da carga da doença, a carga econômica que as DTN infligem aos pacientes e suas 
famílias também é pesada, mas apenas alguns estudos investigaram o impacto das DTN 
nos pagamentos diretos e na perda de produtividade de indivíduos, famílias e sociedades. 
 
Esta tese 
Ao estudar o efeito socioeconômico das DTN nos indivíduos e na sociedade, esta tese 
teve como objetivo proporcionar uma melhor compreensão sobre esse assunto pouco 
investigado. Primeiro, uma revisão sistemática da literatura descreve como as DTN 
afetam a perda de produtividade em adultos afetados. Os dois capítulos subsequentes 
relatam a estimativa do benefício econômico (para indivíduos) do cumprimento das 
metas da OMS para 2020 para DTN tratadas por PCT e IDM, respectivamente. O 
próximo capítulo apresenta avaliações de custos de um projeto piloto de uma nova e 
testada estratégia de diagnóstico para permitir o tratamento da oncocercose em áreas 
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estudado. Uma revisão sistemática abrangente da literatura foi realizada em novembro de 
2013, relacionando todas as 10 NTD constantes da Declaração de Londres a impacto 
econômico. Foram pesquisadas onze bases de dados e, de 5.316 artigos encontrados 
sobre todas as DTN, apenas alguns descreveram perda de produtividade 
quantitativamente: 13 relacionadas a FL, 10 a oncocercose, 11 a esquistossomose, 6 a 
geo-helmintíases, nenhum a tracoma, 3 a HAT, 12 a doença de Chagas, 10 a LV e 4 a 
hanseníase. 
Houve muita variação na definição de perda de produtividade e, consequentemente, na 
metodologia para mensurá-la. Por exemplo, a faixa anual de perda de produtividade para 
FL foi de 10 a 23% para sintomas crônicos e de 0,9 a 9% para sintomas agudos, medindo 
principalmente horas ou dias de trabalho perdidos. Os estudos sobre oncocercose 
analisaram efeitos mais específicos, como a diferença no salário diário entre indivíduos 
com e sem a doença, ou a diferença no tamanho da área que homens saudáveis 
conseguem manter livres de ervas daninhas em comparação com homens afetados. 
Doenças de pele relacionadas à oncocercose causaram perda de produtividade variando 
de 10 a 34% e a perda de produtividade por cegueira por oncocercose foi assumida como 
sendo de 100%. Estudos analisando a esquistossomose mediram a perda absoluta de 
produtividade em dias perdidos, mas também compararam indivíduos infectados com 
saudáveis, com uma variação de 8,7% a 23%, dependendo do sintoma. Os estudos 
relacionados às geo-helmintíases também investigaram a perda de produtividade absoluta 
e comparada, variando de 0,1 a 35%. A qualidade também diferiu entre os estudos para 
cada doença, com 60% dos artigos com um alto risco geral de viés. 
Este artigo mostrou que, apesar da escassez de publicações e da variação causada por 
diferentes métodos de pesquisa, fica claro que as DTN afetam a perda de produtividade. 
O tipo e a gravidade da doença interferem diretamente no impacto sobre a produtividade, 
assim como o contexto em que a DTN ocorre. 
O benefício econômico de serem alcançadas as metas para 9 NTD 
da Declaração de Londres 
A OMS definiu metas para o controle/eliminação das DTN até 2020, reforçadas pela 




limitados a ganhos em saúde. O benefício econômico de essas metas serem atingidas foi 
primeiramente calculado para um cenário de alcance das metas. Esses custos foram 
ent~ao subtraídos dos custos do cenário contrafactual de nada ter sido feito em relação 
a essas doenças para as metas serem atingidas. O cálculo foi feito para o período entre 
2011 e 2030 (dez anos antes e após o alcance da meta). Para o cálculo dos custos, a 
frequência estimada da doença foi combinada com a perda de produtividade resultante 
da doença, na perspectiva de uma pessoa afetada por cada uma das DTN. O mesmo foi 
feito com os custos de saúde pagos pelos indivíduos afetados. Para estimar o impacto 
econômico do cumprimento das metas da Declaração de Londres, dados de várias fontes, 
contextos heterogêneos e qualidade variável tiveram que ser combinados. Os resultados 
baseados em premissas conservadoras foram: 




DTN 2011 - 2020 2021 - 2030 2011 - 2020 2021 - 2030 
Quimioterapia 
Preventiva               
(PCT) 




23.1 bilhões 35.9 bilhões 14 bilhões 18 bilhões 
 (I$) - Dólares internacionais (paridade do poder de compra de 2005) 
O impacto econômico variou entre DTN e regiões, uma vez que foi determinado pela 
prevalência da doença, pelos OPPs e pelo grau de perda de produtividade causada pelas 
sequelas de cada DTN. 
Além de garantir o direito humano fundamental de almejar o mais alto padrão de saúde 
possível, o controle e a eliminação das DTN também teriam um efeito direto e 
sustentável no crescimento econômico e no bem-estar financeiro das populações 
afetadas e, consequentemente, levariam a uma maior prosperidade nacional e global. A 
combinação desses argumentos com as estimativas de custo e retorno do investimento e 
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de saúde e incentivar ações de prevenção e controle, garantindo aos financiadores e 
formuladores de políticas que os recursos comprometidos com esses esforços são um 
bom investimento. 
Custos e direcionadores de custos relacionados a uma nova 
estratégia de diagnóstico visando atingir a meta de oncocercose: o 
exemplo de Loa loa 
Técnicas de diagnóstico aprimoradas são essenciais para monitorar o progresso e o 
impacto de intervenções e orientar estratégias de tratamento, controle, interrupção de 
transmissão, eliminação e vigilância pós-eliminação. São necessárias tecnologias de ponto 
de atendimento (point-of-care, em inglês), que podem ser usadas em lugares remotos, 
projetadas em um formato “entrada de amostra e saída de resposta” (“sample-in-answer-
out” em inglês), exigindo treinamento mínimo e fornecendo resultados em um período 
de tempo relativamente curto. 
Um exemplo é uma estratégia de ponto de atendimento para testar e não tratar (TaNT, 
sigla para test-and-not-treat em inglês) indivíduos com altos níveis de microfilárias de Loa 
loa em seu sangue, em áreas hipoendêmicas para oncocercose e coendêmicas para loíase, 
pois apresentam alto risco de eventos adversos graves. Este estudo calculou os custos de 
uma rodada piloto de implementação com base em despesas reais, incluindo custos 
financeiros e custos de oportunidade que provavelmente serão arcados, no futuro, pelos 
programas de controle e pelas partes interessadas. Além das análises empíricas, foram 
calculados três cenários (caso base, uso de recursos menos intensivo e uso de recursos 
mais intensivo) para explorar como os custos podem diferir se o TaNT for implementado 
programaticamente. Essa estratégia custou US$ 4,0 por pessoa na população, US$ 9,2 
para cada pessoa testada e US$ 9,5 para cada pessoa tratada. Nos cenários alternativos de 
implementação, esses custos foram estimados em US$ 2,2 [1,9–3,6], US$ 5,2 [4,5–8,3] e 
US$ 5,4 [4,6–8,6] (estimativas do caso base, cenários de uso de recursos menos e mais 
intensivo entre colchetes), assumindo 42% de cobertura programática. Esses custos 
foram mais altos que a administração de medicamentos em massa usual, mas ainda são 
acessíveis e com espaço para reduções adicionais, dependendo das escolhas de 




diagnóstico e dos capilares pode ser reduzido pela produção em larga escala e o pessoal 
de supervisão pode ser reduzido. 
Efeito da combinação de pagamentos diretos e perda de 
produtividade na avaliação do empobrecimento relacionado à 
doença 
Uma causa importante de pobreza é adoecimento e suas conseqüências econômicas 
(grandes gastos e perda de produtividade). A literatura sobre dificuldades econômicas 
devido a doenças e seus efeitos sobre a pobreza quase nunca abordou os pagamentos 
diretos (OPPs) e a perda de produtividade conjuntamente. 
O impacto da combinação de perda de produtividade e OPPs na probabilidade de 
empobrecimento relacionado à doença foi examinado observando em que momento a 
renda residual de um indivíduo afetado pela doença ultrapassaria os limites de US$ 1,9 e 
US$ 3,2 da linha da pobreza (LP): após dedução isolada dos OPPs relacionados a doenças 
ou após dedução de OPPs somados à perda de produtividade. O exemplo utilizado foi 
insuficiência cardíaca secundária à doença de Chagas em todos os países endêmicos da 
mesma doença. Analisando o impacto conjunto, a porcentagem de países onde os 
indivíduos afetados foram empurrados abaixo da linha da pobreza aumentou claramente 
(de 0% para 46% usando a LP de US$ 1,9; de 5% para 80% usando a LP de US$ 3,2). 
A inclusão da perda de produtividade na avaliação do empobrecimento relacionado a 
doenças pode fornecer uma imagem mais completa de uma das causas da pobreza, 
apoiando a conquista do objetivo principal dos Objetivos de Desenvolvimento 
Sustentável (ODS): acabar com a pobreza até 2030. 
 
Perspectivas futuras 
Embora a luta contra as DTN tenha visto um grande progresso, ainda há muitos desafios 
a serem enfrentados antes que as metas possam ser alcançadas em escala universal. 
Alguns desses desafios dizem respeito à falta de evidências disponíveis sobre muitos 
aspectos que podem influenciar a formulação de políticas. Como mostrado nesta tese, 
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relacionadas às DTN, desde pagamentos diretos e perda de produtividade até efeitos 
intangíveis, características e comportamento das populações afetadas. 
Este trabalho também mostra que o benefício econômico estimado de se alcançar as 
metas para 2020 para nove DTN mencionadas na Declaração de Londres é considerável, 
totalizando várias centenas de bilhões de dólares em todo o mundo durante um período 
de 20 anos. Além disso, é possível realizar estudos para investigar os custos de novas 
estratégias de diagnóstico para atingir as metas da Declaração de Londres para DTN, o 
que é apoiado pelo estudo sobre oncocercose e por outros estudos citados na literatura. 
Além disso, como visto na literatura sobre OPP e ainda mais literatura sobre perda de 
produtividade, bem como em nosso estudo de custos da estratégia de teste e não 
tratamento (TaNT), a maneira como as informações são coletadas deve ser 
individualizada por cada país e talvez cada região de um país, dependendo dos desafios 
específicos que enfrentam. A fim de reunir dados necessários e confiáveis para 
indicadores socioeconômicos globais e, concomitantemente, abordar questões de 
transferibilidade, nosso trabalho sugere globalizar a estrutura científica, individualizar os 
métodos e localizar as evidências. 
E, finalmente, combinar OPPs e perda de produtividade na avaliação do 
empobrecimento relacionado à doença oferece uma visão mais abrangente sobre a 
probabilidade de empobrecimento relacionado à doença. Essas informações podem 
apoiar o desenvolvimento de políticas para lidar melhor com o empobrecimento 
relacionado à doença e alcançar o ODS 1. Há um vínculo inegável entre alcançar as metas 
para DTN e alcançar os ODS. O compromisso central dos ODS de "não deixar ninguém 
para trás" exige um foco global em alcançar os mais pobres, excluídos e desfavorecidos, 
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